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ABSTRACT 
 
FACULTY OF ENGINEERING, SCIENCE & MATHEMATICS 
 
SCHOOL OF CHEMISTRY 
 
Doctor of Philosophy 
 
THE DEVELOPMENT OF A SIMPLE PROCESS FOR PRODUCING MEDICINAL 
DIAGNOSTIC 
18F AGENTS FOR MOLECULAR IMAGING USING POSITRON-
EMISSION-TOMOGRAPHY 
 
By Amy Clare Topley 
 
A range of resin bound sulfonate ester linkers were developed for use in the resin-
linker-vector (RLV) approach for the synthesis of [
18F]-fluoride radiotracers for use as 
imaging agents in positron-emission-tomography (PET).  The RLV strategy 
immobilises a precursor to the desired radiotracer on a solid support which is cleaved on 
exposure to [
18F]-fluoride ion to give the 
18F-labelled radiotracer in solution.  The RLV 
methodology allows for easier purification of the 
18F-labelled radiotracer as a simple 
filtration step removes the unreacted starting material and the cleaved resin. 
 
Synthetic routes to a 4-allkylphenylsulfonate linker and a 4-nitrophenylsulfonate linker 
were developed and these were shown to work as desired as part of the RLV construct 
in [
19F]-fluoridolysis reactions.  [
18F]-Fluoridolysis reactions using the 4-
alkylphenylsulfonate linker gave the desired 
18F-labelled product in excellent 
radiochemical purity.  The RLV strategy with this linker type was applied in a new 
synthetic route to O-(2-[
18F]-fluoroethyl)-L-tyrosine.   
 
A fluorinated analogue of Alzheimer’s disease drug (−)-galanthamine was synthesised 
with complete stereocontrol as a potential new imaging agent for use in PET.  
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Chapter 1 – Introduction 
Positron-emission-tomography (PET) is a nuclear imaging technique which is used to 
produce three-dimensional images to map functional processes in vivo and has both 
medical and research applications.  The work of this project involved the development 
of a solid phase approach to the synthesis of [
18F]-fluoride imaging agents for medicinal 
diagnostic applications using PET.  This chapter is composed of a general overview of 
PET as an imaging technique and the 
18F-labelled radiopharmaceuticals used in PET, as 
well as covering the background to this work and the scope of the project.  Further 
introductory material for more specific areas of the project can be found in the relevant 
chapters. 
 
To ensure the reader is familiar with the radiochemical terminology used in this report 
the common radiochemical terms are defined at this juncture. 
 
Specific activity – The activity of a radioactive element (the number of decays per unit 
time) divided by the mass of the material in which it exists.  It is used to describe the 
amount of a sample that is the radioactive element and non-radioactive element, high 
specific activity meaning a high proportion of 
18F with a low proportion of 
19F, for 
example. 
 
Incorporation – Calculated from the integration of the radioactive HPLC trace of a 
sample and in this work it is used describes the percentage of total 
18F present that is 
part of the desired product.  The rest of 
18F could be present as unreacted [
18F]-fluoride 
or as other 
18F-containing products. 
 
Radiochemical yield – The yield of the radiochemical product of a reaction.  This is 
calculated from the starting 
18F activity and the product activity and can be quoted as 
either non decay corrected (calculated directly from the starting 
18F activity and the 
product activity measurements) or decay corrected (where the product activity is 
corrected based on the time elapsed since the starting activity was measured and the 
product isolated and the half-life of the radioactive element).  The decay corrected yield 
will always be higher than the non decay corrected yield. 
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Radiochemical purity – The amount of desired radiochemical product compared to any 
other radiochemical products formed in the reaction.  High radiochemical purity would 
be the result of the formation of the desired radiochemical product only. 
 
1.1  History of PET 
The use of positrons in medicinal applications was first reported in 1951 when a simple 
brain probe was developed to localise brain tumours.
1  The first PET tomograph was 
built in 1973 by Phelps and co-workers who carried out studies to establish the 
principles of PET and were the first to image blood flow and metabolism in animals.
2  
The following year, the first PET tomograph for studies with human subjects was 
constructed.
3,4  It was made up of a hexagonal array of 48 sodium iodide (NaI(T1)) 
detectors and it was used to produce the first human PET images of blood flow, oxygen 
and glucose metabolism and [
18F]-fluoride bone scans.  The first commercial PET 
scanner become available only a few years later and so provided the means for PET to 
be established in research programs worldwide.  This tomograph, trade named ECAT II 
(which stood for Emission Computed Axial Tomograph), was made up of 96 NaI(T1) 
crystal detectors and sold for approximately US$600,000 in 1978.
1  The late 1970s saw 
the development of the scintillation material used in the detectors and bismuth-
germanate (BGO) replaced NaI(T1) as the material of choice.  The mid-eighties saw the 
development of radio-pharmaceutical delivery systems (RDS) which incorporated mini-
cyclotrons and allowed the automated synthesis of the radiotracers.  In 1991, Phelps and 
co-workers obtained the first whole-body oncology images
5 which could be used to 
detect primary and metastatic disease, differentiate benign from malignant lesions and 
access therapeutic responses by being able to image all of the organs of the body in a 
single examination.
1  Developments in PET are ongoing with tomographs in the early 
2000s typically having in the order of 120,000 detectors, now made of lutetium 
oxyorthosilicate (LSO).  PET imaging is now a well established and important 
diagnostic tool in modern medicine. 
 
1.2  The principles of PET 
PET imaging involves a radioactive tracer molecule or radiotracer which is usually a 
small, biologically active compound that contains a positron-emitting radionuclide.  The     3
radiotracer is injected into the blood stream of the living subject and after a short time 
the active molecule becomes concentrated in the tissues of interest and can be detected 
by an imaging scanner.  The radionuclide undergoes positron decay (also known as 
positive beta decay) and emits a positron, which is the antimatter component to an 
electron.  When this positron collides with an electron in the surrounding tissue it forms 
a positronium which promptly annihilates producing two γ-rays (photons).  These γ-rays 
have identical energies (511 keV
6) but travel in opposite directions and are detected by 
an external imaging device (Figure 1.  1).  The detector is made of a scintillator material 
(NaI(T1) or LSO) which absorbs the γ-rays to produce bursts of light which are detected 
by photomultiplier tubes and the data is then processed to give an image of the subject. 
 
 
Figure 1.  1  The physical basis of PET imaging using a [
18F]-fluoride labelled 
radiotracer.  Image reproduced from the microreview by Cai, L., Lu, S. and Pike, V. W., 
“Chemistry with [
18F]-Fluoride Ion”, Eur. J. Org. Chem., 2008, 2853-2873.  Copyright 
Wiley-VCH Verlag GmbH & Co. KGaA and reproduced with kind permission from the 
author and the publisher. 
 
The imaging device must completely surround the subject, either as a single ring of 
detectors (for two-dimensional images) or multiple rings effectively making a cylinder 
of detectors (for three-dimensional images), as the technique depends on the 
simultaneous detection of both γ-rays of the pair.  Those not arriving within a few 
nanoseconds of each other are ignored when the data is processed. 
 
Single photon emission computerised tomography (SPECT) is an imaging technique 
related to PET which similarly uses a radiotracer and the detection of γ-rays to produce 
an image of the subject.  In contrast to PET, the radiotracers used in SPECT emit γ-    4
radiation directly, which is then detected by a γ-camera that is rotated around the 
subject.  Although PET gives higher resolution images, SPECT is a simpler, cheaper 
and more widely available technique that can be applied to clinical populations more 
easily than PET.
7 
 
1.3  Radionuclides 
The radionuclides used in PET and SPECT are typically isotopes with short half lives so 
as to limit the exposure to radiation of the patient.  The radionuclide is incorporated into 
the radiotracer which is either a compound normally used by the body (water, ammonia, 
glucose or a glucose analogue) or a biologically active molecule which binds to a drug 
receptor.  The radionuclides most commonly used in SPECT are 
99mTc, 
123I and 
133Xe 
although these can be hard to incorporate into compounds that behave in a natural 
biochemical fashion in the body.
7  Radiotracers for use in PET most commonly contain 
11C, 
13N, 
15O or 
18F although the use of 
64Cu, 
68Ga, 
86Y and 
124I is becoming increasingly 
prevalent.
8  This list is by no means exhaustive and many other isotopes are currently 
under development, such as 
74As.
9  The four positron-emitting radioisotopes, 
11C, 
13N, 
15O and 
18F, are used more than any of the others because they can be easily substituted 
directly onto biomolecules.  Substitution of the so called “elements of life” (carbon, 
nitrogen and oxygen) with their radioactive isotope is easy to achieve and does not 
significantly affect the properties of a molecule.  Due to the steric similarities between a 
fluorine atom and an oxygen atom, 
18F may be incorporated by the replacement of a 
hydroxyl group as it has a similar bond length to carbon and has similar polarity.  The 
presence of the more electronegative fluorine atom may affect one or more aspect of the 
biological behaviour of the molecule (for example distribution, metabolism or protein 
binding) although this change may be advantageous resulting in a molecule with 
enhanced properties compared to the original compound.  Since the van der Waals 
radius of the fluorine atom is similar to that of hydrogen (1.20 Å and 1.47 Å, 
respectively)
6, 
18F may also be substituted for a hydrogen atom with very little affect on 
the sterics of the molecule.  Shown in Table 1.1 is data for the characteristics of the four 
most common PET radionuclides. 
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Nuclide  Half Life  Decay Mode  Maximum 
Energy 
Maximum 
Range 
11C 20.4  min 100% β
+  0.96 MeV  4.1 mm 
13N 9.98  min 100% β
+  1.19 MeV  5.4 mm 
15O 2.03  min 100% β
+  1.7 MeV  8.0 mm 
18F 109.8  min  97% β
+ 3% EC  0.69 MeV  2.4 mm 
Table 1.1  Characteristics of the four most common PET radionuclides.
10  β
+ = positron 
emission.  EC = electron capture.  Maximum range in water. 
 
The comparatively short half lives of 
13N and 
15O pose problems in the synthesis of 
radiotracers containing these isotopes and so their use has been limited to the production 
of radiolabelled ammonia, oxygen, carbon dioxide, carbon monoxide and water.  Due to 
the short half lives of 
11C, 
13N and 
15O, it is normally necessary to produce these 
isotopes using a cyclotron (a compact particle accelerator) which is in very close 
proximity to the scanning facility.  In general, a PET radiotracer needs to be 
synthesised, purified, analysed and formulated ready for injection into the subject before 
2-3 half lives of the radionuclide have passed.
11  Radiotracers containing 
11C are 
typically prepared in around 30 min to retain enough radioactivity for the PET scan and 
so the longer half life of 
11C allows more time for the synthesis of radiolabelled 
compounds.  The use of 
18F in radiotracers is becoming increasingly popular due to the 
advantages in it’s characteristics over those of the other commonly used radionuclides.  
The significantly longer half life of 
18F (over five times that of 
11C) allows for a more 
complex synthesis of the radiotracer within the decay time of the radioisotope and 
permits the investigation of biological processes with slower kinetics as PET scans can 
be acquired over a few hours.
6  This also means that the radiotracers can be transported 
over considerable distances and so in-house cyclotrons at each scanning facility can be 
replaced with a central production centre covering many facilities.  Upon decay, 
18F 
emits a quite low energy positron (up to 0.69 MeV) which has a short path in vivo 
before its annihiliation.  The maximum range of a positron emitted from 
18F is shorter 
than a positron emitted from 
11C (which has a higher maximum energy) leading to 
superior resolution of the resulting PET image with a radiotracer containing 
18F. 
 
There are a number of nuclear reactions which can be used to produce 
18F,
12 the most 
common of which is the proton irradiation of [
18O]-enriched water.
13  In this nuclear 
reaction (
18O(p,n)
18F, which stands for the bombardment of 
18O with protons causing     6
the ejection of a neutron to give 
18F), the 
18F is obtained as a solution of [
18F]-fluoride in 
irradiated target water and is obtained “no-carrier-added” (NCA).
6  This means that the 
ratio of [
18F]-fluoride to the total fluoride ion content is high and so the [
18F]-fluoride 
ion produced is said to have a very high specific radioactivity.  The reaction is high 
yielding and can be carried out using small, compact cyclotrons to give several Curies 
of product from a single irradiation, of which only 5-15 mCi is required for injection 
into a human subject for a single PET examination.
6  The other commonly used 
reaction, particularly for the production of electrophilic 
18F, is the irradiation of neon 
gas (
20Ne(d,α)
18F, which stands for the bombardment of 
20Ne with deuterium ions 
causing ejection of an α-particle to give 
18F).
14  Although the yield obtained from this 
reaction is substantially lower than that of the previous method the natural abundance of 
the target material is advantageous. 
 
1.4  Applications of PET 
PET is seen as the most specific and sensitive means of quantitatively imaging 
molecular pathways and interactions in vivo as it is regarded as having a level of 
sensitivity that is unmatched by other imaging techniques.
15  Hence, it is unsurprising 
that PET imaging is now routinely used in medicinal diagnostics both to locate and 
assess abnormalities in a wide range of medical fields and also to research physiological 
processes.
16  PET is one of the techniques used in neurology to further the 
understanding of the pathophysiological mechanisms of neurological diseases and to aid 
the assessment of neurological patients.  The areas of neurology which have been 
studied using PET include: the recovery mechanism after a stroke; the 
pathophysiological aspects of migraine headaches and epilepsy; Parkinson’s and 
Huntington’s disease; Alzheimer’s disease and other forms of dementia; and multiple 
sclerosis.
7  In cardiology, PET has been used to image blood flow using [
13N]-ammonia 
and for investigating glucose metabolism using a 
18F-labelled glucose analogue
1 and 
also as an aid in cardiac surgery.
17  PET is a very versatile and powerful imaging 
method in oncology where it is used to image tumours using 
18F-labelled glucose 
analogues to investigate glucose metabolism
18 and 
18F-labelled steroids for imaging 
hormone-responsive cancers.
19 
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1.5 
18F-labelled radiopharmaceuticals for used in PET 
A large number of radiotracers containing 
18F for use in PET have been synthesised, 
which include 
18F-labelled aromatic amino acids, phenethyamines, steroids, tropanes 
and antibodies as well as other small molecules.
20  The chemical reactions used for the 
labelling of these organic molecules with 
18F can be categorised as either electrophilic 
or nucleophilic, based on the form of 
18F employed.  Historically, electrophilic 
fluorination was used although as the field has developed the use of higher yielding, 
higher specific activity nucelophilic routes have dominated.  The electrophilic 
fluorination uses [
18F]-F2 in aliphatic or aromatic addition-elimination reactions, 
although the latter tend to be non-regioselective leading to a mixture of [
18F]-fluorinated 
products.  Electrophilic fluorination reactions also suffer from low radiochemical yield 
since the maximum achievable radiochemical yield is only 50% as only one of the two 
fluorine atoms in [
18F]-F2 are incorporated into the product.  An example of 
electrophilic fluorination is the synthesis of [
18F]-5-fluorouracil ([
18F]-FU, Figure 1.1, 
Scheme 1) which is a radiolabelled analogue of the commonly used cancer 
chemotherapeutic 5-fluorouracil and was synthesised by the reaction of [
18F]-F2 with 
uracil (1.01).
21  The glucose analogue [
18F]-2-fluoro-2-deoxy-D-glucose ([
18F]-FDG) 
and the 
18F-labelled phenylalanine analogue L-3,4-dihydroxy-6-[
18F]-
fluorophenylalanine ([
18F]-FDOPA) can both be synthesised by either electrophilic or 
nucleophilic methods (Figure 1.1, Schemes 2 and 3).  The synthetic routes to [
18F]-FDG 
are discussed in the next section of this chapter.  An electrophilic fluorination approach 
to [
18F]-FDOPA involved the fluorodestannylation of the trimethylstannyl precursor 
(1.02) followed by removal of the protecting groups and this pathway has been applied 
in an automated synthesis of the radiotracer.
22  In the nucleophilic approach to [
18F]-
FDOPA, [
18F]-fluoride displaces the nitro group of nitroaldehyde 1.03 followed by 
reaction with 2-phenyl-5-oxazolone and hydrolysis to remove the protecting groups to 
give the product as a racemic mixture of the L and D forms.  Chiral HPLC was then used 
to separate the enantiomers and the whole procedure was reported to take 100 min to 
complete.
23 
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The synthesis of [18F]-FDG is discussed in
detail in the next section of this chapter.
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BocO Sn(CH3)3
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O
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H
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Figure 1.1  The fluorination step in the synthesis of some 
18F-labelled radiotracers for 
use in PET.  Reagents and conditions: a) [
18F]-F2, TFA;
21 b) (i) [
18F]-F2, CFCl3, (ii) 
HBr;
22 c) (i)  [K/K2.2.2]
+ 
18F
−, DMSO, (ii) 2-phenyl-5-oxazolone, DABCO, EtOH, (iii) 
AcOH, red phosphorus;
23 d) (i) TBA
18F, DMSO, (ii) AlCl3, LiAlH4, (iii) EtSH, AlBr3;
19 
e) [K/K2.2.2]
+ 
18F
−, MeCN.
24 
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The nucleophilic reactions use [
18F]-fluoride ion to displace a leaving group on the 
precursor molecule.  This is generally carried out in dipolar aprotic solvents and in the 
presence of a cationic counterion (typically a soft metal ion complexed by a cryptand 
such as Kryptofix [2.2.2]) to increase the reactivity of the [
18F]-fluoride ion.   
Nucleophilic fluorination was used in the synthesis of the 
18F-labelled steroid 2-[
18F]-
fluoroestradiol (2-[
18F]-FES, Figure 1.1, Scheme 4) from a precursor (1.04) containing a 
quaternary ammonium salt as the leaving group.
19  The promising dopamine D2 
antagonist [
18F]-fallypride (Figure 1.1, Scheme 5) has also been synthesised using a 
nucleophilic fluorination reaction to displace an alkyl tosylate leaving group on the 
precursor (1.05).
24 
 
1.6  [
18F]-2-Fluoro-2-deoxy-D-glucose 
Glucose analogue [
18F]-2-fluoro-2-deoxy-D-glucose ([
18F]-FDG, Figure 1.1, Scheme 2) 
is by far the most widely used radiotracer in clinical use in PET.  This is because it has 
been shown to be a multipurpose radiotracer with applications in a variety of diagnostic 
fields including neurology, cardiology and oncology.
16  For example, the use of [
18F]-
FDG in conjunction with whole body PET scanners enables the detection of broad 
varieties of tumour tissue and its metastases at an early stage of the disease with a single 
scan of the whole body.  This is due to the increased glucose metabolism in tumour cells 
and so the uptake of [
18F]-FDG is significantly higher in tumour tissue compared to 
“normal” tissue since the biochemical behaviour and the initial metabolism of glucose 
and [
18F]-FDG are very similar. 
 
The first synthesis of [
18F]-FDG was published by Ido et al. in 1977
25,26 and the 
subsequent development of the synthetic route has been driven by the need for reliable, 
high yielding reactions which give the desired product in high purity with minimal 
preparation time and at low cost.  This first synthesis of [
18F]-FDG was carried out by 
the addition of [
18F]-F2 across the double bond of 3,4,6-tri-O-acetyl-D-glucal (1.06).  
This electrophilic fluorination reaction formed two isomers, the 1,2-difluoro-glucose 
isomer (1.07) and the 1,2-difluoro-mannose isomer (1.08), which were formed in a ratio 
of 3:1 (Scheme 1.1).  Hydrolysis of isomer 1.07 using hydrochloric acid gave the 
desired [
18F]-FDG in approximately 10% overall radiochemical yield. 
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Scheme 1.1  The first published synthesis of [
18F]-FDG using electrophilic 
fluorination.
25  Reagents and conditions: a) [
18F]-F2; b) HCl. 
 
A modification to this route, published in 1982, improved the overall radiochemical 
yield to around 20% by the use of 
18F-labelled acetyl hypofluorite (CH3CO2
18F, 
generated in situ from [
18F]-F2 and ammonium acetate) as the electrophilic fluorinating 
reagent.
27  This reagent was also found to improve the selectivity of the fluorination 
reaction which was thought to be due to the larger size of acetyl hypofluorite relative to 
elemental fluorine, resulting in the selective addition to the less hindered side of the 
molecule.
27  The highest selectivity for the fluorination reaction was achieved through 
the reaction of 3,4,6-tri-O-acetyl-D-glucal (1.06) with CH3CO2
18F in CFCl3 which gave 
a mixture of [
18F]-FDG and [
18F]-FDM in a ratio of 95:5.
28 
 
 
Scheme 1.2  Synthesis of [
18F]-FDG by nucleophilic fluorination.
29  Reagents and 
conditions: a) [K/K2.2.2]
+ 
18F
−, MeCN; b) HCl. 
 
The low yields and limited stereoselectivity of the electrophilic fluorination addition 
reaction were overcome by the development of a synthetic route using nucleophilic 
fluorination and it is this method that is now routinely used in the majority of the 
world’s PET facilities.
16  This route utilises 1,3,4,6-tetra-O-acetyl-2-    11
trifluoromethanesulfonyl-β-D-manno-pyranose (1.09), which is prepared selectively in 
two steps from D-mannose, as the precursor (Scheme 1.2).
29  The combination of the 
powerful triflate leaving group and the use of no-carrier-added [
18F]-fluoride of very 
high specific activity leads to high yields for the fluorination reaction, giving fluoride 
1.10 with a 95% incorporation of [
18F]-fluoride.  The precursor is combined with the 
aminopolyether potassium complex [K/K2.2.2]
+ 
18F
− as a phase-transfer agent which 
generates a highly reactive [
18F]-fluoride ion due to the masking of the potassium 
counterions with Kryptofix [2.2.2].  The cleavage of the protecting groups is carried out 
rapidly under mild conditions using hydrochloric acid as before.  The radiochemical 
yield for this strategy is 60% (non-decay corrected) over the two steps which represents 
a significant improvement over the electrophilic fluorination approach. 
 
Automated procedures for the production of [
18F]-FDG have been developed to 
minimise the radiation risk during the synthesis and to improve the reliability and 
reproducibility of the fluorination reaction.
16  The use of polymer-supported reagents in 
[
18F]-fluorination reactions can be easily adapted for automated radiosynthesis and has 
the advantage of simplifying the purification of the final product.
6  Two solid-phase 
strategies have been explored for use in the synthesis of [
18F]-FDG, one approach traps 
the [
18F]-fluoride ion on a polymer support with a weakly basic counterion and the other 
approach attaches the precursor to the polymer-support (Scheme 1.3). 
 
The resin-supported [
18F]-fluoride ion approach uses 4-aminopyridinium (1.11) or tris-
(n-butyl)-phosphonium salts which are attached to a polymer support and are used for 
on-column fluorination.
30,31  The quaternary salts immobilise the [
18F]-fluoride ions 
(1.12) and act as the phase-transfer catalyst negating the need for Kryptofix [2.2.2], 
which can appear as a contaminant in the final product.  This approach has been used to 
synthesise [
18F]-FDG in radiochemical yields of >70% (Scheme 1.3).  The alternative 
strategy was recently developed in collaboration between the Brown group at the 
University of Southampton and GE Healthcare in Amersham.
32-34  This approach 
immobilised the precursor on a solid support which liberated protected [
18F]-FDG into 
solution upon treatment with [
18F]-fluoride ions.  A perfluoroalkylsulfonate linker was 
used to attach the precursor to a solid support consisting of polystyrene resin beads.  
When this resin (1.13) was subjected to the normal conditions used in nucleophilic 
fluorination, [
18F]-fluoride in the presence of Kryptofix [2.2.2], the [
18F]-fluoride     12
cleaved the precursor from the solid support.  This method has been used to obtain 
[
18F]-FDG in excellent chemical purity and in an average radiochemical yield of 73% 
(decay corrected).  Both of these strategies could be applied in the preparation of other 
18F-labelled radiotracers. 
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Scheme 1.3  Solid-phase routes to [
18F]-FDG using polymer-supported [
18F]-fluoride 
ion
31 (top) or polymer supported precursor
33,34 (bottom).  Reagents and conditions: a) (i) 
18F
−/H2
18O, (ii) MeCN; b) (i) 1,3,4,6-tetra-O-acetyl-2-trifluoromethanesulfonyl-β-D-
manno-pyranose (1.09), MeCN, 100 °C, (ii) 1 N HCl, 100 °C; c) (i) [K/K2.2.2]
+ 
18F
−, 
MeCN, 86 °C, (ii) 6 M HCl, 125 °C. 
 
1.7  Recent strategies for the production of 
18F-labelled radiopharmaceuticals 
In addition to the solid phase approaches developed for the synthesis of [
18F]-FDG 
discussed previously, a couple of other strategies have been recently developed for the 
synthesis of 
18F-labelled radiotracers.  Bejot et al. reported the use of a fluorous tag 
attached to the precursor of the 
18F-labelled radiotracer which was displaceable upon 
nucleophilic fluorination with [
18F]-fluoride ion.
35  This novel application of fluorous 
chemistry paralleled the use of solid phase chemistry by Brown et al.
33,34 discussed 
earlier as the highly perfluorinated region on the fluorous tag allows for easy 
purification of the crude reaction mixtures using fluorous solid phase extraction (FSPE) 
in much the same way as the solid support allows easy purification by filtration.
35      13
When compared to solid phase chemistry, fluorous chemistry is seen as a solution phase 
synthesis technique and so has more favourable reaction kinetics than solid phase 
synthesis although the benefit of separation tagging is retained.  The use of nucleophilic 
fluorination in the oxidative de-tagging of a molecule containing a fluorous tag and the 
subsequent FSPE purification was developed by Boldon et al. in the novel strategy for 
the synthesis of allylic fluorides from fluorous allylsilanes
36 and this approach was also 
used in the oxidative de-tagging of fluorous organosilanes to give alcohols.
37  T h is  
application of fluorous organosilanes was combined with the use of sulfonate leaving 
groups, which are generally employed in the synthesis of 
18F-labelled radiotracers, to 
give a sulfonate leaving group with a fluorous tag made up of a polyfluorinated alkyl 
chain.
35 
 
 
Scheme 1.4  The fluorous synthesis of [
18F]-cis-4-fluoro-L-proline.
35  Reagents and 
conditions: a) (i) [K/K2.2.2]
+ 
18F
−, MeCN, 100-120 °C, (ii) FSPE, (iii) TfOH, 
MeCN/H2O. 
 
This fluorous protocol, using nucleophilic fluorination for the removal of a fluorous tag, 
was applied in the synthesis of [
18F]-cis-4-fluoro-L-proline (Scheme 1.4).  Fluorous 
precursor 1.14 was subjected to the normal conditions used in nucleophilic fluorination, 
[
18F]-fluoride in the presence of Kryptofix [2.2.2], and the [
18F]-fluoride ion removed 
the fluorous tag whilst fluorinating the precursor.  Purification using FSPE separated the 
unreacted fluorous precursor 1.14 and the cleaved fluorous tag from the reaction 
mixture and deprotection with triflic acid afforded [
18F]-cis-4-fluoro-L-proline in a 
radiochemical yield of 42%.
35  However, it was found that the presence of the fluorous 
tag caused a decrease in the specific activity of the product compared to a non-fluorous 
precursor, possibly due to leaching of [
19F]-fluoride ion from the tag. 
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There is a continuing drive to broaden the spectrum of molecular scaffolds that can be 
used as 
18F-labelled radiotracers for imaging with PET.  Some substrates are 
incompatible with [
18F]-fluoride ion most commonly used in the labelled step making it 
necessary to separate the 
18F-C bond formation step from the molecule to be labelled.
38  
The approach recently developed for this strategy is the synthesis of 
18F-labelled 
reagents that chemoselectively bind to substrates under mild conditions and the use of 
“click labelling” in this application has rapidly grown in popularity in recent years.  
“Click” chemistry is the term used for the 1,3-dipolar cycloaddition reaction of a 
terminal alkyne with a substituted azide, first discovered by Michael in 1893,
39 and 
developed in the early twenty-first century after the discovery of the use of copper(I) to 
catalyse the reaction (Scheme 1.5).
40-42  “Click labelling” utilises click chemistry in the 
synthesis of 
18F-labelled radiotracers by attaching a 
18F-labelling reagent, containing an 
alkyne or azide functional group, to a substrate molecule with the opposite group.  The 
1,4-disubstituted 1,2,3-triazole formed in the cycloaddition reaction is stable under in 
vivo conditions and can result in an improvement in the pharmacological properties of 
the resulting radiotracer.
38 
 
 
Scheme 1.5  “Click” chemistry: the copper(I) catalysed 1,3-dipolar cycloaddition of 
substituted alkynes and azides. 
 
A range of alkynes and azides have been radiolabelled for use as 
18F-labelling reagents 
in click labelling and these have been shown to be easily reacted with the appropriate 
substrate to give the desired 
18F-labelled small molecule (a selection of 
18F-labelled 
small molecules and the 
18F-labelling reagents used in their synthesis are shown in 
Figure 1.2).  Among the 
18F-labelled small molecules synthesised using click labelling 
are the glucose derivative 1.20 and [
18F]-FDG derivative 1.24.  Glucose derivative 1.20 
was obtained from the reaction of a fluorinated alkyne 1.15
43 with a glucose molecule 
containing an azide functionality.
44  Conversely, the synthesis of [
18F]-FDG derivative 
1.24  was carried out using a protected [
18F]-FDG molecule containing an azide 
functional group (1.19) and a substituted glycine derivative.
45      15
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Figure 1.2  A selection of 
18F-labelling reagents for use in “click labelling” and some of 
the 
18F-labelled small molecules obtained from the reaction with an appropriate 
substrate (a complete list of the 
18F-labelling reagents and 
18F-labelled small molecules 
published between 2006 and 2009 can be found in the review by Glaser et al.).
38 
 
18F-Labelled triazole 1.21 was synthesised from azide 1.16 and was used as a model 
compound to study the “click labelling” chemistry.
46  The purification of either of the 
18F-alkyne or 
18F-azide reagents is generally found not to be necessary and the synthesis 
of the 
18F-labelled small molecules can be carried out by a simple one-pot chemistry 
technique, as shown in the synthesis of 
18F-labelled triazole 1.22 from alkyne 1.17.
47      16
Azide 1.18 was used in the synthesis of 
18F-labelled phenylalanine derivative 1.23 in a 
model reaction to investigate the click labelling of peptides.
48  A variety of 
18F-labelled 
peptides have also been synthesised by click labelling which has been shown to be a 
chemoselective and high-yielding coupling method that does not require the use of 
protecting groups making it advantageous over other 
18F-labelling methods.
38 
 
1.8  Resin-linker-vector strategy 
The approach used by Brown in collaboration with GE Healthcare for the synthesis of 
[
18F]-FDG from a solid-supported precursor (Scheme 1.3) utilised the resin-linker-
vector (RLV) strategy.{,  #156}  The idea behind the RLV strategy is that the precursor 
to the labelled product (known as the vector) is attached to a solid support via a linker of 
appropriate length and reactivity, forming a functionalised resin that makes up the RLV 
construct.  When this resin is used in the fluorination reaction, [
18F]-fluoride ions cleave 
the vector molecule from the linker to give the 
18F-labelled vector molecule in a solution 
containing a suspension of the resin.  Since the unreacted precursor remains attached to 
the resin it can be easily removed from the reaction mixture, along with the spent resin, 
by a simple filtration to give pure 
18F-labelled vector in solution and so making lengthy 
purification processes unnecessary (Figure 1.3). 
 
 
Figure 1.3  Schematic of the resin-linker-vector (RLV) strategy. 
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The developed RLV strategy uses a sulfonate ester functionality for the attachment of 
the vector molecule to the linker portion.  This can be easily constructed by the reaction 
of a sulfonyl chloride (or a shelf-stable alternative such as a pentafluorophenyl (PFP) 
sulfonate
50) on the end of the linker with a hydroxyl group on the vector molecule at the 
position where the [
18F]-fluorine is required on the 
18F-labelled vector.  When reacted 
with a nucleophile, the linker part of RLV construct behaves as a good leaving group 
aiding the modifying cleavage reaction of the vector molecule. 
 
Perfluoroalkylsulfonate linkers, like the one used in the Brown group synthesis of [
18F]-
FDG (section 1.6), have been used previously as traceless linkers in solid-phase 
synthesis to carry out simple transformations on small organic molecules.  Pan et al. 
used them as traceless linkers in a solid-phase approach to carry out the deoxygenation 
of phenols
51 and for the carbon-carbon bond forming reaction in the synthesis of biaryls 
through Suzuki cleavage (Figure 1.4, Scheme 1).
52  The use of traceless  linkers in 
solid-phase synthesis is advantageous as the functional group present in the linkage is 
modified upon cleavage and so does not remain on the vector molecule.
53  A wide range 
of solid-phase sulfonate linkers have been developed showing them to be very useful for 
the attachment and subsequent modifying cleavage of small molecules using 
nucleophiles – a few examples are discussed here.  A tetrafluoroarylsulfonate linker that 
behaves like a triflate leaving group was developed simultaneously by two separate 
groups in 2004 and has also been shown to be of use as a traceless linker in 
deoxygenation and cross-coupling reactions (Figure 1.4, Scheme 2).
54,55  An 
arylsulfonate linker, first used for the synthesis of arginine-containing peptides by a 
guanidine attachment to a solid support,
56 was further developed for use in the 
preparation of amine libraries (Figure 1.4, Scheme 3).
57  In this work the amine 
functionality was formed from an immobilised alkyl chain, attached via a sulfonate ester 
linkage, by cleavage with amines, thiolates or imidazoles.  Cyclic molecules can also be 
formed from solid-supported precursors as shown by Holte et al. in their solid-phase 
synthesis of 3,5-disubstituted 1,3-oxazolidin-2-ones (Figure 1.4, Scheme 4).
58  In this 
work the solid-phase linker acts as both a protecting group and an activated leaving 
group.  The authors attached 1,2-diols to a solid support via a sulfonate ester linkage to 
the primary alcohol functionality of the diol.  This allowed the selective activation of 
the secondary alcohol by an on-resin reaction with p-toluenesulfonyl isocyanate and the 
subsequent cyclo-elimination then occurred with concurrent detachment from the resin.       18
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Figure 1.4  Other applications of solid-supported sulfonate linkers.  Reagents and 
conditions: a) R
1C6H4OH, K2CO3, DMF;
51,52 b) Pd(OAc)2, dppp, Et3N, HCO2H, 
DMF;
51,54,55 c) R
2C6H4B(OH)2, PdCl2(dppf), Et3N, DMF
52,55 or Pd(dppf), K2CO3, 
THF/H2O;
54 d) R
1C6H4OH, Et3N
54 or i-Pr2NEt
55, CH2Cl2; e) R
3ZnI, Ni(PPh3)2Cl2, PPh3, 
LiCl, THF;
54 f) R
1OH;
57 g) R
3R
2NH neat or in DMF, THF or MeCN; h) R
2S
−Na
+, 
MeCN; i) Imidazole, MeCN; j) RCH(OH)CH2OH, Et3N, CH2Cl2;
58 k) Tosyl isocyanate, 
CH2Cl2; l) DBN, CH2Cl2. 
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The use of enantiopure 1,2-diols in this solid phase system gave oxazolidinones of high 
enantiopurity. 
 
1.9  Scope of this project 
The objective of this project, which was sponsored by GE Healthcare, was to develop 
the synthesis of a range of linker types that mimic sulfonate leaving groups for use as 
part of the RLV construct.  This would allow the RLV strategy to be applied in the 
synthesis of a variety of 
18F-labelled radiotracers.  This involved the synthesis of a 
selection of linker types which had differing reactivity so that the leaving group ability 
of the linker could be tuned for different vector molecules.  The developed linkers were 
attached to a suitable vector molecule and immobilised on a solid support to give a 
collection of RLV constructs.  Fluoridolysis to give the cleaved vector molecule was 
carried out for each of the RLV constructs synthesised to establish if the linker 
methodology was successful. 
 
 
Figure    1.5  Linker types of interest for use as part of the RLV construct: 4-
alkylphenylsulfonate (1.25), 4-alkoxyphenylsulfonate (1.26), 4-nitrophenylsulfonate 
(1.27) and alkylsulfonate (1.28).  In each case, n denotes variation in the alkyl chain 
length of the linker. 
 
In the first instance, we were interested in the development of a 4-alkylphenylsulfonate 
linker type which would mimic a toluene sulfonate leaving group (1.25, Figure   1.5).  A 
number of other possible linker types that would mimic nosylate or mesylate leaving 
groups were also desired (1.26, 1.27 and 1.28) and solution model studies were carried     20
out to determine which of these linkers were worthy of investigation.  Each linker 
contained a different sulfonate ester type, an alkyl chain spacer and appropriate 
functionality to allow the attachment to a solid support.  The optimum length of the 
alkyl chain of the linkers (n) was determined by evaluation of the efficiency of 
fluoridolysis of the RLV construct.  [
19F]-Fluoridolysis was carried out at The 
University of Southampton and [
18F]-fluoridolysis by scientists from GE Healthcare at 
The Grove Centre, Amersham.  Small organic molecules were used as the vector 
molecule to establish that the linkers performed as desired and then the newly 
developed linker was applied in a novel synthetic pathway for the synthesis of a known 
radiotracer.     21
Chapter 2  – Linkers 
This chapter covers the development of the synthesis of the 4-alkylphenylsulfonate 
linker.  This was used to synthesise RLV constructs of varying linker lengths.  Solution 
phase model studies determined that the second linker type to be developed was the 4-
nitrophenylsulfonate linker and the synthesis of this linker is presented.  RLV constructs 
of both linker types were synthesised with multiple vector molecules. 
 
2.1  Synthesis of the 4-alkylphenylsulfonate linker 
2.1.1  Development of linker synthesis 
The 4-alkylphenylsulfonate linker was synthesised using 6-phenylhexanoic acid (2.01) 
as the starting material, which would produce a linker with an alkyl chain length of five 
methylene units.  This commercially available starting material was chosen as it 
contained a carboxylic acid group for attachment to the solid support and a benzene ring 
which would permit the introduction of the sulfonyl chloride functionality, and thence 
the vector molecule. 
 
 
Scheme 2.1  Reagents and conditions: a) TMSCl, MeOH, 0 °C; b) i) ClSO2OH, 
CH2Cl2, 0 °C to rt, ii) AcCl, MeOH, CH2Cl2, 0 °C; c) Neopentyl alcohol, NaHMDS, 
THF. 
 
The first step in the synthesis was the protection of 6-phenylhexanoic acid (2.01) to give 
methyl ester 2.02 which was carried out in quantative yield using chlorotrimethylsilane 
in methanol following the procedure of Hanessina et al. (Scheme 2.1).
59  This reaction 
was shown to proceed very cleanly by 
1H NMR and so crude methyl ester 2.02 could be     22
used in subsequent reactions without further purification.  Methyl ester 2.02 was 
converted directly into sulfonyl chloride 2.03 using excess chlorosulfonic acid 
following the procedure of Shirley et al. although the yield was only 45%.
60  The use of 
an excess of chlorosulfonic acid in this reaction is important as the intermediate sulfonic 
acid can be prepared using the same reagent and is then converted to the chloride with 
the extra equivalents of the reagent.
61  In an attempt to improve the yield of this reaction 
a different strategy was tested whereby methyl ester 2.02 was first transformed into the 
corresponding sulfonic acid using a single equivalent of chlorosulfonic acid
62 or using 
concentrated sulfuric acid
63 and then converted to sulfonyl chloride 2.03 using 
phosphorus pentachloride.
63  The sulfonic acid was found to be very difficult to handle 
and so was not isolated before the second step and the crude reaction mixture was 
carried through.  Although an overall yield of 19% of the desired sulfonyl chloride 2.03 
was achieved over the two steps, this result was not an improvement on the original 
method. 
 
On re-examination of the original reaction conditions it was found that the reaction had 
given 45% of the desired sulfonyl chloride 2.03 along with 30% of the desired product 
where the methyl ester had been hydrolysed to the free acid.  Acetyl chloride in 
methanol had been used in the literature for carboxylate ester formation from the 
corresponding free acid
64 and so a second step was added to the transformation whereby 
the crude reaction mixture from the first step was exposed to acetyl chloride and 
methanol.  This converted the free acid by-product to the methyl ester and gave the 
desired sulfonyl chloride 2.03 in an improved 68% yield over two steps.  Sulfonyl 
chloride 2.03 was then reacted with neopentyl alcohol to give sulfonate ester 2.04, albeit 
in very poor yield.  This result showed the attachment of a vector molecule to this linker 
to be viable although it indicated that the conditions for the sulfonate ester formation 
needed some work. 
 
Sulfonyl chloride 2.03 was then reacted with 3-phenyl propan-1-ol (2.05) which was 
chosen because it represented a more realistic example of vector molecule that could be 
investigated in the cleavage reaction with [
19F]-fluoride.  The reaction was carried out 
using varying equivalents of sulfonyl chloride 2.03 and alcohol 2.05 as well as a range 
of reagents and conditions (Table 2.1).  Alcohol 2.05 and the desired product, sulfonate 
ester 2.06, were found to be extremely difficult to separate by chromatography (entry 3)     23
and so subsequent reactions were carried out using the alcohol as the limiting reagent.  
The best conditions were found to be entry 5 using sulfonyl chloride 2.03 (2 eq), alcohol 
2.05 (1 eq) and triethylamine (2.5 eq) at reflux which gave the highest yield of product 
whilst limiting the amount of excess sulfonyl chloride 2.03 used.  Attempts to further 
reduce the number of equivalents of sulfonyl chloride 2.03 used in the reaction gave 
either a decrease in yield (entry 6) or inseparable mixtures where the reaction had not 
gone to completion (entries 7 & 8). 
 
 
Entry  Sulfonyl 
chloride 2.03 
Alcohol 
2.05 
Reagents and 
conditions 
Yield of 2.06 
1  1 eq  1 eq
a  Et3N/1 eq, 3.25 h 
then NaHMDS/1 
eq, rt, 21 h 
17% 
2  1 eq  1.2 eq
a  Pyridine/4 eq, 20 h  32% 
3 1  eq 1eq
a  Pyridine/4 eq, 
DMAP/0.1 eq, rt 
38 mg mixture of  2.05 
and 2.06 plus 2% 2.03 
4  3 eq  1 eq
c  Et3N/2.5 eq 3 h 
then at 50 °C for 
5.5 h 
85% 
plus 40 % of starting 
2.03 
5  2 eq  1 eq
b  Et3N/2.5 eq at 50 
°C for 7 h 
82% 
plus 11 % of starting 
2.03 
6  1.5 eq  1 eq
a  Et3N/2.5 eq at 50 
°C for 7.5 h 
36% 
plus 15 % of starting 
2.03 
7  1.2 eq  1 eq
b  Et3N/2.5 eq at 50 
°C for 24 h 
13 mg mixture of 2.06 
& 2.03 
8  1 eq  1 eq
b  Et3N/2.5 eq at 50 
°C for 7 h 
60 mg mixture of 2.06 
& 2.05 plus 4% 2.06  
and 3% of starting 2.03 
Table 2.1  Effect of number of equivalents of starting materials and the reagents and 
conditions on the outcome of the sulfonate ester formation reaction. 
aReaction carried out on a <25 mmol scale.  
bReaction carried out on a 0.25-0.50 mmol 
scale.  
cReaction carried out on a >0.50 mmol scale.     24
An enzyme mediated method using Novozym 435® was employed for the hydrolysis of 
methyl ester 2.06 to give free acid 2.07 in moderate yield along with 22% recovered 
unreacted ester (Scheme 2.2).  The procedure was developed previously in the group by 
Thomas Logothetis
65 as a mild method for the orthogonal deprotection of carboxylic 
acids.  A neutral phosphate buffer was present in the reaction mixture to prevent the 
solution becoming acidic on generation of the free acid which would cause degradation 
of the enzyme and eventually stop the reaction.
66 
 
 
Scheme 2.2  Reagents and conditions: a) Novozym 435®, aq phosphate buffer (pH 7), 
CH2Cl2/acetone/Et2O, 50 °C; b) Benzylamine, HOBt, DIC, CH2Cl2; c) Amino methyl 
polystyrene resin, HOBt, DIC, DMF/CH2Cl2. 
*Calculated from the theoretical mass gain using the loading of the unfunctionalised 
resin and the observed mass gain of the product resin. 
 
A solution phase equivalent to the RLV construct was then prepared by reacting acid 
2.07 with benzylamine (a solution phase analogue of amino methyl polystyrene resin) 
under standard coupling conditions to give amide 2.08.  This showed the attachment of 
the linker-vector portion to the solid phase to be viable.  The poor yield of this     25
unoptimised reaction was of no great concern as when this step is transferred to the 
solid phase it will employ an excess of reagents relative the amount of resin.  This 
would drive the reaction to completion and the excess reagents could then be easily 
removed during the workup by a simple filtration.  Acid 2.07 was then attached to a 
solid support in the form of amino methyl polystyrene resin using the same conditions 
employed in the solution phase but using excess reagents.  After gentle stirring for 19 h 
at room temperature a ninhydrin test on a small sample of resin was negative indicating 
that the coupling had been successful as there was no primary amine functionality 
remaining on the resin.  The MAS 
1H and 
13C NMR spectra of the resin were obtained 
to confirm that resin 2.09 had been formed. 
 
 
Scheme 2.3  Reagents and conditions: a) ClSO2OH, CH2Cl2, 0 °C to rt; b) 3-Phenyl 
propan-1-ol, pyridine, CH2Cl2. 
 
The synthesis of acid 2.07 was also investigated using unprotected 6-phenylhexanoic 
acid (2.01) as this route would save two transformations in the synthetic pathway.  The 
chlorosulfonation reaction of acid 2.01 to form acid 2.10 proceeded in a reduced yield 
(54% down from 68% with the methyl ester equivalent) although the second step using 
acetyl chloride was of course not necessary (Scheme 2.3).  The sulfonate ester 
formation reaction gave greatly reduced yields and was less clean due to the formation 
of by-products including the product of the reaction of the carboxylic acid group with 
the alcohol to give ester 2.11.  The lower yields and extra by-products minimised the     26
potential advantage of losing the protection/deprotection steps and so this route was not 
pursued further. 
 
Cleavage of the vector molecule from sulfonate ester 2.06 and amide 2.08 was 
attempted using potassium fluoride as the source of [
19F]-fluoride in the presence of the 
phase-transfer agent Kryptofix [2.2.2] (1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo 
[8.8.8] hexacosan) following the procedure described previously by the Brown group 
(Scheme 2.4).
33  In both cases, an inseparable mixture of the corresponding sulfonic 
acid (2.12 or 2.13) and Kryptofix [2.2.2] were isolated from the crude product but the 
labelled vector, 3-fluoropropylbenzene, was not isolated.  The boiling point of 3-
fluoropropylbenzene has been reported to be 45-46 °C/3 mm
67 so it was thought that 
any fluorinated product that may have formed had been lost either during the reaction or 
when the crude or purified product was dried under vacuum. 
 
 
Scheme 2.4  Reagents and conditions: a) KF, Kryptofix [2.2.2], MeCN, reflux. 
 
Due to the volatility of 3-fluoropropylbenzene, alcohol 2.05 had clearly been a poor 
choice of model to test the RLV approach.  So that the fluoridolysis could be 
investigated, a different vector molecule with a higher molecular weight was required so 
that the fluorinated vector could be more easily detected. 
 
2.1.2  (4-Hydroxy butyl) phenyl carbamic acid tert-butyl ester as vector molecule 
(ω-Fluoroalkyl)phenylamines have been used as model systems by GE Healthcare when 
investigating tracers for functional imaging with 
18F PET scanners.  Accordingly, these 
less volatile targets were selected as vector molecules to use in the development and 
testing of the new linkers for the RLV strategy.  The synthesis of (4-hydroxy butyl) 
phenyl carbamic acid tert-butyl ester (2.14) was developed previously by Thomas     27
Logothetis as a straightforward, two step procedure starting from aniline and 4-
chlorobutanol, affording product in moderate yield.
65 
 
The reaction of sulfonyl chloride 2.03 with alcohol 2.14 using the previously optimised 
conditions gave a disappointing yield of 53% of sulfonate ester 2.15.  After 
investigating this reaction further it was found that the yield could be greatly improved 
by the addition of a catalytic amount of DMAP to the reaction mixture.  Test reactions 
also showed there to be no need to reflux the reaction mixture as the same yield was 
achieved when the reaction was carried out at room temperature and these new 
conditions resulted in an improved yield of 81% of sulfonate ester 2.15 (Scheme 2.5).  
The fluoridolysis was first attempted in solution phase to establish whether the new 
vector molecule could be detected and pleasingly the desired fluoride 2.18 was easily 
isolated in moderate yield. 
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Scheme 2.5  Reagents and conditions: a) Sulfonyl chloride 2.03 (1.2 eq), Et3N, DMAP, 
CH2Cl2; b) Novozym 435®, aq phosphate buffer (pH 7), CH2Cl2/acetone, 50 °C; c) 
Amino methyl polystyrene resin, HOBt, DIC, DMF/CH2Cl2; d) KF, Kryptofix [2.2.2], 
MeCN, reflux. 
*Calculated from the theoretical mass gain using the loading of the unfunctionalised 
resin and the observed mass gain of the product resin. 
 
The enzymatic hydrolysis was carried out as before to give free acid 2.16 which was 
then coupled to amino methyl polystyrene resin using the standard conditions to give     28
resin 2.17.  The solid phase fluoridolysis was carried out using resin 2.17, the resin was 
then removed by filtration and the crude reaction mixture was passed through a plug of 
silica to remove the Kryptofix and gave the desired fluorinated vector, fluoride 2.18 (the 
low yield of this reaction would be optimised during the radiochemistry experiments).  
This showed the 4-alkylphenylsulfonate linker to work as required in regards to the 
attachment of the vector molecule to the solid phase and the subsequent cleavage to give 
the labelled vector molecule. 
 
2.1.3  Synthesis of shorter 4-alkylphenylsulfonate linkers 
Previous studies as part of the synthesis of a solid supported precursor to [
18F]-FDG 
showed that altering the chain length of the linker had an effect on the radiochemical 
yield of the fluorinated vector.
33  The 4-alkylphenylsulfonate linker synthesised to date 
had an alkyl chain of five methylene units so we wanted to synthesise linkers with 
shorter alkyl spacers from commercially available starting materials by the same 
pathway.  The efficiency of fluoridolysis of these linkers could then be compared and 
the optimum linker length could be determined based on the fluorination yield and 
efficiency of synthesis. 
 
 
Scheme 2.6  Reagents and conditions: a) TMSCl, MeOH, 0 °C; b) i) ClSO2OH, 
CH2Cl2, 0 °C to rt, ii) AcCl, MeOH, CH2Cl2 0 °C; c) Alcohol 2.14, Et3N, DMAP, 
CH2Cl2; d) Novozym 435®, aq phosphate buffer (pH 7), CH2Cl2/acetone, 50 °C; e) 
Amino methyl polystyrene resin, HOBt, DIC, DMF/CH2Cl2. 
*Calculated from the theoretical mass gain using the loading of the unfunctionalised 
resin and the observed mass gain of the product resin. 
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4-Alkylphenylsulfonate linkers with shorter alkyl chain lengths of three and one 
methylene unit were synthesised from commercially available acids 2.19 and 2.25, 
respectively, following the synthetic pathway developed for the longer linker (Scheme 
2.6 and Scheme 2.7). 
 
Firstly, the carboxylic acid groups were protected as the corresponding methyl esters in 
good to quantative yields to give methyl esters 2.20 and 2.26, respectively.  These were 
then converted into the sulfonyl chlorides using the optimised two step procedure which 
gave sulfonyl chloride 2.21 in good yield, although the yield for sulfonyl chloride 2.27 
was significantly lower.  This was thought to be due to the increased reactivity of 
sulfonyl chloride 2.27 because of the shorter alkyl chain length, which made the product 
less stable.  However, the increased reactivity of sulfonyl chloride 2.27 meant that the 
original conditions (without the use of DMAP) were used in the formation of sulfonate 
ester 2.28 and a yield of 83% was obtained, while sulfonate ester 2.22 was formed in a 
slightly higher yield with the addition of DMAP to the reaction mixture.  The methyl 
esters were deprotected in moderate to good yields and the resulting free acids 2.23 and 
2.29 were coupled to the solid support to give resins 2.24 and 2.30. 
 
 
Scheme 2.7  Reagents and conditions: a) TMSCl, MeOH, 0 °C; b) i) ClSO2OH, 
CH2Cl2, 0 °C to rt, ii) AcCl, MeOH, CH2Cl2, 0 °C; c) Alcohol 2.14, Et3N, CH2Cl2, 
reflux; d) Novozym 435®, aq phosphate buffer (pH 7), CH2Cl2/acetone, 50 °C; e) 
Amino methyl polystyrene resin, HOBt, DIC, DMF/CH2Cl2. 
*Calculated from the theoretical mass gain using the loading of the unfunctionalised 
resin and the observed mass gain of the product resin.     30
2.2  Solution phase model studies 
Solution phase model studies were carried out to determine the identity of the next 
linker type for synthesis.  The efficiency of the sulfonate ester forming reaction and the 
subsequent fluoridolysis of the developed 4-alkylphenysulfonate linker was compared 
to some model solution phase linker types.  Sulfonate esters with tosylate, nosylate and 
mesylate functionality were synthesised from the appropriate sulfonyl chloride using (4-
hydroxy butyl) phenyl carbamic acid tert-butyl ester (2.14) as the vector molecule.   
These linker models were chosen as they were expected to have varying reactivity’s.  
The tosylate group was expected to have a similar reactivity to the 4-
alkylphenylsulfonate linker.  The nosylate group was expected to be more reactive than 
the 4-alkylphenylsulfonate linker due to the electron withdrawing effect of the nitro 
group in the para position on the phenyl ring.  The mesylate group was chosen so that a 
comparison could be made with a linker that did not contain a phenyl ring. 
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Sulfonate Ester Formation  Fluoridolysis  Entry  Sulfonate 
ester  Reaction 
time 
Yield  Sulfonyl chloride 
recovered 
Reaction 
time 
Yield 
1  2.15  16 h  35%  32%  1 h  48% 
2  2.31  16 h  47%  31%  45 min  64% 
3  2.32  1.5 h  49%  46%  30 min  62% 
4  2.33  1.5 h  69%  -  3.5 h  75% 
Table 2.2  Reaction details for the solution phase model studies. 
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Tosylate  2.31 (Table 2.2, entry 2) was formed in a similar reaction time as the 4-
alkylphenylsulfonate linker, sulfonate ester 2.15 (Table 2.2, entry 1), while nosylate 
2.32 and mesylate 2.33 required significantly shorter reaction times (Table 2.2, entries 3 
& 4).  The yields for the sulfonate ester formation were slightly better with the solution 
models than with the developed linker, with the best yield occurring with the mesylate.  
The recovery of the excess sulfonyl chloride starting material was reasonable in most 
cases. 
 
Fluoridolysis reactions using the standard conditions of potassium fluoride and 
Kryptofix [2.2.2] were carried out with each sulfonate ester, using HPLC to monitor the 
rates of the reactions.  Unfortunately, a reliable HPLC method could not be developed 
and so the reactions were compared on the basis of reaction time and yield only.   
Tosylate 2.31 was expected to give similar results for the fluoridolysis to those obtained 
for sulfonate ester 2.15 and gave fluoride 2.18 in a slightly higher yield after a similar 
reaction time.  Nosylate 2.32 gave the same yield of fluoride 2.18 as the tosylate but 
required a shorter reaction time, as anticipated, due the electron withdrawing effect of 
the nitro group.  Mesylate 2.33 gave the best yield of fluoride 2.18 although it required a 
longer reaction time of three and a half hours, which could be impractical if the reaction 
was to be carried out under radiochemical conditions due to the half-life of 
18F (t1/2 = 
109.8 min). 
 
It was decided that the next linker type to be investigated as part of this project should 
be the nosylate type linker on the basis of the increased rates of fluoridolysis and yield.  
This was because a linker mimicking a nosylate leaving group would offer a more 
reactive alternative to the 4-alkylphenylsulfonate linker already developed. 
 
2.3  Synthesis of the 4-nitrophenylsulfonate linker 
2.3.1  Development of linker synthesis 
The synthesis of a 4-nitrophenylsulfonate linker, with the nitro group in the para 
position and the carbonyl functionality in the meta position relative to the sulfonate 
group, was developed.  A similar nosylate linker with the nitro group and carbonyl 
functionality in the ortho and para positions, respectively, had been previously     32
synthesised by Thomas Logothetis on an earlier project for GE Healthcare and some of 
the same reaction conditions were used in the synthesis of this new nosylate type 
linker.
65  Earlier work showed that the conversion of the disulfide species to the 
corresponding sulfonyl chloride gave a greatly reduced yield in comparison with 
starting with the methyl sulfide and so the perhaps more efficient use of 5,5’-
dithiobis(2-nitrobenzoic acid) (2.34) as the starting material was discounted.  Instead, 5-
chloro-2-nitrobenzoic acid (2.35) was chosen as the starting material for the synthesis 
(Figure 2.1) and it was thought that the sulfonyl chloride functionality could be easily 
introduced at the desired 5-position via the methyl sulfide. 
 
 
Figure 2.1  Possible starting materials in the synthesis of the 4-nitrophenylsulfonate 
linker, 5,5’-dithiobis(2-nitrobenzoic acid) (2.34) and 5-chloro-2-nitrobenzoic acid 
(2.35). 
 
6-Aminohexanoic acid (2.36) was converted into methyl ester 2.37 in quantative yield 
following the procedure of Lin et al. (the hydrochloric acid salt was formed in the same 
step to prevent cyclisation of the product).
68  Benzoic acid 2.35 was converted in 
excellent yield to acid chloride 2.38 using the standard conditions of thionyl chloride in 
benzene.  The use of benzene as a reaction solvent is to be avoided if possible, so the 
reaction was also carried out in dichloromethane although a reduced yield of 68% was 
obtained.  Both these high yielding reactions were found to give very clean conversions 
and the products could be used either without purification or after recrystallisation 
(Scheme 2.8).  The coupling between methyl ester 2.37 and acid chloride 2.38 using 
Hünig’s base gave the nosylate linker backbone in chloride 2.39 in high yield after 
recrystallisation.   
 
Alternatively, chloride 2.39 could be synthesised directly by the coupling of methyl 
ester 2.37 with benzoic acid 2.35 using carbodiimide coupling conditions.  This direct 
reaction was found to give the same yield of chloride 2.39 as the two-step pathway     33
although it was necessary to purify the product by lengthy column chromatography to 
remove the close running urea by-product.  The use of a water soluble coupling agent 
could possibly simplify the purification of chloride 2.39 although this was not 
attempted. 
 
HO
O
O2N
Cl
2.35
HO
O
NH2 MeO
O
NH2.HCl
Cl
O
O2N
Cl
2.38
N
H
O
O2N
Cl
2.39
MeO
O
2.36 2.37
a
99%
b
91%
c
89%
d
81%
 
Scheme 2.8  Reagents and conditions: a) SOCl2, MeOH, 0 °C to rt; b) SOCl2, benzene, 
reflux; c) DIPEA, dioxane, 70 °C; d) Methyl ester 2.37, HOBt, DIC, DIPEA, 
DMF/CH2Cl2. 
 
Chloride 2.39 was reacted with sodium thiomethylate under phase transfer conditions to 
give methyl sulfide 2.40 in good yield (Scheme 2.9).  Efforts to convert methyl sulfide 
2.40 into the corresponding sulfonyl chloride using an excess of chlorine gas and glacial 
acetic acid
69 only gave a trace of the desired product although the intermediates that 
were isolated from the reaction give an insight into a possible alternative mechanism for 
the oxidative chlorination reaction which will be discussed later.  The addition of small 
quantities of distilled water to the reaction mixture, which some authors employed in 
this reaction,
70,71 was found not to improve the outcome and was suspected to cause 
hydrolysis of the methyl ester.  It was thought that the electron withdrawing effect of 
the para nitro group was making the methyl sulfide less nucleophilic towards oxidative 
chlorination.   
 
Benzyl sulfides have been used under these reaction conditions to give sulfonyl 
chlorides in excellent yields
71 and so the corresponding benzyl sulfide 2.41 was 
synthesised and was obtained in high yield from chloride 2.39 using benzyl mercaptan     34
and sodium hydroxide under phase transfer conditions.  It was suspected that poisoning 
of the phase transfer catalyst, tetrabutylammonium chloride, was occurring during the 
course of the reaction as 
1H NMR monitoring of the reaction showed the ratio of 
starting chloride 2.39 and product benzyl sulfide 2.41 to remain constant after several 
days in the presence of the other reagents.  This was overcome by working the reaction 
up and then subjecting the crude product to the same reaction conditions using fresh 
reagents.  The oxidative chlorination of benzyl sulfide 2.41 was successful to yield 62% 
of the desired sulfonyl chloride 2.42. 
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Scheme 2.9  Reagents and conditions: a) NaSMe, Bu4NCl, CH2Cl2/H2O, 30-35 °C; b) 
BnSH, NaOH, Bu4NCl, CH2Cl2/H2O, 30-35 to 55 °C; c) Cl2, AcOH. 
 
Sulfonyl chloride 2.42 was successfully reacted with vector molecule alcohol 2.14 to 
give sulfonate ester 2.43 in good yield (Scheme 2.10).  The enzyme mediated hydrolysis 
using Novozym 435®, as used previously for the analogous transformation with the 4-
alkylphenylsulfonate linker in moderate to good yields, worked less satisfactory with 
the 4-nitrophenylsulfonate linker.  The hydrolysis of sulfonate ester 2.43 under the 
established conditions gave only 25% of the desired free acid 2.44 and 57% recovered 
starting material.  The conversion of the reaction was found to be no better when the 
reaction time was increased to four days.  A range of different esterases, sourced from 
Amano Enzyme Inc (Lipase AY “Amano” 30, Lipase PS “Amano” and Lipase AK 
“Amano” 20) were trialled in the hydrolysis reaction under the same conditions to see if     35
an improvement in the yield could be achieved.  However, analysis of the reaction 
mixtures (by TLC) found no product to have formed with any of these other enzymes.  
An alternative procedure for the use of Novozym 435® using acetonitrile
72 instead of 
CH2Cl2/acetone as the organic solvent was tested.  Once again these conditions were 
found not to give the desired product and isolated from the reaction mixture was alcohol 
2.14 from the undesired hydrolysis of the vector molecule.  The reasons behind the 
lower yield for the enzyme mediated hydrolysis of the 4-nitrophenylsulfonate linker 
remain unknown.  Acid 2.44 was successfully coupled to amino methyl polystyrene 
resin to give resin 2.45. 
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Scheme 2.10  Reagents and conditions: a) Alcohol 2.14, Et3N, DMAP, CH2Cl2; b) 
Novozym 435®, aq phosphate buffer (pH 7), CH2Cl2/acetone, 50 °C; c) Amino methyl 
polystyrene resin, HOBt, DIC, DMF/CH2Cl2. 
*Calculated from the theoretical mass gain using the loading of the unfunctionalised 
resin and the observed mass gain of the product resin. 
 
2.3.2  Oxidative chlorination mechanism 
The specific mechanism for the formation of sulfonyl chlorides by oxidative 
chlorination using chlorine gas in glacial acetic acid has not been published in the 
literature although the identity of the likely intermediates in the mechanistic pathway 
has been discussed in some detail by Douglass et al.
69  They found that when forming     36
sulfinyl chlorides from mercaptans or disulfides the stoichiometry of the chloride and 
the acetic acid was very important in determining the outcome of the reaction (two 
equivalents of chlorine and one equivalent of acetic acid are required for each 
equivalent of mercaptan or disulfide).  If less then the required amount of chloride was 
used then the product was found to be contaminated with the sulfenyl chloride 
(Langler
71 also proposed that sulfenyl chloride was an intermediate in the formation of 
sulfonyl chloride from benzyl methyl sulfide although, unlike Douglass, was not able to 
provide experimental evidence to support this theory).  If less than one equivalent of 
acetic acid was used then some sulfur trichloride was formed, which implies that the 
oxygen in the sulfinyl chloride is derived from the acetic acid used in the reaction.  If 
more than two equivalents of chlorine and an excess of acetic acid were used then some 
of the sulfinyl chloride was converted to the sulfonyl chloride.  If wet or aqueous acetic 
acid is used then it is likely that water rather than acetic acid may provide the final 
oxygen atom to give the sulfonyl chloride. 
 
Taking account of all of these observations, it is likely that the mechanism for the 
oxidative chlorination of alkyl sulfides to give sulfonyl chlorides goes by the stepwise 
formation of the sulfenyl chloride and the sulfinyl chloride.  The alkyl sulfide first 
reacts with one equivalent of chlorine to give the sulfenyl chloride with loss of the 
methyl group by attack of chloride in a manner similar to that seen in the Arbuzov 
reaction.  The sulfenyl chloride then reacts with the second equivalent of chlorine 
which, in the absence of acetic acid, forms the sulfur trichloride.  In the presence of 
acetic acid, the charged dichloro species reacts with the acetic acid to give the sulfinyl 
chloride.  This reacts with a third equivalent of chlorine and then with either a second 
equivalent of acetic acid or water to give the sulfonyl chloride.  The suggested 
mechanism for the formation of sulfonyl chlorides by oxidative chlorination of methyl 
sulfides based on these literature observations is shown in Scheme 2.11. 
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Scheme 2.11  Proposed mechanism for oxidative chlorination based on information 
from literature sources.
69,71 
 
However, this mechanism does not account for the formation of the intermediates 
isolated from the reaction of methyl sulfide 2.40 under oxidative chlorination conditions 
(Figure 2.2).  The first intermediate was isolated from a clean spot to spot reaction of 
methyl sulfide 2.40 with chlorine in acetic acid was identified as the 
chloromethylsulfoxide (2.46).  This was previously thought to be a by-product of the 
oxidative chlorination reaction
65 but it was found that when re-exposed to the reactions 
conditions some sulfonyl chloride was isolated.  Hence, sulfoxide 2.46 is proposed as an 
intermediate in an alternative mechanistic pathway.  The second intermediate, sulfonyl 
dichloromethane  2.47, was formed when sulfoxide 2.46 was again re-exposed to 
chlorine in acetic acid and continued exposure led to the formation of the sulfonyl 
chloride.  Therefore, sulfonyl dichloromethane 2.47 is thought to be another     38
intermediate rather than a by-product.  The discovery of these intermediates implies that 
the mechanism of the oxidative chlorination of the methyl sulfide in this system 
proceeds via the formation of the chloromethylsulfoxide followed by the sulfonyl 
dichloromethane and from there forms the sulfonyl chloride. 
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Figure 2.2  Intermediates isolated from the reaction of methyl sulfide 2.40 with chlorine 
in acetic acid. 
 
A proposed alternative mechanism that accounts of the formation of the isolated 
intermediates is shown in Scheme 2.12.  First, chlorination of the methyl sulfide occurs 
to form a chlorosulfonium ion as before but instead of the loss of the methyl group to 
give the sulfenyl chloride chlorination of the methyl group occurs.  The 
chlorosulfonium ion loses a proton to form a sulfonium ylid.  The chloride ion is then 
transferred from the sulfur atom to the adjacent carbon atom by the Pummerer 
rearrangement.  This species then reacts with acetic acid give the 
chloromethylsulfoxide.  This reacts with a second equivalent of chlorine and then a 
molecule of acetic acid or water, followed by a second chlorination of the methyl group 
to give the sulfonyl dichloromethane.  A third chlorination of the methyl group then 
takes place and then chloride displaces a trichloromethane ion in an iodoform type 
reaction to give the sulfonyl chloride. 
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Scheme 2.12  Proposed alternative mechanism for oxidative chlorination accounting for 
the formation of the isolated intermediates, the chloromethylsulfoxide and the sulfonyl 
dichloromethane (highlighted in boxes). 
 
The key difference between the two mechanisms is seen in the early steps of the 
mechanistic pathway, the difference being whether the initially formed chlorosulfonium 
ion loses the methyl group to give the sulfenyl chloride or chlorination of the methyl     40
group occurs via the loss of a proton to give the sulfonium ylid followed by chloride 
transfer by the Pummerer rearrangement.  The conditions of the mechanism shown in 
Scheme 2.11 support the SN1 loss of the methyl group.  Since methyl groups are very 
poor in SN1 reactions due to the formation of the unstable methyl cation this would be 
very unfavourable.  Conversely, with the benzyl sulfide, the benzyl group is much more 
prone to loss under SN1 conditions and so this pathway would be favourable.  Benzyl 
ether protecting groups are removed with a nucleophilic conjugate base, normally 
hydrogen bromide in acetic acid.  The conditions for the oxidative chlorination reaction 
are essentially the same as for the deportection of a benzyl group so it would be 
reasonable to presume that the benzyl sulfide reacts via the initial removal of the benzyl 
group and so by the mechanism shown in Scheme 2.11.  The methyl sulfide would more 
readily form the sulfonium ylid, as shown in the mechanism in Scheme 2.12.  Whilst the 
benzyl sulfide would form a stabilised sulfonium ylid (due to the carbanion being 
conjugated into the benzene ring) and so be less reactive by this pathway, the methyl 
sulfide forms an unstabilised sulfonium ylid.  This would be more reactive and so would 
readily undergo a Pummerer rearrangement to chlorinate the methyl group, as shown in 
the mechanism in Scheme 2.12.  While the evidence suggests that the methyl sulfide 
reacts via the mechanism shown in Scheme 2.12, no intermediates were isolated in the 
oxidative chlorination reaction of the benzyl sulfide so we can only speculate that it 
would be more likely to react via the mechanism shown in Scheme 2.11. 
 
2.4  3-(2-Naphthlenoxy)-1-propanol as vector molecule 
The mesylate of 3-(2-naphthlenoxy)-1-propanol has been used as a model compound by 
Chi and co-workers in a range of studies investigating nucleophilic fluorination with 
respect to 
18F labelling
73-76 and so the use 3-(2-naphthlenoxy)-1-propanol (2.48) as a 
vector molecule with the linkers developed as part of the RLV construct would enable 
our results to be compared with solution studies from the literature.  Therefore, resins 
with the 4-alkylphenylsulfonate linker and the 4-nitrophenylsulfonate linker and with 
alcohol 2.48 as the vector molecule were prepared. 
 
Alcohol 2.48 was synthesised in good yield from 2-naphthol and 3-bromo-1-propanol 
following the published procedure.
77  For the 4-alkylphenylsulfonate linker construct, 
alcohol 2.48 was reacted with sulfonyl chloride 2.03 to give sulfonate ester 2.49 in     41
quantative yield (Scheme 2.13).  Sulfonate ester 2.49 was hydrolysed using the 
Novozym 435® to give acid 2.50 in good yield which was coupled to the solid support 
to give resin 2.51.  Similarly for the 4-nitrophenylsulfonate linker construct, alcohol 
2.48 was reacted with sulfonyl chloride 2.42 to give sulfonate ester 2.52 in good yield.  
This was hydrolysed to give acid 2.53 in moderate yield (which was an improvement on 
the yield obtained previously for the enzyme mediated hydrolysis with this linker type, 
Scheme 2.10).  The acid was coupled to the solid support to give resin 2.54. 
 
O HO
O O
S
O
O
R
O
O O
S
O
O
O2N
N
H
O
R
O
2.49 R=O M e
2.50 R=O H
2.51 R= NH
b7 3 %
c8 3 % *
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a
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d
65%
2.52 R=O M e
2.53 R=O H
2.54 R= NH
b5 5 %
e8 8 % *
 
Scheme 2.13  Reagents and conditions: a) Sulfonyl chloride 2.03, Et3N, DMAP, 
CH2Cl2; b) Novozym 435®, aq phosphate buffer, CH2Cl2/acetone, 50 °C; c) Amino 
methyl polystyrene resin, N-hydrosuccinimide, DIC, DMF/CH2Cl2; d) Sulfonyl chloride 
2.42, Et3N, DMAP, CH2Cl2; e) Amino methyl polystyrene resin, HOBt, DIC, 
DMF/CH2Cl2. 
*Calculated from the theoretical mass gain using the loading of the unfunctionalised 
resin and the observed mass gain of the product resin. 
 
As the enzyme mediated hydrolysis of the 4-nitrophenylsulfonate linkers gave poor 
yields of the free acids, more standard hydrolysis conditions of sodium hydroxide in 
methanol/water were tested using sulfonate ester 2.52.  None of the desired acid 2.53 
was isolated from the crude reaction mixture which was found to contain alcohol 2.52 
as a result of the cleavage of the vector molecule and acid 2.55 where the methyl ester 
had been hydrolysed as required but the nitro group had been replaced with a methoxy     42
group (Figure   2.3).  Hence, the necessity of the orthogonal enzyme mediated hydrolysis 
reaction was shown in the synthesis of the 4-nitrophenylsulfonate linkers. 
 
 
Figure    2.3  Undesired products isolated from the hydrolysis the methyl ester of 
sulfonate ester 2.52 under standard conditions. 
 
The observation of the substitution of the nitro group via a SNAr reaction to give acid 
2.55 highlighted a possible problem with the 4-nitrophenylsulfonate linker when used to 
immobilise a precursor for use in [
18F]-fluoridolysis reactions.  The nitro group has been 
to shown to be a better leaving group than halogens in nucleophilic displacement 
reactions using [
18F]-fluoride to give labelled aryl fluorides.
78  This transformation was 
used in the synthesis of [
18F]-FDOPA (discussed in Chapter 1, Section 1.5) and [
18F]-
flumazenil which used a precursor containing an aryl nitro group to give the desired 
product with an [
18F]-fluoride incorporation of 55-60% (Scheme 2.14).
79  I f  t h e  
nucleofugicity of the nitro group on the linker is similar to that of the sulfonate then the 
fluoridolysis reaction may be complicated by fluorination on the linker itself rather than 
cleavage of the vector. 
 
 
Scheme 2.14  The synthesis of [
18F]-flumazenil via the nucleophilic fluorination of the 
nitro analogue.
79  Reagents and conditions: a) [K/K2.2.2]
+ 
18F
−, DMF, 160 °C. 
 
2.5  Conclusions 
The synthesis of a 4-alkylphenylsulfonate linker was developed and applied to produce 
a range of resins containing this linker type with varying lengths of alkyl spacer and (4-    43
hydroxy-butyl)-phenyl-carbamic acid tert-butyl ester (2.14) as the vector molecule.  A 
solution model study was carried out to investigate the efficiency of the sulfonate ester 
formation and subsequent [
19F]-fluoridolysis for various sulfonate ester types to 
determine the second linker type for development.  The nosylate gave the most 
promising results and so the synthesis of a 4-nitrophenylsulfonate linker was developed.  
Difficulties with the oxidative chlorination reaction to give the sulfonyl chloride were 
overcome by the replacement of a methyl sulfide with a benzyl sulfide as the starting 
material in this reaction and the mechanism for this transformation was discussed.   
Resins containing the 4-alkylphenylsulfonate and the 4-nitrophenylsulfonate linker type 
and 3-(2-naphthlenoxy)-1-propanol (2.48) as the vector molecule were prepared so that 
the results of the fluoridolysis reaction could be compared with those published for this 
vector molecule. 
 
The results of the [
19F]- and [
18F]-fluoridolysis of all the of the resins synthesised in this 
chapter, along with a comparison of the results using the 3-(2-naphthlenoxy)-1-propanol 
vector with the literature, are presented in Chapter 3. 
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Chapter 3  – [
19F] Experiments and [
18F] Radiolabelling 
This chapter covers all of the [
19F]-fluoride experiments carried out with the range of 
resins developed as part of this project, the synthesis of which was discussed in Chapter 
2.  Following this, the results of the [
18F]-fluoridolysis reactions are presented and 
discussed for which we gratefully acknowledge Imtiaz Khan of GE Healthcare for 
carrying out these experiments. 
 
3.1  Solid phase fluoridolysis of RLV constructs containing the two linker types 
The [
19F]-fluoridolysis of the resins utilising the RLV construct was carried out using 
potassium fluoride as the source of [
19F]-fluoride and Kryptofix [2.2.2] in acetonitrile at 
80 °C to give [
19F]-2.18 or [
19F]-2.57 after a reaction time of 30 min.  Purification of the 
fluorinated products involved filtration of the reaction mixture to remove the resin 
followed by elution through a short silica column to remove the Kryptofix [2.2.2].  The 
yields of the fluorinated products were calculated based on the loading of the resin used 
(the loadings were estimated from the results of the elemental analyses of sulfur for the 
individual resins). 
 
All of the resins were found to yield the desired fluorinated product as the only major 
product isolated from the reaction mixture showing the RLV construct to work as 
intended.  Resins 2.17,  2.24 and 2.30, with the 4-alkylphenylsulfonate linker, gave 
consistent yields of [
19F]-2.18 for the three linker lengths (Table 3.1).  The yields were 
congruent with what would be expected for nucleophilic fluorination reactions.   
Radiochemistry experiments would be carried out using a large excess of resin relative 
to the amount of [
18F]-fluoride and so would result in good radiochemical yields for the 
fluoridolysis.  Resin 2.45 with the 4-nitrophenylsulfonate linker gave a lower yield of 
[
19F]-2.18 than with the other linker type which was surprising as the nosylate 
mimicking linker was expected to be more reactive.  Similarly, for the 3-(2-
naphthlenoxy)-1-propanol vector molecule, resin 2.51, with the 4-alkylphenylsulfonate 
linker, yielded about twice as much fluorinated product ([
19F]-2.57) than resin 2.54, 
with the 4-nitrophenylsulfonate linker (Table   3.2).  Higher yields were obtained for this 
vector than the (4-hydroxy butyl) phenyl carbamic acid tert-butyl ester vector for both     45
linker types which may be due to the structure of the vector molecule being more 
lipophilic and easier to manipulate. 
 
 
Resin  Structure and loading  Yield of 
[
19F]-2.18 
2.17 
 
0.80 mmolg
−1 
28% 
2.24 
 
0.81 mmolg
−1 
28% 
2.30 
 
0.95 mmolg
−1 
27% 
2.45 
 
0.58 mmolg
−1 
13% 
Table 3.1  Results of the [
19F]-fluoridolysis of the resins with the (4-hydroxy butyl) 
phenyl carbamic acid tert-butyl ester vector molecule. 
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Resin  Structure and loading  Yield of 
[
19F]-2.57 
2.51 
 
0.67 mmolg
−1 
37% 
2.54  O O
S
O
O
O2N
N
H
O H
N
O
 
0.66 mmolg
−1 
22% 
Table   3.2  Results of the [
19F]-fluoridolysis of the resins with the 3-(2-naphthlenoxy)-1-
propanol vector molecule. 
 
Chi and co-workers used the mesylate of 3-(2-naphthlenoxy)-1-propanol (2.58) as a 
model compound in studies investigating new methods of nucleophilic fluorination 
using ionic liquids,
75,76 protic solvents
73 and tertiary alcohols.
74  They carried out the 
fluorination of mesylate 2.58 using standard conditions so that a comparison could be 
made with results using their new reaction conditions.  They reported that the reaction 
of mesylate 2.58 with potassium fluoride and 18-crown-6 (a crown ether reagent, 
similar to Kryptofix [2.2.2]) in acetonitrile at 100 °C for 24 h gave [
19F]-2.57 in a 40% 
yield after extraction of the reaction mixture into organic solvent followed by column 
chromatography (Scheme   3.1).
75  This result is comparable to the yield obtained from 
the fluoridolysis of resin 2.51, although our solid phase reaction required a much shorter 
reaction time (30 min) and a far simpler workup and purification procedure.  
 
 
Scheme   3.1  Fluorination of mesylate 2.58 using standard conditions as carried out by 
Chi et al.
75  Reagents and conditions: a) KF, 18-crown-6, MeCN, 100 °C, 24 h. 
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3.2 
19F NMR Kinetic study 
A 
19F NMR kinetic study was carried out to compare the relative rates of fluoridolysis 
for resins containing the RLV constructs with the three different length 4-
alkylphenylsulfonate linkers (resins 2.17,  2.24 and 2.30) and the resin with the 4-
nitrophenylsulfonate linker (resin 2.45).  Previous work in the group on a RLV 
construct designed to release protected [
18F]-fluoro-2-deoxy-D-glucose ([
18F]-FDG) 
from a perfluoroalkylsulfonate linker found that the radiochemical yield was affected by 
altering the chain length of the linker.  A steady rise in radiochemical yield was 
observed with increasing linker length up to a point where any further increase in linker 
length resulted in no additional improvement in the yield of the product.
33,34  Hence, we 
wanted to investigate if the linker chain length of resins with the 4-alkylphenylsulfonate 
linker had an effect on the rate of cleavage of the fluorinated product and to see if 
changing the linker type to the 4-nitrophenylsulfonate linker (which was thought to be 
more reactive) would have an effect on the rate of cleavage. 
 
To establish the feasibility of the use of 
19F NMR spectroscopy to monitor the 
fluoridolysis and to investigate the conditions for the reactions, a series of trial reactions 
was first carried out.  A reaction mixture containing 50 mg of resin 2.30 and an excess 
of potassium fluoride and Kryptofix [2.2.2] in deuterated acetonitrile was made up in an 
NMR tube and 
19F NMR spectra were acquired as the reaction progressed.  The 
fluoridolysis reactions are usually carried out at 80 °C but were also shown in test 
reactions to proceed at room temperature, albeit at a reduced rate.  As a temperature of 
80 °C was too high to be maintained by the NMR probe the first trial reaction was 
carried out at room temperature.  The concentration of [
19F]-fluoride 2.18 formed in the 
reaction was calculated by comparison of the size of the 
19F NMR peak due to [
19F]-
fluoride 2.18 (−218 ppm) with that of the internal standard (hexafluorobenzene, −162 
ppm), which was present in the deuterated acetonitrile at a known concentration. 
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Figure    3.1  Graph to show the results of the first trial reaction carried out at room 
temperature. 
 
The results of the first trial reaction (Figure   3.1) showed an increase in product 
concentration with time up to 3090 min (51.5 h) at which point it was assumed that the 
reaction had gone to completion.  This showed that it was feasible to investigate the 
kinetics of the reaction using 
19F NMR spectroscopy although some optimisation of the 
procedure was necessary.  As the reaction took over two days for the product 
concentration to remain constant it was clear that the use of an elevated temperature 
would be necessary so that the reaction was complete within a more reasonable 
timescale.  This would also allow the acquisition of 
19F NMR spectra at more regular 
intervals during the reaction giving a more even data set.  The hexafluorobenzene 
internal reference peak occurs at −162 ppm which coincided with an unavoidable bump 
in the baseline of the 
19F NMR spectrum.  This broad bump in the baseline, occurring 
over the range −150 to −200 ppm, appears in the blank spectra so is not related to the 
reaction mixture.  It originates from components within either the spectrometer or the 
probe which contain fluorine nuclei.  These fluorine containing components are solid 
and so result in an unavoidable broad bump in the baseline of the spectra (similar issues 
are observed with boron NMR as the tubes and other glass components are made of 
borosilicate glass).  This bump in the baseline would affect the accuracy of the 
integration of the reference peak and so an alternative internal reference compound was     49
sought.  Commercially available trifluorotoluene has a 
19F NMR chemical shift of −63 
ppm
80 which did not coincide with the bump on the baseline although it was considered 
to be too far away from the chemical shift of [
19F]-fluoride 2.18 (−218 ppm) as this 
would result in a large spectral window for acquisition.  Benzyl fluoride (3.02) has a 
19F 
NMR chemical shift of −207 ppm
81 and so was chosen as the internal reference as it has 
a similar shift to the product meaning a small spectral window for acquisition could be 
used, over a region that had a nice flat baseline. 
 
Benzyl fluoride was not available from commercial sources so the synthesis was 
attempted in one step from benzyl bromide (3.01) following the procedure of Clark et 
al.
82  This method used potassium fluoride and tetraphenylphosphonium bromide in 
acetonitrile at 80 °C using conventional heating and required over seven days for the 
reaction to approach completion (monitored by 
1H NMR).  In order the speed up the 
reaction the use of microwave heating was investigated as it had been shown to greatly 
accelerate halogen exchange reactions.
83  Using microwave heating, the reaction time 
was significantly reduced to one hour at 120 °C followed by six hours at 150 °C to give 
the desired benzyl fluoride (3.02) in a 16 % isolated yield.  The poor yield achieved for 
this reaction was attributed to the low boiling point of the product (139.9 °C at 780 
mm/Hg
84) which caused difficulties in handling and purification.  Further work on this 
reaction showed it to proceed as desired using simply benzyl bromide and an excess of 
potassium fluoride in acetonitrile, negating the need for the tetraphenylphosphonium 
bromide.  Using these modified conditions microwave heating at 150 °C for two hours 
gave the desired benzyl fluoride (3.02) in an 18% isolated yield (Scheme   3.2). 
 
 
Scheme   3.2  Reagents and conditions: a) KF, MeCN, 150 °C (microwave heating). 
 
To check the stability of benzyl fluoride (3.02) under the fluoridolysis reaction 
conditions, a 
19F NMR spectrum of a sample of deuterated acetonitrile containing a 
small amount of benzyl fluoride (3.02) and hexafluorobenzene (known to be stable) was 
acquired.  The sample was then incubated at 50 °C for three days before a second     50
spectrum was acquired.  The relative integrals of the benzyl fluoride (3.02) and 
hexafluorobenzene fluorine peaks on the before and after spectra were found to be 
consistent showing no loss or degradation of the benzyl fluoride (3.02) to have taken 
place. 
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Figure    3.2  Graphs to show the result of the second and third trial reactions.   
Conditions: Left – 50 mg resin 2.30, 2.7 μmolmL
−1 BnF (3.02) internal reference, 50 
°C, no agitation; Right – 20 mg resin 2.30, 27.0 μmolmL
−1 BnF (3.02) internal 
reference, 40 °C, with agitation. 
 
A second trial reaction was carried out using 50 mg of resin 2.30 and an excess of 
potassium fluoride and Kryptofix [2.2.2] in deuterated acetonitrile containing benzyl 
fluoride (3.02) as the internal reference (2.7 μmolmL
−1).  The 
19F NMR probe was 
maintained at 50 °C and spectra were acquired at regular intervals (Figure   3.2, left).  
The product concentration was observed to have levelled out after only one hour which, 
when you consider it takes around 15 min to acquire one spectrum, was considered to 
be too fast to get adequate data points for analysis.  The internal reference peak was 
observed to be too small which would make measuring the integration less accurate and 
so a higher concentration of benzyl fluoride (3.02) in the deuterated acetonitrile was 
deemed necessary.  The resin itself appeared visually to contain two layers in the 
bottom of the NMR tube at the end of the experiment implying only the upper portion 
had reacted due to poor mixing.  To improve on these issues, the third trial reaction was 
carried out using less resin (20 mg), the spectra were acquired at 40 °C and the reaction     51
mixture was removed from the spectrometer and agitated between each acquisition 
(Figure   3.2, right).  The concentration of the internal reference was also increased to 
27.0 μmolmL
−1 which gave a larger reference peak for more accurate integration.  At 
this lower reaction temperature the rate of the reaction was reduced and the product 
concentration levelled off after around three hours.  The combination of using a smaller 
amount of resin and agitating the reaction mixture gave much better results.  Both data 
sets from these two trial reactions (Figure   3.2) showed a slower reaction rate at the start 
of the reaction, up until around 20 min, which gave a slightly sigmoidal shape to the 
data.  This is thought to be due to the initial swelling of the resin in the reaction solvent 
as the resins were not pre-swollen prior to use. 
 
The [
19F]-fluoridolysis reactions for the kinetic study were carried out using a stock 
solution of deuterated acetonitrile containing benzyl fluoride (3.02) as the internal 
reference at a concentration of 10.6 μmolmL
−1 and were carried out in 0.5 mL of 
solvent.  Each reaction used 19 μmol of resin-bound substrate (based on the loadings of 
the resin calculated by elemental analysis of sulfur) along with 1.5 eq of potassium 
fluoride and Kryptofix [2.2.2].  The spectra were acquired with the temperature of the 
NMR probe at 40 °C, which was checked prior to commencing the reaction by analysis 
of the peak separation in the 
1H NMR of 80% glycol (1,2-ethanediol) in DMSO.
85  
Agitation of the reaction mixture took place between each spectral acquisition to ensure 
ample mixing of the resin suspension.  
19F NMR spectra were acquired at regular 
intervals (every 12-15 min) until the amount of product in the reaction mixture 
remained constant, indicating that the cleavage was complete.  The reaction was 
repeated for each resin (Figure   3.3) until consistent results had been achieved.  Graphs 
of amount of product cleaved (μmol) against time (min) were plotted for each reaction 
and the data were found to give good kinetic curves.  The gradient of the linear portion 
of the kinetic curves over the region 10-85 min were used to calculate the rate of 
cleavage of the fluorinated product from the RLV construct (Figure   3.4). 
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Figure   3.3  The resins analysed as part of the 
19F NMR kinetic study. 
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Figure   3.4  Graph to show the results of the kinetic study fluoridolysis reactions for 
resin 2.17 (light blue), resin 2.24 (pink), resin 2.30 (dark blue) and resin 2.45 (green).  
Shown are the linear portion of the kinetic curves over the region 10-85 min which were 
used to calculate the rate of cleavage of the fluorinated product from the RLV construct. 
 
The data showed the rate of cleavage of the RLV constructs containing the 4-
alkylphenylsulfonate linker to increase with linker chain length, as the rate for resin 
2.30 was the slowest at 0.136 μmolmin
−1, resin 2.24 was 0.202 μmolmin
−1 and resin     53
2.17 was the fastest at 0.216 μmolmin
−1.  This was the expected trend as the increasing 
chain length would allow the sulfonate ester group to have a more “solution-like” 
character and to be more easily accessed by the fluoride ion nucleophile and hence the 
reaction would proceed quicker.  The results for the 4-nitrophenylsulfonate linker were 
unexpected as this linker was thought to be more electron withdrawing and so was 
expected to have a faster rate of fluoridolysis.  The rate for resin 2.45 was found to be 
just 0.027 μmolmin
−1 which was significantly lower than the rates for the 4-
alkylphenylsulfonate linkers.  Further examination of the complete kinetic curves found 
the graphs for resins 2.17, 2.24 and 2.30 to level out at 15-20 μmol of product showing 
that, within experimental error, all the 19 μmol of immobilised vector had been cleaved.  
The graphs for resin 2.45 were found to level out at around 2 μmol of product which 
was significantly less than the expected amount and indicated the possibility of a side 
reaction taking place. 
 
A possible complication with the 4-nitrophenylsulfonate linker was thought to be 
fluorination of the phenyl ring of the linker by displacement of the nitro group with 
[
19F]-fluoride (as discussed in Chapter 2).  If this side reaction was taking place then it 
would be quantified as an additional peak in the 
19F NMR spectrum in the region 
characterised by aryl fluorides (around −100 to −125 ppm).  No additional peak, in this 
region or elsewhere, was detected during the kinetic study experiments with the 4-
nitrophenylsulfonate linker (resin 2.45) and only peaks for the benzyl fluoride internal 
reference and the fluorinated product were seen which implied that the displacement of 
the nitro group with [
19F]-fluoride was not taking place, nor were any side reactions 
involving [
19F]-fluoride occurring.  On examination of the reaction mixture at the end of 
the experiment, the resin was observed as being “clumpy” and the solution had turned 
pale brown.  At the end of the experiments with the 4-alkylphenylsulfonate linkers the 
resins remained free flowing and the solutions were colourless and so it was assumed 
that degradation of the 4-nitrophenylsulfonate linker had taken place during or prior to 
the reaction.  The resin was removed from the reaction mixture by filtration and a 
1H 
NMR spectrum of the concentrated filtrate was acquired.  The resulting spectrum 
contained peaks for the fluorinated product as expected but also contained other peaks 
in the aromatic region which were thought to originate from the phenyl ring in the 4-
nitrophenylsulfonate linker.  Although the speculations that fluorination of the linker     54
itself may occur were unsupported, as the sulfonate ester was found to perform better in 
the nucleophilic fluorination reaction than the nitro group, this work supported the 
assumption that degradation of the 4-nitrophenylsulfonate linker had occurred. 
 
3.3  Repeat cleavage experiments using resin 2.17 
A series of fluoridolysis reactions using limited fluoride were carried out on a batch of 
resin to demonstrate the ability of the RLV construct to release multiple portions of the 
fluorinated product.  The use of limiting fluoride also more closely resembled the 
conditions that would be employed in the radiochemistry experiments involving the 
resins. 
 
 
Scheme   3.3  Reagents and conditions: a) KF, Kryptofix [2.2.2], MeCN, 80 °C. 
 
A sample of resin 2.17 was reacted under the usual fluoridolysis conditions with a 
limited amount of potassium fluoride and Kryptofix [2.2.2] in acetonitrile at 80 °C for 
30 min after which time the resin was removed by filtration and the reaction mixture 
was passed through a short silica column (Scheme   3.3).  The recovered resin was re-
exposed to the reaction conditions and was shown to release further fluorinated product 
[
19F]-2.18 for a total of seven cycles.  The first five cleavage reactions gave consistent 
yields of 30-45% of [
19F]-fluoride  2.18 and subsequent reactions gave significantly 
lower yields (Figure   3.5). 
 
These results clearly demonstrate that the unreacted vector molecule remained attached 
to the solid phase via 4-alkylphenylsulfonate linker during the fluoridolysis reactions 
and could be released upon further exposure to fluoride ions.  The RLV approach 
clearly showed that the crude product was easy to separate from both the unreacted 
starting material and from the reagents used in the cleavage reaction.  The release of 
multiple portions of fluorinated product from one batch of resin means that the RLV 
construct could be easily adapted for automated radiosynthesis.  A cartridge containing     55
some appropriately functionalised resin could, in principle, be used in an automated 
setup to produce multiple batches of radiotracer. 
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Figure   3.5  Graph to show the yield of [
19F]-2.18 obtained from successive fluoridolysis 
reactions carried out using the same batch of resin 2.17. 
 
3.4  Radiochemistry results 
We gratefully acknowledge Imtiaz Khan of GE Healthcare, White Lion Road, 
Amersham, UK, for carrying out the radiochemistry experiments with our resins.  These 
experiments are described and discussed in the ensuing section. 
 
The radiolabelling experiments were carried out manually using potassium [
18F]-
fluoride, potassium carbonate and Kryptofix [2.2.2] in acetonitrile with a reaction time 
of 15 min and the radiochemical yields were established by reverse-phase HPLC 
analysis of the crude reaction mixture using UV (254 nm) and γ-detection (a full 
experimental procedure can be found in Chapter 6).  The reactions used a severely 
limiting amount of [
18F]-fluoride compared to the amount of vector immobilised on the 
resin, the latter being in excess by an order of a few thousand.  The unreacted resin was 
easily removed from the reaction mixture by filtration and so the HPLC traces were not 
complicated by the presence of large peaks due to the starting material. 
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Entry  Resin  Loading/mmolg
−1  [
18F]-fluoride 
incorporation 
Non-decay 
corrected yield 
of [
18F]-2.18 
1  2.17  0.80 >60%  30% 
2  2.24  0.81 31%  14% 
3  2.30  0.95 40%  12% 
Table    3.3  Results of the [
18F]-fluoridolysis reactions.  Reagents and conditions: 
a) K
18F, K2CO3, Kryptofix [2.2.2], MeCN, 100-110 °C. 
 
The results of experiments with resins 2.17, 2.24 and 2.30 (which were made up of the 
4-alkylphenylsulfonate linker with varying lengths and with the (4-hydroxy-butyl)-
phenyl-carbamic acid tert-butyl ester vector molecule) are shown in Table   3.3.  In each 
case, the desired product [
18F]-2.18 was formed as the only radiochemical product and 
its identity was confirmed by comparison of the retention time with that of the cold 
standard [
19F]-2.18.  Resin 2.17, with the longest linker length, resulted in the highest 
incorporation of [
18F]-fluoride (Table   3.3, entry 1) which correlates with the fastest rate 
of cleavage seen in the kinetic study and is thought to be due to the increased “solution-
like” character of the sulfonate ester with the longer linker length.  Resins 2.24 and 2.30 
were expected to show a sequential reduction in the incorporation of [
18F]-fluoride 
although their results were found to be comparable (Table   3.3, entries 2 & 3).  This was 
attributed to the higher loading of resin 2.30 which would be expected to yield slightly 
more product than resin 2.24 as the same mass of resin was used for the reactions.  
Stirring of the resin suspension during the reaction was found to greatly improve the 
outcome of the reaction, in the reaction of resin 2.17 without stirring a reduced 34% 
incorporation of [
18F]-fluoride was observed (14% non-decay corrected yield). 
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Figure   3.6  Reverse phase HPLC analyses of the [
18F]-fluoridolysis reaction with resin 
2.24 of the crude reaction mixture (top) and the formulated reaction mixture (bottom).  
In both cases the red line is the radioactive trace and the blue line is the UV trace (254 
nm). 
 
The HPLC analyses of the [
18F]-fluoridolysis reaction with resin 2.24 are shown in 
Figure   3.6, where, in both analyses, the radioactive trace is shown as the red line and the 
UV trace is shown as the blue line.  The top trace is the HPLC analysis of the crude 
reaction mixture which was acquired after filtration of the reaction mixture through an 
acrodisc to remove the resin from the solution.  The radioactivity trace showed only two 
peaks, the first peak had a retention time of less than two min and is due to unreacted 
[
18F]-fluoride, the second peak had a retention time of 16 min and is due to the [
18F]-
fluorinated product, [
18F]-2.18.  The [
18F]-fluoride incorporation of 31% for this 
reaction was calculated from the relative areas of the unreacted [
18F]-fluoride peak and 
the [
18F]-fluorinated product peak.  The reaction mixture was then formulated into a 
form that would be injectable into a patient (a solution containing a mixture of 
18F
− 
[
18F]-2.18
[
18F]-2.18
Chemical impurities 
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phosphate buffered saline and ethanol).  The sample was passed through a C18 Sep-Pak 
cartridge, eluting with water and ethanol before phosphate buffered saline was added to 
the filtrate and the HPLC analysis was repeated.  The radioactive trace now had only 
one peak due to the [
18F]-fluorinated product as the unreacted [
18F]-fluoride has been 
removed from the sample.  This shows that [
18F]-2.18 had been formed in excellent 
radiochemical purity as it was the only radiochemical product formed in the reaction.   
 
The UV traces, the blue lines, show the chemical make-up of the crude and formulated 
reaction mixtures, from which information can be obtained regarding the chemical 
purity of the reaction.  Since the unreacted precursor remained attached to the resin and 
was removed by filtration, the UV traces don’t contain a large peak due to the excess of 
precursor used in the reaction.  Due to the tiny amount of [
18F]-fluoride used in the 
reaction, a chemical peak due to the [
18F]-fluorinated product was not expected and so 
all of the UV peaks seen are a result of side reactions or degradation of the RLV 
construct or the resin beads themselves.  The UV traces show chemical impurities with 
retention times of around 4, 8 and 16 min, with the latter being the most significant 
(although the peak at 16 min appears close to the product peak on the radioactivity trace 
it is not the chemical peak for the product).  Attempts were made to identify these 
chemical impurities but with limited success.  The impurity giving the peak at 8 min is 
thought to be the product of hydrolysis of the vector molecule from a comparison of the 
HPLC analysis of a sample of the alcohol.  The more significant impurity resulting in 
the peak at 16 min was thought to most likely be the elimination product, although this 
was not confirmed.  It should be noted that the elimination product was not obtained in 
the [
19F]-fluorination reactions, highlighting the difference in the reaction conditions for 
the [
19F]- and [
18F]-fluoridolysis reactions.   
 
The [
18F]-fluoridolysis reaction of resin 2.17 also resulted in the formation of some 
chemical impurities (Figure   3.7, top).  HPLC purification of the reaction mixture 
removed most of the chemical impurities although the impurity at 16 min that was 
close-running to the [
18F]-fluorinated product was not separated under the HPLC 
conditions and setup employed by the radiochemists (Figure   3.7, bottom). 
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Figure   3.7  Reverse phase HPLC analyses of the [
18F]-fluoridolysis reaction with resin 
2.17 of the crude reaction mixture (top) and the HPLC purified reaction mixture 
(bottom).  In both cases the red line is the radioactive trace and the blue line is the UV 
trace (254 nm). 
 
A [
18F]-fluoridolysis reaction was carried out with resin 2.45 (with the 4-
nitrophenylsulfonate linker and the (4-hydroxy-butyl)-phenyl-carbamic acid tert-butyl 
ester vector molecule) although no [
18F]-fluorinated products were observed.  The 
radioactivity level of the filter, containing the resin after the reaction, was checked and 
found to be of a comparable low level as for the resins with the 4-alkylphenyl sulfonate 
linkers.  This indicated that displacement of the nitro group on the linker by [
18F]-
fluoride was not taking place.  However, the lack of [
18F]-fluorinated product formed in 
the reaction implied that the RLV construct had undergone significant degradation 
during storage at room temperature prior to the [
18F]-fluoridolysis reaction.  [
18F]-
Fluoridolysis results were not obtained for resins 2.51 and 2.54 with the 3-(2-
[
18F]-2.18
[
18F]-2.18
18F
− 
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naphthlenoxy)-1-propanol vector due to the reverse phase HPLC conditions and setup 
employed by the radiochemists not being appropriate for this vector molecule. 
 
3.5  Conclusions 
All of the resins synthesised as part of this project (discussed in Chapter 2) successfully 
gave the desired [
19F]-fluorinated product when exposed to the conditions of [
19F]-
fluoridolysis.  A kinetic study was carried out using 
19F NMR to investigate the effect of 
altering the alkyl chain length of the 4-alkylphenylsulfonate linker and concluded that 
the rate of cleavage of the [
19F]-fluorinated product increased with linker length.  The 4-
nitrophenylsulfonate linker, thought to be the more reactive linker type, was found to 
have a lower cleavage rate than the shortest 4-alkylphenylsulfonate linker which was 
thought to be due to degradation of the 4-nitrophenylsulfonate linker rather than a true 
comparison of the relative reaction rates.  A repeat cleavage experiment was carried out 
on a RLV construct containing the 4-alkylphenylsulfonate linker and showed that the 
same batch of resin was able to give consistent yields of the [
19F]-fluorinated product 
for up to five cycles before a significant drop in yield was observed.  This showed that 
an appropriately functionalised resin, with the developed RLV construct, could be used 
to produce multiple batches of radiotracer and could, in principle, be easily adapted for 
use in automated radiosynthesis of 
18F-labelled radiotracers.  [
18F]-Fluoridolysis 
reactions were carried out successfully on resins with the 4-alkylphenylsulfonate linker 
to give the desired 
18F-labelled vector molecule as the only radiochemical product, the 
highest yield of which was obtained with the resin with the longest linker length.  The 
[
18F]-fluorinated products were formed in excellent radiochemical purity although were 
found to contain some chemical impurities most of which could be removed by HPLC 
purification although a close-running impurity was not separated.  The results of the 
[
19F]-fluoridolysis reactions, kinetic study and lack of product formed in the [
18F]-
fluoridolysis reaction implied that the 4-nitrophenylsulfonate linker had degraded since 
the completion of the synthesis which indicated there were problems with the stability 
of this linker type.  Hence, of the two linker types developed, the 4-
alkylphenylsulfonate linker was concluded as being the superior linker for use as part of 
the RLV construct.  The 4-alkylphenylsulfonate linker with the longest linker length 
was found to have the fastest reaction kinetics and gave the best yields in the [
18F]-
fluoridolysis reactions.     61
Chapter 4 – O-(2-[
18F]-Fluoroethyl)-L-tyrosine 
This chapter discusses the application of the 4-alkylphenylsulfonate linker as part of the 
RLV construct in a novel synthetic route to O-(2-[
18F]-fluoroethyl)-L-tyrosine. 
 
4.1  Introduction 
4.1.1  Background 
While the glucose analogue (2-deoxy-2-[
18F]-fluoro)-D-glucose ([
18F]-FDG) is routinely 
used in PET imaging for tumour diagnosis, the high uptake of [
18F]-FDG in brain and 
non-malignant, inflammatory tissue can lead to a loss of contrast when imaging brain 
tumours and peripheral tumours (such as lymphoma, lung tumours and breast cancer).
86  
Hence it is possible that false-positive results could be obtained when imaging with 
[
18F]-FDG if tumours and inflammatory processes are both present in the patient.
87  The 
normal excretory route of [
18F]-FGD is via the kidneys which also makes it of limited 
use for the investigation of renal and bladder cancers.
88,89  Amino acids have a much 
lower uptake in normal brain tissue and so the contrast obtained when imaging brain 
tumours could be greatly improved by the use of positron-labelled amino acids instead 
of [
18F]-FDG.
90   
 
 
Figure   4.1  O-(2-[
18F]-Fluoroethyl)-L-tyrosine ([
18F]-FET). 
 
In 1999, Wester et al. developed the synthesis of the tyrosine derivative O-(2-[
18F]-
fluoroethyl)-L-tyrosine ([
18F]-FET, Figure   4.1) as a tracer for the imaging of cancer.
90,91  
Tyrosine derivatives could potentially give very good tracer molecules since tyrosine 
shows a high brain uptake and fluoroalkylation of the hydroxyl group gives a 
metabolically stable product.
90  [
18F]-FET is a tracer for the imaging of amino acid 
transport (a higher demand for which is related to increased needs for tumour growth
91) 
and should not incorporate into newly formed proteins and so no significant     62
accumulation of the tracer in peripheral organs would be expected.
90  [
18F]-FET has 
been shown to be superior to [
18F]-FGD for brain tumour imaging in studies using rats
92 
and mice
93 and is now in clinical use for tumour imaging.
20 
 
4.1.2  Previous Syntheses 
The synthesis of [
18F]-FET developed by Wester et al.
90 involved a two-step reaction 
pathway consisting of the [
18F]-fluorination of ethylene glycol-1,2-ditosylate (4.01) and 
the subsequent [
18F]-fluoroethylation of unprotected L-tyrosine (Scheme   4.1).  Reverse 
phase HPLC purification was required after each step of the synthesis and the product 
was passed through a strong cation exchange cartridge before formulation.  The 
synthesis was completed in around 60 min with a radiochemical yield of 40% (based on 
[
18F]-fluoride) and a radiochemical purity of 97-99%.  In 2006, the purification of 1-
[
18F]-2-tosyloxyethane (4.02) was reported using disposable SPE cartridges instead of 
HPLC.
94  The mono-fluorination of ditosylate 4.01 was carried out and the reaction 
mixture was then passed through a Sep-Pak silica cartridge, using n-hexane/ether (3:1) 
as eluent.  However, the use of a range of solvents in the different purification steps was 
thought to make this method unsuitable for automated production.
95 
 
 
Scheme   4.1  The synthesis of [
18F]-FET by the [
18F]-fluoroethylation of L-tyrosine.
90  
Reagents and conditions: a) [K/K2.2.2]
+ 
18F
−, MeCN, 90 °C; b) L-Tyrosine (di-
potassium salt), DMSO, 90 °C. 
 
In 2002, an alternative synthesis of [
18F]-FET was reported by Hamacher et al. which 
implemented a direct nucleophilic radiofluorination of protected alkyl tyrosine 
derivative O-(2-tosyloxyethyl)-N-trityl-L-tyrosine (4.03).
96  The synthesis (Scheme   4.2) 
involves the [
18F]-fluorination of tosylate 4.03, using the tetra butyl ammonium cation 
as the phase transfer agent rather than Kryptofix [2.2.2] as this gave higher 
radiochemical yields (the average radiochemical yield obtained for this reaction was 
>80%).  Deprotection of the trityl and tertiary butyl ester groups was carried out using     63
TFA and was followed by a solid phase extraction using a Si60 silica gel cartridge.  The 
eluted [
18F]-FET was then purified by reverse phase HPLC to give a radiochemical 
yield of 55-60% over the two steps and a radiochemical purity of >99%, with a total 
synthesis time of about 80 min. 
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Scheme   4.2  The synthesis of [
18F]-FET by the direct nucleophilic [
18F]-fluorination of 
protected alkyl tyrosine 4.03.
96   Reagents and conditions: a) Bu4N
+ 18F
−, MeCN, 85 °C; 
b) TFA, 1,2-dichloroethane, 70 °C. 
 
Further studies on a similar precursor to tosylate 4.03 but with different protecting 
groups were reported by Wang et al. in 2005.
92  In this work, a self-modified automated 
PET tracer synthesiser was used following the same synthetic pathway to [
18F]-FET that 
was previously outlined (Scheme   4.2) with the starting tosylate containing N-Boc and 
O-benzyl protecting groups.  After [
18F]-fluoroethylation, the reaction mixture was 
purified using Sep-Pak Silica Plus cartridges before the deprotection, which was carried 
out using 1 N HCl rather than TFA and final HPLC purification was not required.  The 
synthesis took approximately one hour to complete and gave [
18F]-FET in a 
radiochemical yield of 50-55% (decay corrected) and with a radiochemical purity of 
>98%. 
 
An automated commercial synthesis of [
18F]-FET, following the original synthetic 
pathway (Scheme   4.1), was developed by Tang et al. in 2003.
87  This fully automated 
synthesis utilised the commercial PETtrace FDG Microlab which is a computer 
controlled automated radiochemistry system that is routinely used for the synthesis of 
[
18F]-FDG for clinical use.  In this system, the chemical transformations and the final 
production of [
18F]-FDG take place within a disposable cassette (one cassette per batch     64
production run of [
18F]-FDG) and the same cassettes were used for the synthesis of 
[
18F]-FET.  The synthetic strategy involves first the trapping of [
18F]-fluoride ions on a 
solid phase extraction column, where the trapping agent is 4-(4-
methylpiperidinyl)pyridinium cations.  Di-tosylate 4.01 is then passed through the 
column where it reacts with the trapped [
18F]-fluoride and is eluted as 1-[
18F]-2-
tosyloxyethane (4.02), which is transferred to the [
18F]-fluoroethylation vessel along 
with L-tyrosine, sodium hydroxide and DMSO.  Heating for 20 min at 100 °C followed 
by elution through silica, C-18 and Al2O3 Sep-Pak cartridges gave [
18F]-FET in an 
overall radiochemical yield of 8-10% (non-decay corrected) and with a radiochemical 
purity of >95%.  The synthesis time of 52 min is comparable to the original method 
although HPLC purification of the intermediate and the final product is not required and 
no operator handling is necessary except to remove the final product vial.
87 
 
 
Scheme    4.3  The synthesis of [
18F]-FET from Ni
II Schiff’s base precursor 4.05.
95  
Reagents and conditions: a) Bu4N
+ 18F
−, MeCN, 80 °C; b) 0.5 M HCl, 120 °C. 
 
Most recently, in 2008 Krasikova et al. pursued a different approach to the synthesis of 
[
18F]-FET by elaborating the structure of a new labelling precursor.
95  Their precursor 
was based on a Ni
II complex of a Schiff’s base of (S)-[N-2-(N’-
benzylprolyl)amino]benzophenone (BPB) with alkylated L-tyrosine, Ni-(S)-BPB-(S)-
Tyr-OCH2CH2OTs (4.05).  Tosylate 4.05 was synthesised from the reaction of (S)-BPB 
and racemic tyrosine in the presence of a nickel nitrate salt to form the Ni
II complex 
followed by O-alkylation of the hydroxyl group of tyrosine and then tosylation of the O-
hydroxyethyl group.  The one-pot radiosynthesis of [
18F]-FET is then accomplished in 
two steps (Scheme   4.3), the nucleophilic fluorination again using the tertiary butyl 
ammonium cation followed by hydrolysis/deprotection using moderate aqueous     65
conditions (only minimal intermediate purification steps were required).  The crude 
product was then purified by semi-preparative HPLC to give [
18F]-FET in a 
radiochemical yield of 57% and a radiochemical purity of >99% with an overall 
synthesis time of 55 min. 
 
4.1.3  The Brown group approach to the synthesis of O-(2-[
18F]-fluoroethyl)-L-
tyrosine 
Our strategy for the synthesis of [
18F]-FET utilises a solid supported precursor, based on 
the resin-linker-vector (RLV) construct, which can be used in a direct nucleophilic 
radiofluorination reaction followed by a quick deprotection step to give the product.  
Our 4-alkylphenylsulfonate linker, which mimics the tosylate leaving group, was used 
to synthesise a solid supported FET precursor analogous to the solution phase tosylate 
precursors discussed previously.
92,96  A solid supported precursor to [
18F]-FET has not 
been reported in the literature and has the potential to simplify the purification of the 
product through the use of filtration to remove the solid supported leaving group in the 
fluorination reaction and the unreacted precursor.  Ideally, the use of this precursor 
would make HPLC purification unnecessary.  The strategy involves the synthesis of 
alcohol  4.07 (an alcohol precursor to FET, Figure   4.2) which uses a different 
combination of protecting groups to those previously reported.
92,96  This would be 
attached to a solid support via the 4-alkylphenylsulfonate linker in the manner 
developed as part of this work. 
 
 
Figure   4.2  Alcohol 4.07 for attachment to the solid phase to give the solid supported 
precursor to [
18F]-FET. 
 
4.2  Synthesis of solid supported FET precursor 
The alcohol precursor to FET for use as part of the RLV construct was synthesised from 
commercially available N-(tert-butoxycarbonyl)-L-tyrosine (4.08).  The first step in the 
synthesis was the protection of the free acid as the tertiary butyl ester (4.09) which was     66
carried out following a modified procedure to that described by Chevallet et al. in 
excellent yield (Scheme   4.5).
97  The O-alkylation of ester 4.09 to give alcohol 4.07 (the 
alcohol precursor to FET) turned out to be much harder than anticipated due to the 
consistent low conversion from this reaction when carried out directly. 
 
 
Entry  Bromoethanol Base  Additive Solvent  Outcome  
(ratio 4.09:4.07) 
1 3  eq  K2CO3 -  DMF  5.5:1
a 
2 3  eq  K2CO3 -  Acetone
98 7.9:1
b 
3 3  eq  K2CO3 -  Benzene
99 10:1
a 
4 3  eq  K2CO3 -  MeCN  5.8:1
a 
5 3  eq  K2CO3 -  THF  7.5:1
a 
6 3  eq  K2CO3 BTEAC  DMF  1.2:1
b 
7 1  eq  K2CO3  BTEAC DMAC  1.7:1
b 
 
8 1.1  eq  K2CO3 Bu4NI DMF
100 2:1
b 
9 5  eq  K2CO3  NaI Acetone
101 1:0
a 
10 3  eq  Cs2CO3 -  DMF  9.8:1
a 
11 3  eq  Cs2CO3 -  Acetone  11:1
a 
12 1  eq  NaOH  -  MeOH
102 1:0
a 
Table   4.1  Test reactions for step (b), Scheme   4.4. 
aYields were determined from the 
1H NMR of the crude products.  
bYields of 
compounds isolated by chromatography. 
 
A series of test reactions were carried out using a range of bases, additives and solvents 
in order to establish the best conditions for the O-alkylation reaction (Table   4.1).  None 
of the reactions were found to go to completion and some of the conditions tried were 
found not to give any of the desired product (entries 9 and 12).  The use of potassium 
carbonate gave a better conversion than caesium carbonate with the same solvent 
(entries 1 and 2 compared with 10 and 11).  The use of BTEAC or Bu4NI as additives 
resulted in an increase in the conversion of the reaction although the final yield was still 
less than 50% (entries 6-8).  Of the solvents tested, DMF gave the best conversion and 
was found suppress the multiple additions of the O-ethoxy unit which was observed as a 
by-product with other solvents (namely acetonitrile, tetrahydrofuran, acetone and     67
methanol).  The best conversion was seen with potassium carbonate and BTEAC in 
DMF (entry 6) although isolation of the product resulted in only a 33% yield of the 
desired product after a reaction time of 48 h. 
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Scheme   4.4  Reagents and conditions: a) Ethylbromoacetate, Cs2CO3, dioxane, 80 °C; 
b) LiOH, MeOH/H2O; c) Alcohol 4.13, tri-n-butylphosphine, ADDP, CH2Cl2/THF, 
0 °C to rt; d) 1% aq NaOH/MeOH. 
 
An alternative method for the O-alkylation of ester 4.09 was investigated involving the 
formation of ethyl ester 4.10 and then the successive hydrolysis to carboxylic acid 4.11 
and then reduction to alcohol 4.07 in an attempt to improve the overall yield of this 
transformation (Scheme   4.4).
103  The formation of ethyl ester 4.10 was successful albeit 
in only moderate yield but the subsequent hydrolysis to give carboxylic acid 4.11 failed.  
This was thought to be due to the acidic workup causing the cleavage of the N-Boc and 
tertiary butyl protecting groups.  A two-step method via protected alcohol 4.12 was 
found to be much more successful.  Mono-protected ethylene glycol (4.13) (synthesised 
in good yield following the procedure described by Wiseman et al.
104) was coupled to 
ester 4.09 in a moderately yielding Mitsunobu reaction using the modified conditions of 
tri-n-butylphosphine and 1,1’-(azodicarbonyl) dipiperidine (ADDP) which had been     68
reported to be good reagents for the O-alkylation of tyrosine
105 (more standard 
Mitsunobu reagents, triphenylphosphine and DIAD, gave lower yields).  Removal of the 
benzoyl protecting group under standard conditions gave alcohol 4.07 in good yield.  
The yield over the two steps was only 27% which is less than the one step method and 
although the total reaction time was considerably shorter (less than six hours verses 
forty-eight hours) the two step route did not prove to be a better strategy than the direct 
method.   
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Scheme   4.5  Reagents and conditions: a) 2-Bromo-2-methylpropane, K2CO3, BTEAC, 
DMAC, 55 °C; b) Bromoethanol, K2CO3, BTEAC, DMF, 50 °C. 
 
Gratifyingly, when the direct O-alkylation reaction was performed on a much larger 
scale (>10 mmol) using bromoethanol (1.1 eq, followed by 0.5 eq after forty-eight 
hours), K2CO3 (3 eq) and BTEAC (2 eq) in DMF at 50 °C for a total reaction time of 72 
h the conversion was greatly improved and a 73% yield of alcohol 4.07 was obtained, 
along with 9% recovered phenol 4.09 (Scheme   4.5).  This reaction completed the 
synthesis of the FET precursor which followed a two step pathway with an overall yield 
of 67%. 
 
Alcohol  4.07 was reacted in excellent yield with sulfonyl chloride 2.03 (the 4-
alkylphenylsulfonate linker type with the longest chain length of five methylene units) 
to give sulfonate ester 4.14 (Scheme   4.6).  The solution phase fluoridolysis was carried 
out using sulfonate ester 4.14 to make sure the reaction worked before it was transferred 
to the solid phase and a 48% yield of protected [
19F]-FET ([
19F]-4.15) was obtained 
which was very encouraging.  Enzyme mediated hydrolysis of sulfonate ester 4.14 gave     69
free acid 4.16 in moderate yield which was then coupled to the solid support to give 
resin 4.17. 
 
Scheme   4.6  Reagents and conditions: a) Sulfonyl chloride 2.03, Et3N, DMAP, CH2Cl2; 
b) KF, Kryptofix [2.2.2], MeCN, 80 °C; c) Novozym 435®, aq phosphate buffer (pH 7), 
CH2Cl2/acetone, 50 °C; d) Amino methyl polystyrene resin, HOBt, DIC, DMF/CH2Cl2. 
*Calculated from the theoretical mass gain using the loading of the unfunctionalised 
resin and the observed mass gain of the product resin. 
 
A small scale test reaction to investigate the removal of the N-Boc and tertiary butyl 
protecting groups was carried out using the standard reagent, trifluoroacetic acid.  TLC 
of the reaction showed a clean, spot to spot conversion of the starting material after a 
reaction time of only 10 min and mass spectroscopy confirmed the presence of the 
desired molecular ion indicating the formation of the product.  No further work was 
carried out on this reaction as the deprotection step would need to be optimised as part 
of the radiochemical studies with resin 4.17 and some tyrosine derivative deprotection 
strategies have been previously reported.
92,95,96  This work showed the feasibility of the 
synthesis of [
18F]-FET by the cleavage and subsequent deprotection of a solid supported 
precursor using our developed RLV strategy. 
     70
4.3  Solid phase fluoridolysis 
[
19F]-Fluoridolysis of resin 4.17 was carried out using potassium fluoride and Kryptofix 
[2.2.2] in acetonitrile at 80 °C to give [
19F]-4.15 in a 50% yield after a reaction time of 
45 min (Scheme   4.7).  The purification of [
19F]-4.15 involved filtration of the reaction 
mixture which was then passed through a short silica column.  The yield of product was 
comparable to that obtained from the analogous solution phase reaction and 
significantly higher than the yields achieved for the (4-hydroxy-butyl)-phenyl-carbamic 
acid tert-butyl ester (2.14) vector molecule with the same linker type. 
 
 
Scheme   4.7  Reagents and conditions: a) KF, Kryptofix [2.2.2], MeCN, 80 °C. 
 
4.4  Radiochemistry results 
We gratefully acknowledge Imtiaz Khan of GE Healthcare, White Lion Road, 
Amersham, UK, for carrying out the radiochemistry experiments with our resins. 
 
The [
18F]-fluoridolysis reaction using resin 4.17 was carried out as discussed in Chapter 
3 to give [
18F]-4.15 with a 53% incorporation of [
18F]-fluoride and a non-decay 
corrected yield of 23% and was formed in excellent radiochemical purity.  These results 
were comparable with those obtained for resin 2.17 which was made up of the same 
length 4-alkylphenylsulfonate linker and the (4-hydroxy butyl) phenyl carbamic acid 
tert-butyl ester vector molecule.   
 
The HPLC analyses of the [
18F]-fluoridolysis reaction with resin 4.17 are shown in 
Figure   4.3, where, in both analyses, the radioactive trace is shown as the red line and the     71
UV trace is shown as the blue line.  The top trace is the HPLC analysis of the crude 
reaction mixture which was acquired after filtration of the reaction mixture through an 
acrodisc to remove the resin from the solution.  The radioactivity trace showed only two 
peaks due to the unreacted [
18F]-fluoride and the [
18F]-fluorinated product, [
18F]-4.15.  
The reaction mixture was then formulated (as outlined in Chapter 3) and the HPLC 
analysis was repeated.  The radioactive trace now showed only one peak due to the 
desired [
18F]-fluorinated product as the only radiochemical product of the reaction, 
demonstrating that it had been formed in high radiochemical purity. 
 
 
 
Figure   4.3  Reverse phase HPLC analyses of the [
18F]-fluoridolysis reaction with resin 
4.17 of the crude reaction mixture (top) and the formulated reaction mixture (bottom).  
In both cases the red line is the radioactive trace and the blue line is the UV trace (254 
nm). 
 
The UV traces, the blue lines, show the chemical make-up of the crude and formulated 
reaction mixtures and give an idea of the chemical purity of the solutions.  Since the 
unreacted precursor remained attached to the resin and was removed by filtration, the 
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UV traces don’t contain a large peak due to the excess of precursor used in the reaction.  
Due to the tiny amount of [
18F]-fluoride used in the reaction, a chemical peak due to the 
[
18F]-fluorinated product was not expected and so all of the UV peaks seen are a result 
of side reactions or degradation of the RLV construct or the resin beads themselves.  
The UV traces showed some chemical impurities to be present in both the crude and 
formulated reaction mixtures.  At the solvent front, at around the same retention time as 
the [
18F]-fluoride ion peak (around two min), often a response is seen when the solvent 
hits the UV flow cell which may be the cause of the UV peaks with retention times 
between one and three min.  Alternatively, these may be due to hydrophilic by-products 
of the [
18F]-fluoridolysis reaction.  None of the chemical impurities shown in the UV 
traces were identified.  Since there were no chemical impurities with a similar retention 
time to the [
18F]-fluorinated product, HPLC purification of the reaction mixture was 
carried out to remove the chemical impurities (Figure   4.4).  This gave a solution of 
[
18F]-4.15 with excellent chemical purity (only one very minor impurity just before 17 
min remained). 
 
 
Figure   4.4  Reverse phase HPLC analysis of the HPLC purified reaction mixture from 
the [
18F]-fluoridolysis reaction with resin 4.17.  The red line is the radioactive trace and 
the blue line is the UV trace (254 nm). 
 
4.5  Conclusions 
The RLV construct was applied in a new synthetic route to [
18F]-FET.  A precursor to 
FET, alcohol 4.07, was synthesised and was attached to a solid support as part of a RLV 
construct using the developed 4-alkylphenylsulfonate linker to give resin 4.17.  The 
resin was shown to release protected [
18F]-FET in good yield and excellent 
[
18F]-4.15    73
radiochemical purity when exposed to [
18F]-fluoride during radiolabelling experiments.  
HPLC purification of the reaction mixture gave the product in excellent chemical purity.     74
Chapter 5 – Galanthamine Analogue 
This chapter covers the synthesis of a fluorinated analogue of (−)-galanthamine which 
has the potential for use as a new imaging agent for use in PET. 
 
5.1  Introduction to galanthamine 
5.1.1  Background 
(−)-Galanthamine ((−)-5.01, Figure   5.1) is a naturally occurring Amaryllidaceae 
alkaloid which can be isolated from the Caucasian snowdrop (Galanthus woronowii)
106 
and from the bulbs of daffodils (Pseudonarcisses L.).
107  It is a centrally acting, 
selective, reversible and competitive inhibitor of acetylcholinesterase (AChE) as well as 
an allosteric modulator of the neuronal nicotinic receptor for acetylcholine and so is 
used for the symptomatic treatment of Alzheimer’s disease.
106 
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Figure   5.1  Structure of the Alzheimer’s drug (−)-Galanthamine ((−)-5.01). 
 
The key feature of Alzheimer’s disease is a loss in cognitive function which is 
characterised by loss of short-term memory and learning ability, impaired attention 
associated with relentlessness, disturbances of language and emotional instability.
108  In 
early studies, patients with Alzheimer’s disease who were given (−)-galanthamine ((−)-
5.01) showed significant improvement in performance and attention
107 and the 
compound was well tolerated.  Today, (−)-galanthamine ((−)-5.01), which is 
commercially available as galanthamine hydrobromide (Razadyne® or Reminyl®), has 
become one of the top drugs for the symptomatic treatment of early on-set Alzheimer’s 
disease.
106 
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The low yield (0.1-2% dry weight)
106 and high cost (~$50,000/kg)
107 of extracting (−)-
galanthamine ((−)-5.01) from natural sources coupled with the biological interest of (−)-
galanthamine ((−)-5.01) for clinical use has led to significant activity in the 
development of a synthetic process for its large scale commercial production.
109,110 
 
5.1.2  Previous syntheses of galanthamine 
The structure of (−)-galanthamine ((−)-5.01) is complex incorporating four fused rings, 
three of which are bridged with a quaternary stereocentre, and so provides the synthetic 
chemist with a challenging target molecule.  A number of syntheses of racemic 
galanthamine have been published since the early 1960s,
106 the latest of which was 
reported in 2006.
111  The first asymmetric synthesis of enantiomerically pure 
galanthamine was reported in the late 1970s and a number of other syntheses have been 
published since that time.
106,107,112-118  The pharmacological and synthetic strategies to 
(−)-galanthamine ((−)-5.01) have been discussed in detail in a review by Marco-
Contelles et al. published in 2006
106 and in the thesis of Miller in 2008
119 and so will 
only be discussed briefly herein, along with an overview of the more recent work on the 
synthesis of (−)-galanthamine ((−)-5.01). 
 
The synthetic approaches to galanthamine may be categorised into two groups based on 
the method employed for the formation of the stereogenic quaternary centre of the 
molecule: biomimetic approaches and other approaches.
106  The biomimetic approach is 
characterised by the use of phenolic oxidative coupling in the presence of a metal 
oxidant and was first reported by Barton et al. in 1962.
120  In this synthetic pathway, a 
phenolic oxidative coupling is used to close the D ring followed by a Michael addition 
of the phenolic oxygen to the dienone system to give narwedine (5.04) which is then 
reduced to give galanthamine (5.01).  Node and co-workers investigated this strategy in 
2001
113 which led to their total synthesis of (−)-galanthamine ((−)-5.01) in an overall 
yield of 23% over 14 steps in 2004
112 which was further elaborated in 2006 (22% over 
13 steps).
114  More recently, in 2008 this approach was used by Reddy et al. in an 
alternative synthesis of (−)-galanthamine hydrobromide.
115  The pilot scale process for 
the kilogram synthesis of (−)-galanthamine ((−)-5.01) was developed utilising the 
phenolic oxidative coupling to give racemic narwedine ((±)-5.04) which then underwent     76
a crystallisation-induced chiral conversion to give (−)-narwedine ((−)-5.04).
109,110  This 
second order asymmetric transformation is achieved without the use of a chiral auxiliary 
other than the presence of seed crystals of (−)-narwedine ((−)-5.04).  Reduction using L-
Selectride® gives (−)-galanthamine ((−)-5.01) which is finally reacted with hydrogen 
bromide to give (−)-galanthamine hydrobromide, the active component in drugs used in 
the treatment of Alzheimer’s disease.  This large scale, commercial synthesis of (−)-
galanthamine hydrobromide obtained yields of up to 19% over nine steps. 
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Scheme   5.1  Biomimetic synthesis of (−)-galanthamine ((−)-5.01). 
 
The non-biomimetic approaches utilise several alternative strategies for the construction 
of the stereogenic quaternary centre.  The use of an intermolecular Heck reaction was 
employed in the asymmetric synthesis of (−)-galanthamine ((−)-5.01) by Trost et al. in 
2005 (10 steps from commercially available materials, 8% overall yield, 96% ee)
118 and 
was also used in 2007 by Satcharoen et al. (11 linear steps).
116  Hu et al. generated the 
quaternary centre in their synthesis of (±)-galanthamine using a semipinacol 
rearrangement (13 steps, 12% overall yield).
111  Finally, the asymmetric synthesis of 
(+)-galanthamine using a Claisen rearrangement was reported by Tanimoto et al. in 
2007.
117  The stereoselective total synthesis of (+)-galanthamine, the enantiomer of the     77
natural product, could be applied in the synthesis of structural analogues that are not 
available by the chemical modification of (−)-galanthamine ((−)-5.01).
117 
 
5.1.3  Structural analogues of galanthamine 
The desire to synthesise structural analogues of (−)-galanthamine ((−)-5.01) originates 
from the need to develop more potent drug molecules.  Structure-activity studies had 
identified four sites on the structure of (−)-galanthamine ((−)-5.01) which could undergo 
chemical modification: the hydroxyl group, the B ring, the tertiary amine and the 
methoxy group.
121  This work led to the synthesis of a number of galanthamine 
analogues of which galanthamine n-butyl carbamate (5.05) was found to have greater 
AChE inhibitory activity than (−)-galanthamine ((−)-5.01) (Figure   5.2).
121 
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Figure   5.2  (−)-Galanthamine analogues which were found to have increased AChE 
inhibitory activity compared to the parent compound. 
 
The crystallographic structure of AChE from electric fish (Torpedo californica) was 
determined in 1991 to contain an active site composing of a catalytic triad located in the 
bottom of a narrow gorge along with peripheral binding sites at the bottom of the cavity     78
and at the opening of the gorge.
122  This information provided the rationale behind the 
synthesis of a series of bis-ligand galanthamine analogues which were designed to 
simultaneously interact with the active site of AChE and the peripheral sites and thereby 
optimise the inhibition potency.
123  Compounds 5.07, 5.08 and 5.09 (Figure   5.2) were 
found to be more active than (−)-galanthamine ((−)-5.01) in inhibiting AChE.  The 
simpler iminium salt of galanthamine, compound 5.06 (Figure   5.2), was confirmed as 
able to cross the blood-brain barrier (thought to be due to the presence of an equilibrium 
between the iminium functionality and the neutral carbinol amine) as it was shown to 
enhance learning and memory in young and old rats.
124,125 
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Figure    5.3  (−)-Galanthamine analogues which were found to have lower or no 
inhibitory activity compared to the parent compound. 
 
The synthesis of a series of (−)-galanthamine analogues with open D rings (compounds 
5.10, 5.11 and 5.12, Figure   5.3) was reported by Herem et al. although these were found 
to have lower activity than the parent compound.
126  Treu and co-workers synthesised a 
sulfur analogue (5.13)
127 and an analogue with a crinine-type alkaloid structure 
(5.14),
128 both of which showed no inhibitory activity toward AChE.  (−)-Galanthamine 
analogue  5.15 was synthesised by Liang et al. but it was found to have very poor     79
activity which highlighted the importance of the C ring in the structure of the parent 
compound.
129 
 
5.1.4  Labelled analogues of galanthamine 
In 2001, the US Food and Drug Administration approved the use of the hydrobromic 
acid salt of (−)-galanthamine ((−)-5.01) for the treatment of mild to moderate 
Alzheimer’s disease (under the name Razadyne® or Reminyl®).  In the process leading 
to the final approval, [
14C]-carbon-, tritium- and stable-isotope-labelled galanthamine 
analogues were synthesised for use in pharmacokinetic research.
130  The [
14C]-carbon-
containing galanthamine analogues were synthesised by the selective N- or O-
demethylation of galanthamine followed by reaction with [
14C]-methyl iodide to give 
compounds  5.16 and 5.17, respectively (Figure   5.4).  The stable-isotope-labelled 
galanthamine analogue 5.18 was obtained likewise by 
13CD3OD-methylation of O-
demethylated galanthamine under Mitsunobu conditions.  A tritium-containing (−)-
galanthamine analogue 5.19 was synthesised by the reduction of racemic (±)-1-
bromonarwedine using L-Selectride® and then bromo-tritium exchange followed by a 
final resolution. 
 
Also in 2001, Linnemann et al. synthesised a tritium-containing (−)-galanthamine 
analogue (5.20) to facilitate further investigation of AChE inhibition by galanthamine 
and to analyse the interaction between galanthamine and the nicotinic acetylcholine-
receptor (Figure   5.4).
131  The authors used tritiated L-Selectride® to reduce (−)-
narwedine ((−)-5.04) to give  tritiated (−)-galanthamine (5.20) in good yield.  This 
compound was subsequently used as a photoaffinity probe to aid the localisation of the 
allosteric binding site of (−)-galanthamine ((−)-5.01) at the nicotinic acetylcholine 
receptor (nAChR) in studies in vitro.
132  To examine the mechanism of the interaction of 
(−)-galanthamine ((−)-5.01) derivatives with nicotinic acetylcholine receptors, Schildan 
and co-workers synthesised tritium labelled 10-methylgalanthamine hydroiodide (5.21) 
(Figure   5.4).
133,134  Galanthamine was reacted with tritritium methyl iodide to give 
tritiated 10-methylgalanthamine hydroiodide (5.21) in a radiochemical yield of >70%. 
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More recently in 2008, Rouleau et al. reported the synthesis of deuterium labelled (−)-
galanthamine (5.22) for use in biological studies (Figure   5.4).
135  Their synthesis, 
starting with (−)-galanthamine ((−)-5.01), involved the selective O-demethylation and 
then the previously unknown N-demethylation via the N-oxide.  The secondary amine 
was then protected and alkylation of the phenol using dimethylsulfate-d6 was carried 
out.  Removal of the protecting group and treatment with deuterated sodium 
borohydride gave hexadeuterated (−)-galanthamine 5.22 in an overall yield of 25% over 
seven steps.  The inclusion of six deuterium atoms would allow better detection of this 
compound by a method based on deuterium analysis.
135 
 
 
Figure   5.4  Labelled analogues of (−)-galanthamine. 
 
Schildan and co-workers also mentioned, in an earlier symposium abstract, the synthesis 
of [
18F]-fluoride containing (−)-galanthamine derivatives 5.23 and 5.24, that had the     81
potential for use in PET studies and psychopharmacological examinations.
133  Their 
synthesis involved the fluoroalkylation of O-demethylated and N-demethylated (−)-
galanthamine using 2-[
18F]-fluoroethyltosylate in the same manner as in the first 
synthesis of [
18F]-FET (see Chapter 4).
90  The [
18F]-fluoride (−)-galanthamine 
derivatives 5.23 and 5.24 were found to have an allosteric potentiating affect (albeit 
weak) and an increased nicotinic response, although this was only 50% of that seen with 
(−)-galanthamine.
133  However, this showed that some activity was retained when the 
fluoroethoxy units were added to the basic structure of (−)-galanthamine ((−)-5.01) 
making them promising imaging agents for use in PET. 
 
The fluorinated (−)-galanthamine analogues 5.23 and 5.24 were of much interest to us 
due to the Brown group’s previous work on the total synthesis of (−)-galanthamine
116,119 
and our work on the RLV concept for the synthesis of labelled drug molecules for PET.  
Hence, we decided to undertake the synthesis of (−)-galanthamine analogue 5.23. 
 
5.1.5  Our strategy for the synthesis of galanthamine analogue 5.23 
The Brown group’s asymmetric synthesis of (−)-galanthamine ((−)-5.01) was published 
in 2007,
116 with a second generation synthesis completed a year later by Miller.
119  Our 
synthesis of (−)-galanthamine analogue 5.23 follows the synthetic pathway developed 
by Miller, using a modified starting material, to give diol 5.25.  Instead of starting with 
iso-vanillin, 3,4-dihydroxybenzaldehyde (5.26) would be selectively alkylated on the 4-
position using O-Boc protected bromoethanol (5.27) and then undergo a series of 
transformations, as previously described, to give aromatic fragment 5.28 (Scheme   5.2).  
Enantiomerically enriched propargylic fragment 5.29 would be coupled to aromatic 
fragment 5.28 before oxidative cleavage of the terminal olefin to give aldehyde 5.30.  
Asymmetric allylation would give alcohol 5.31 and enyne RCM would then be used to 
close the B ring.  Hydroboration, Heck coupling to close the C ring and finally azepine 
ring formation would provide alcohol 5.33.  Activation of the free hydroxyl group, 
either in solution phase via the formation of the tosylate or by attachment to the solid 
phase using the developed 4-alkylphenylsulfonate linker, followed by fluoridolysis 
would give fluorinated (−)-galanthamine analogue 5.23.     82
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Scheme   5.2  Retrosynthetic analysis of (−)-galanthamine analogue 5.23. 
 
5.2  Synthesis of galanthamine analogue (−)-5.25 
5.2.1  Synthesis of aromatic fragment 5.28 
The  O-hydroxy ethyl group, replacing the methoxy group on galanthamine, was 
installed at the beginning of the synthesis of aromatic fragment 5.28 as the O-Boc 
derivative.  Aromatic fragment 5.28 was synthesised from cheap, commercially 
available starting materials bromoethanol (5.34) and 3,4-dihydroxybenzaldehyde.  A 
range of reagents and conditions were tested in the reaction to form the O-Boc protected     83
bromoethanol (5.27).  The best yield was obtained following a modified procedure to 
that described by Mejorado et al. which used di-tert-butyldicarbonate, catalytic DMAP 
and DIPEA and gave bromoalkane 5.27 in good yield (Scheme   5.3).
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Scheme    5.3  Reagents and conditions: a) Di-tert-butyldicarbonate, DMAP, DIPEA, 
THF; b) 3,4-Dihydroxybenzaldehyde (5.26), NaH, DMF, 0 to 40 °C; c) ICl, pyridine, 
dioxane, 0 °C to rt; d) i) MeNH2, MeOH, ii) NaBH4, MeOH, molecular sieves, iii) Di-
tert-butyldicarbonate, sat aq NaHCO3, brine, CHCl3, 50 °C. 
 
The selective addition of bromoalkanes to the 4-position of 3,4-dihydroxybenzaldehyde 
(5.26) using sodium hydride in DMF had been reported previously by Nicolaou et al.
137  
In our hands, the reaction of bromoalkane 5.27 with 3,4-dihydroxybenzaldehyde (5.26) 
gave, in moderate yield, the desired aldehyde 5.35 as the major product, with addition to 
the 4-position.  The reaction also gave addition to the 3-position and the double addition 
product as minor by-products.  The double addition product was found to be an oil and 
so could be easily separated from the white solid of aldehyde 5.35 by recrystallisation.  
The 3-position addition product was found to be a solid of similar polarity to the 
product and so was very difficult to separate by column chromatography.  However, it 
was found not to react under the conditions of iodination, the next step in the synthesis, 
and so small amounts could be carried through and removed after the next step.  The O-
alkylation reaction to give aldehyde 5.35 was found not to have gone to completion 
even after reaction times of up to 5 days (
1H NMR of the crude reaction mixture showed 
30% of the starting 3,4-dihydroxybenzaldehyde to still be present).  Efforts to improve     84
the conversion of the reaction either by using more than one equivalent of sodium 
hydride or by increasing the reaction temperature above 40 °C were found to give 
predominately the undesired double addition product.  The use of sodium 
bis(trimethylsilyl)amide instead of sodium hydride was tested but upon addition this 
was observed to give an insoluble precipitate and TLC of the reaction mixture after 24 h 
showed no product to have formed. 
 
The regioselective iodination of aldehyde 5.35 was achieved using iodine monochloride 
according to the procedure described by Markovich et al.
138  The reaction is extremely 
slow requiring five days at room temperature to give aldehyde 5.36 in a yield of 51%.  
Aldehyde  5.36 was converted to N-Boc protected amine 5.28 via a three step 
condensation, reduction and N-Boc protection sequence.  The intermediate compounds 
were not isolated and the crude mixtures were carried through to give protected amine 
5.28 in a yield of 80% over three steps.  The conditions for the N-Boc protection were 
adjusted from those used by Miller (di-tert-butyldicarbonate, sodium hydroxide, 
dioxane)
119 because there was evidence to show that the phenol was also being 
protected.  The milder conditions of di-tert-butyldicarbonate in chloroform and a 
mixture of aqueous sodium carbonate and brine were successful to give protected amine 
5.28 with the free phenol group. 
 
5.2.2  Synthesis of enantiomerically enriched propargylic alcohol (+)-5.29 
The synthesis of enantiomerically enriched alcohol (+)-5.29 was achieved via the 
enzymatic resolution of racemic alcohol (±)-5.29 following the procedure described by 
Burova  et al.
139.  A Mitsunobu reaction was included to recycle the undesired 
enantiomer, transforming alcohol (−)-5.29 into acetate (+)-5.39 (Scheme   5.4). 
 
Commercially available TMS acetylene (5.37) was formylated in good yield following 
the procedure described by Journet et al.
140  The low boiling point of aldehyde 5.38 (40 
ºC, 25 mm/Hg
141) can make isolation and purification of the product difficult and lead 
to lower yields.  Miller reported a yield of 56% for this reaction carried out on a 56 
mmol scale and isolating the product by careful distillation at atmospheric pressure 
followed by purification by Kugelrohr distillation.
119  In our hands, the reaction was 
carried out on a 145 mmol scale, the bulk of the solvent was removed by distillation at     85
atmospheric pressure and the remaining solvent was removed under reduced pressure to 
give an increased yield of 81% of aldehyde 5.38 which was used without further 
purification.  Aldehyde 5.38 was then treated with allylmagnesium bromide to give 
racemic propargylic alcohol (±)-5.29 in good yield. 
 
 
Scheme    5.4  Reagents and conditions: a) n-BuLi, Et2O,  −40  °C, then DMF; b) 
Allylmagnesium bromide, Et2O, −50 to −10 °C; c) Amano® AK20 lipase, vinyl acetate, 
molecular sieves, hexane; d) DIAD, PPh3, AcOH, pyridine, THF, −50  °C to rt; e) 
DIBAL-H, CH2Cl2, −78 °C. 
 
The enzymatic resolution of racemic alcohol (±)-5.29 was achieved using Amano® 
AK20 lipase in the presence of vinyl acetate
139 which acylated only the desired (+)-
enantiomer to give acetate (+)-5.39 in excellent yield (94% theoretical maximum yield).  
The undesired enantiomer (−)-5.29 was inverted to give acetate (+)-5.39 in good yield 
through a Mitsunobu reaction using acetic acid as described by Jin et al.,
142 using DIAD 
as the azodicarboxylic coupling agent rather than DEAD as was published.   
Deprotection using DIBAL-H selectively cleaved the O-Ac protecting group and left the 
C-TMS protection in place to give alcohol (+)-5.29 in quantitative yield. 
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5.2.3  Mosher ester analysis to determine the absolute configuration and 
enantiomeric excess of alcohols (+)-5.29 and (−)-5.29 
The stereochemistry of alcohol (+)-5.29 fixes an important stereogenic centre in the 
final galanthamine analogue 5.23 and so we wanted to check that we had made the 
desired enantiomer and to establish enantiomeric purity.  The assignment of absolute 
configuration can be carried out in a number of ways including: the comparison of the 
optical rotation with synthetic analogues with known configuration; X-ray 
crystallographic or optical rotary dispersion methods; the use of NMR spectroscopy.
143  
Out of the NMR based methods, the one now most commonly used for the determining 
the absolute configuration of the stereogenic carbon centre in secondary alcohols was 
first reported in 1973
144 and has come to be known as the Mosher ester analysis.  This 
method involves the reaction of the alcohol of unknown configuration with both the R 
and S enantiomers of Mosher’s acid, α-methoxy-α-trifluoromethyl phenylacetic acid 
(MTPA).  This gives a pair of diastereomeric Mosher esters which will have differing 
1H NMR spectra and from the comparison of the chemical shifts of certain protons the 
absolute configuration of the original alcohol can be deduced. 
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Figure   5.5  Relationship between Mosher esters: dashed line – diastereoisomers; solid 
line – enantiomers. 
 
In order to determine the absolute configuration of alcohol (+)-5.29, the synthesis of the 
corresponding Mosher’s esters would be required.  To check the selectivity of the     87
enzymatic resolution using lipase Amano® AK20 the synthesis of Mosher esters of 
alcohol (−)-5.29 would also be required.  Additionally, this would give us a way of 
deducing the enantiomeric purity of alcohol (+)-5.29 by the comparison of the 
1H NMR 
spectra of the resulting Mosher esters of the two alcohols.  Mosher ester analysis 
normally requires the synthesis of both of the R and S Mosher esters of both alcohols.  
However, because of the relationship between diastereoisomers and enantiomers 
(enantiomers having identical physical and spectroscopic properties) for our strategy it 
was only necessary to synthesise one Mosher ester of each enantiomeric alcohol (see 
Figure   5.5). 
 
Mosher esters (+)-5.40 and (−)-5.40 were synthesised in moderate yields following the 
procedure of Fos et al.
145 using the R enantiomer of Mosher’s acid, (R)-(+)-MTPA.  The 
Mosher’s acid was first converted, using excess thionyl chloride, to the Mosher acid 
chloride, (S)-(+)-MTPA chloride, which was used without further purification in the 
formation of the R Mosher esters (+)-5.40  and  (−)-5.40  (note the change in the 
stereochemical description for the absolute configuration in the transformation from the 
R Mosher acid to the S Mosher acid chloride and back to the R Mosher ester due to a 
change in relative priority of the substituent groups).  The 
1H NMR spectra of the 
Mosher esters (+)-5.40  and  (−)-5.40  were then obtained and fully assigned.  The 
difference in chemical shifts for analogues pairs of protons were calculated according to 
the convention: Δδ(S−R) = δS − δR, the shift for the R Mosher ester is subtracted from the 
shift of the S Mosher ester. 
 
To assign the absolute configuration of alcohol (+)-5.29, the chemical shifts for 
analogues pairs of protons from Mosher ester (+)-5.40 (the R Mosher ester) were 
subtracted from those of Mosher ester (−)-5.40 (the enantiomer of the S Mosher ester, 
see Figure   5.5) and the results were tabulated (Table   5.1).  Protons with positive Δδ(S−R) 
values are found on the same side of the molecule as the phenyl ring of the MTPA 
portion and so are at the front of the molecule as drawn with Table   5.1.  This is due to 
the shielding effect of the phenyl ring which causes a more upfield chemical shift in the 
spatially proximal protons (indicated by the red arrow) and gives rise to the positive 
Δδ(S−R) value.  Protons with negative Δδ(S−R) values are found on the same side as the 
methoxy group of the MTPA and so are at the back of the molecule.     88
 
Proton  S-(MTPA) ester
(analogous to    
(−)-5.40) 
R-(MTPA) 
ester ((+)-5.40) 
Δδ(S−R)  Configuration 
CH=CH2  5.81 ppm  5.72 ppm  +0.09 
CH2  2.62 ppm  2.57 ppm  +0.05 
TMS  0.19 ppm  0.20 ppm  −0.01 
CH(O)  5.58 ppm  5.62 ppm  −0.04 
 
 
R 
Table   5.1  
1H NMR data for the assignment of the absolute configuration of Mosher 
ester (+)-5.40.  The red arrow in the figure represents the shielding effect of the phenyl 
group. 
 
 
Proton  S-(MTPA) ester
(analogous to    
(+)-5.40) 
R-(MTPA) 
ester ((−)-5.40) 
Δδ(S−R)  Configuration 
CH(O)  5.62 ppm  5.58 ppm  +0.04 
TMS  0.20 ppm  0.19 ppm  +0.01 
CH2  2.57 ppm  2.62 ppm  −0.05 
CH=CH2  5.72 ppm  5.81 ppm  −0.09 
 
 
S 
Table   5.2  
1H NMR data for the assignment of the absolute configuration of Mosher 
ester (−)-5.40.  The red arrow in the figure represents the shielding effect of the phenyl 
group. 
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Hence, the stereogenic centre in (+)-5.40  was assigned as R and that the absolute 
configuration of alcohol (+)-5.29 was inferred as being R as expected.  The same 
analysis was carried out for Mosher ester (−)-5.40 and the absolute configuration was 
found to be S (Table   5.2). 
 
The enantiomeric purity of alcohols (+)-5.29 and (−)-5.29 was determined by 
comparing the 
1H NMR spectra of the corresponding Mosher esters (+)-5.40 and (−)-
5.40.  In both spectra, the minor Mosher ester derivative was not observed (within the 
limits of the 300 MHz spectrometer used to acquire the spectra) and so the Mosher 
esters were deduced to be enantiomerically pure.  From this it was concluded that 
alcohols (+)-5.29 and (−)-5.29 were formed with an enantiomeric purity of >99:1. 
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Figure   5.6  
1H NMR spectra of Mosher esters (+)-5.40 (top) and (−)-5.40 (bottom).  
The peak at 3.51 ppm is due to the methoxy group in traces of unreacted MTPA. 
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This analysis has shown the enzymatic resolution using lipase Amano® AK20 to be 
very efficient as all of alcohol (+)-5.29 was converted to acetate (+)-5.39 during the 
reaction and all of alcohol (−)-5.29 was left untouched.  Alcohol (+)-5.29 was shown to 
have the desired absolute configuration and very high enantiomeric purity and so would 
give the galanthamine analogue 5.23 with the correct stereochemistry of the tertiary 
stereogenic centre connecting the B and D rings. 
 
5.2.4  Synthesis and asymmetric allylation of aldehyde 5.30 
The Mitsunobu coupling of phenol 5.28 and alcohol (+)-5.29 was carried out using 
DIAD as the coupling reagent following the modified conditions reported by Miller
119 
to give olefin (+)-5.41 in quantative yield (Scheme   5.5).  A two-step 
dihydroxylation/oxidative cleavage was then employed to afford aldehyde 5.30, as the 
direct conversion had previously been shown not to work for this system.
119 
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I
OH
O
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a
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b
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c
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Scheme   5.5  Reagents and conditions: a) DIAD, PPh3, THF, 55 °C; b) OsO4, NMO, 
citric acid, t-BuOH/H2O; c) NaIO4, acetone/H2O. 
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Dihydroxylation of olefin (+)-5.41 was carried out under acidic conditions as reported 
by Dupau et al. (OsO4, NMO, citric acid)
146 to give a moderate yield of diol 5.42 along 
with 12% recovered starting material.  The oxidative cleavage of diol 5.42 was 
mediated by sodium periodate and gave the desired aldehyde 5.30 in excellent yield. 
 
Scheme   5.6  Reagents and conditions: a) Allylmagnesium bromide, (R,R)-5.43, Et2O, 
−78 °C; b) TBAF, THF, 0 °C. 
 
The enantioselective allylation of aldehyde 5.30 was carried out using TiCpCl-(R,R)-
TADDOL ((R,R)-5.43) as this was found by Miller
119 to be superior to alternative 
asymmetric allylation reagents for this reaction.  The TADDOL complex was prepared 
in one step from commercially available starting materials in good yield following the 
procedure of Hafner et al.
147  The enantioselective allylation reaction afforded alcohol 
(+)-5.31 in excellent yield (Scheme   5.6).  The unmasking of the enyne was necessary 
before the RCM reaction to give the cyclohexene ring B could be performed.  Miller 
employed potassium carbonate in methanol for this transformation
119 although this was 
found to also remove the more labile O-Boc group.  The use of TBAF in this reaction 
left the O-Boc group untouched while successfully cleaving the TMS group to give 
enyne (+)-5.44 in excellent yield. 
 
5.2.5  Closure of the B and C rings 
The next step was a RCM reaction using the Grubbs’ I catalyst (5.45) to afford the 
closure of the B ring of the galanthamine backbone.  Miller previously found the     92
Grubbs’ I catalyst (5.45) mediated enyne RCM reaction to be incompatible with the 
substrate containing the secondary alcohol, possibly due to chelation of the Lewis-basic 
oxygen of the free hydroxyl group to the ruthenium of the catalyst.
119  Hence, it was 
necessary to protect the free hydroxyl group before carrying out the RCM reaction. 
Alcohol (+)-5.44 was protected as the O-TBS ether using standard conditions and in 
excellent yield.  The RCM reaction of enyne (−)-5.46 gave diene (−)-5.32 in good yield 
with low catalyst loading (Scheme   5.7), using two separate additions of Grubbs’ I 
catalyst (5.45).  The hydroboration of the terminal double bond of diene (−)-5.32 was 
carried out using 9-BBN to form the borane species which was then oxidised with 
sodium hydroxide and hydrogen peroxide to give the desired alcohol (−)-5.47 in good 
yield.   
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Scheme   5.7  Reagents and conditions: a) TBSOTf, 2,6-lutidiene, CH2Cl2, −78 to 0 °C; 
b) Grubbs’ I (5.45) (6 mol%), CH2Cl2, 40 °C; c) 9-BBN, THF then NaOH/H2O2; d) 
Pd(OAc)2, dppp, Ag2CO3, toluene, 90 °C. 
Gratifyingly, the O-Boc protecting group was unaffected by this reagent combination.  
Closure of the C ring was achieved via an intermolecular Heck reaction to give tricyclic     93
alcohol  (+)-5.48  in good yield, the stereochemistry at the newly formed quaternary 
centre being controlled by the adjacent stereocentre. 
 
5.2.6  Closure of the D ring to give galanthamine analogue (−)-5.25 
The closure of the D ring turned out to be much more troublesome than initially 
anticipated.  Ideally, we wanted to activate the primary alcohol in (+)-5.48, remove both 
the N-Boc and O-Boc protecting groups and close the D ring but leave the O-TBS 
protecting group in place.  This would then allow us to selectively fluorinate the 
primary alcohol on the O-ethoxy chain without complications arising from reactions of 
the secondary alcohol.  Miller’s strategy for the activation of the primary alcohol was to 
form the sulfonate ester although both the tosylate and mesylate were formed in lower 
than expected yields (53% and 59% respectively).
119  So alternative strategies for the 
activation of the primary alcohol and the subsequent ring closure were investigated. 
 
The first strategy investigated was the activation of alcohol (+)-5.48 as the 
corresponding bromide following the procedure described by Baughman et al. (Scheme 
 5.8).
148  The reaction gave a complex mixture of products that, with careful 
chromatography, gave a poor yield of bromide 5.49 which was found to have lost the O-
TBS protecting group.  The cyclisation of bromide 5.49 was successful to form the D 
ring and give diol (−)-5.25 in moderate yield although the loss of the O-TBS protecting 
group in the first step made this route less attractive.  The second strategy to be 
investigated was the conversion of alcohol (+)-5.48 to the aldehyde followed by 
deprotection of the N-Boc group and cyclisation via imine formation and finally 
reduction to give the tertiary amine (this strategy had been investigated in a earlier total 
synthesis of galanthamine in the Brown group by Satcharoen).
149  Aldehyde 5.50 was 
formed in good yield by the treatment of alcohol (+)-5.48 with Dess-Martin 
periodinane.  However, the two-step deprotection/cyclisation and then reduction 
reaction resulted in a very poor mass recovery and none of the desired cyclised product 
was detected (with or without the O-TBS protecting group present). 
     94
NBoc
O
O
OBoc
OTBS
H
(+)-5.48
OH
NBoc
O
O
OBoc
OH
H
5.49
Br
a
28%
NBoc
O
O
OBoc
OTBS
H
5.50
O
N
O
O
OH
OR
H
d c
67%
( )-5.25 R=H
or 5.32 R=T B S
N
O
O
OH
OH
H
( )-5.25
b
57%
 
Scheme   5.8  Reagents and conditions: a) CBr4, PPh3, CH2Cl2; b) TFA, CH2Cl2 then sat 
aq NaHCO3; c) Dess-Martin periodinane, CH2Cl2; d) (i) TFA, CH2Cl2, (ii) NaCNBH3, 
MeOH, molecular sieves. 
 
Since the alternative strategies failed to achieve the desired outcome, attention was 
turned back to the original method of alcohol activation via the formation of the 
tosylate.  This was a problem step in Miller’s synthesis of galanthamine, who employed 
tosyl chloride and pyridine for this reaction and obtained a disappointing 53% yield of 
the tosylate and 27% recovered starting material.
119  Using our experience in performing 
sulfonate ester forming reactions from the work involving the RLV constructs, we 
modified conditions to tosyl chloride and triethylamine with a catalytic amount of 
DMAP.  These conditions gave a much improved 86% yield of tosylate (+)-5.51 with 
no recovered alcohol starting material (Scheme   5.9).  The deprotection/cyclisation 
reaction was attempted using TFA to remove the Boc protecting groups, followed by 
aqueous sodium hydrogen carbonate to facilitate the SN2 displacement of the tosylate 
group by the free secondary amine.  Again, the reaction gave the cyclised product diol 
(−)-5.25 with undesired loss of the O-TBS protecting group, although it had been 
formed in a 59% yield.  Examination of the intermediates of the reaction indicated that     95
the O-TBS group was the most labile of the protecting groups under these conditions, as 
compounds that had only lost the O-TBS group and cyclised compounds that had lost 
the O-TBS group but still contained the O-Boc group were isolated.  These finding were 
contrary to what would be expected and contrasted with the findings of Miller who 
reported the O-TBS group as being the least labile under similar reaction conditions of 
AcCl in MeOH.
119  Unfortunately, we were unable to find conditions that retained the 
O-TBS group during the formation of the D ring. 
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Scheme   5.9  Reagents and conditions: a) TsCl, Et3N, DMAP, CH2Cl2; b) TFA, CH2Cl2 
then K2CO3, THF. 
 
Diol (−)-5.25 was found to have a significant solubility water, requiring a large number 
(>10) of extractions with organic solvent for it to be completely removed from the 
aqueous phase during workup.  This was impractical and could lead to loss of material 
and so reaction conditions which did not require use of an aqueous base or an aqueous 
workup were sought.  The reaction was tried using DBU as the base and although diol 
(−)-5.25 was formed in the reaction, we were not able to remove all of the DBU from 
the product even after column chromatography and drying under high vacuum.   
Gratifyingly, an alternative method whereby the TFA/CH2Cl2 from the deprotection 
step were removed in vacuo and the residue was re-dissolved in THF and treated with 
potassium carbonate to afford the ring closure gave the desired product after filtration of 
the reaction mixture.  Thus, diol (−)-5.25 was obtained in an improved 65% yield 
without the need for an aqueous workup. 
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5.3  Fluorination to give galanthamine analogue (−)-5.23 
Due to constraints on the amount of material available, it was decided not to attempt to 
attach diol (−)-5.25 to the solid phase using our developed linker system but to carry out 
the fluorination to give galanthamine analogue (−)-5.23 in solution phase only.  The loss 
of the O-TBS protecting group from the secondary alcohol when closing the D ring 
meant that, to give the desired fluorinated galanthamine analogue (−)-5.23, the selective 
fluorination of the primary alcohol in the presence of the secondary alcohol was 
required. 
 
 
Figure   5.7  Reagents that mediate dehydroxyfluorination reactions. 
 
There are a number of reagents available for the dehydroxyfluorination of alcohols, 
from diethylamine sulfurtrifluoride (DAST) which has been commercially available 
since the 1980s, Deoxo-Fluor
TM (a second generation DAST reagent) and more recently 
tetrafluoroethyldimethylamine (TFEDMA) and FLUOLEAD
TM (Figure   5.7).
150  Since 
primary alcohols are more reactive than secondary alcohols, it was postulated that the 
reaction of diol (−)-5.25 with one equivalent of DAST would lead to the desired 
product, fluoride (−)-5.23.  However, due to the small scale of the reaction (<0.02 mmol 
because of constraints in the amount of material remaining) it was extremely difficult to 
accurately add one equivalent of the DAST reagent to the reaction mixture which, upon 
workup, was found to contain both mono- and di-fluorination products. 
 
As the direct fluorination was found not to be selective for fluorination on the primary 
alcohol an alternative strategy involving the activation of the primary alcohol was 
investigated.  The mono-tosylation of diol (−)-5.25 was attempted using the same 
conditions as employed previously for the activation of the alcohol in the formation of 
the D ring and encouragingly, tosylation was observed exclusively on the primary 
alcohol to give tosylate 5.52 (Scheme   5.10).  However, there was evidence to show that 
nitrogen of the tertiary amine was sufficiently nucleophilic to be able to displace a     97
tosylate group on another molecule to form dimer 5.53.  It is believed that this 
dimerisation occurs predominately when the solution of tosylate 5.52 is concentrated 
and so this complication could be avoided by the in situ formation and displacement of 
the tosylate leaving group.  Shimizu et al. reported the use of tosyl fluoride and TBAF 
in THF for the chemoselective fluorination of primary alcohols in the presence of 
secondary and tertiary alcohols.
151  Diol (−)-5.25 was reacted under these conditions and 
although the desired fluoride (−)-5.23 was formed it was not possible to separate the 
TBAF reagent from the product due to the similarity in the polarity of these compounds. 
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Scheme   5.10  Reagents and conditions: a) TsCl, Et3N, DMAP, CH2Cl2. 
 
TLC investigations showed the alternative fluoride source of potassium fluoride and 
Kryptofix [2.2.2] to be separable from fluoride (−)-5.23 and these were also found to be 
soluble in THF.  Hence, the use of TBAF as the fluorinating agent was replaced with 
potassium fluoride and Kryptofix [2.2.2] and the reaction was repeated to give fluoride 
(−)-5.23 which was easily separated from the Kryptofix [2.2.2] by column 
chromatography on alumina.  However, the 
1H NMR spectrum of fluoride (−)-5.23 
showed it to contain impurities with tosyl-like signals and these were still found to be 
present after multiple purification attempts by column chromatography on alumina.   
Finally, passage through an Isolute SCX-2 cation exchange cartridge removed these 
impurities to give fluoride (−)-5.23, albeit in a low 9% isolated yield (Scheme   5.11).  
Unfortunately, there was insufficient material for this reaction to be optimised.       98
However, we are confident that the losses occurred during the purification stage and that 
the knowledge of the new purification strategy would lead to a significantly higher yield 
being obtained if this reaction was to be repeated. 
 
 
Scheme   5.11  Reagents and conditions: a) TsF, KF, Kryptofix, THF, 70 °C. 
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Figure   5.8  
1H NMR of fluorinated (−)-galanthamine analogue, fluoride (−)-5.23. 
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5.4  Conclusions 
An analogue of (−)-galanthamine with a fluoro-ethoxy group in place of the methoxy 
group was synthesised, with the backbone of the parent structure constructed following 
the synthetic pathway previously developed by Miller.
119  A n  O-ethoxy chain was 
installed early in the synthesis of aromatic fragment 5.28.  The synthesis of the 
enantiomerically enriched alcohol (+)-5.29 fragment was achieved using an enzymatic 
resolution and a Mosher ester analysis confirmed that the desired R enantiomer had 
been formed in an enantiomeric purity of >99:1.  The aromatic and alcohol fragments 
were coupled together and underwent a series of transformations to give a (−)-
galanthamine analogue, diol (−)-5.25.  As part of this work, the previously low yielding 
tosylation reaction as part of the formation of the D ring was optimised.  The selective 
mono-fluorination of diol (−)-5.25 gave fluorinated (−)-galanthamine analogue (−)-5.23. 
 
The galanthamine analogues diol (−)-5.25 and fluoride (−)-5.23 have been sent for 
testing to establish whether the activity of the parent compound is retained with the 
structural modifications. 
 
5.5  Further work 
The loss of the O-TBS group during the closure of the D ring made the subsequent 
fluorination more difficult due to complications involving the displacement of the 
protecting group on the secondary alcohol.  Hence, the use of a different protecting 
group on the secondary alcohol would have been desirable.  A series of small scale 
(<0.01 mmol) test reactions were carried out to investigate changing the O-TBS 
protecting group for a benzoyl protecting group (Scheme   5.12).  Due to the small scale 
of these reactions, full data was not obtained for each product although data to support 
the formation of the desired product was collected at each step (
1H NMR or MS).   
Tosylate  (+)-5.51, prior to closure of the D ring, was reacted with TBAF which 
selectively removed the O-TBS protecting group and the free secondary alcohol (5.54) 
was then reprotected as the benzoyl ester (5.55).  The deprotection/cyclisation reaction 
was then carried out using TFA followed by sodium hydrogen carbonate to close the D 
ring and crucially the benzoyl protecting group was retained to give alcohol 5.56.  
Fluorination of the free primary alcohol was then achieved using DAST as there were     100
no longer any issues with the selectivity of the reaction.  The benzoyl protecting group 
was then removed to give fluorinated (−)-galanthamine analogue (−)-5.23.  This 
reaction pathway, although less elegant due to the additional steps for the protecting 
group manipulations, avoids the risk of formation of dimer 5.53 and makes the 
fluorination reaction much simpler.  It could also be applied in the solution phase 
synthesis of [
18F]-fluoride labelled galanthamine analogue ([
18F]-(−)-5.23) by the use of 
[
18F]-DAST (first reported by Straatmann et al. in 1977)
152. 
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Scheme   5.12  A series of test reactions carried out on a <0.01 mmol scale.  Reagents 
and conditions: a) TBAF, THF; b) BzCl, Et3N, DMAP, CH2Cl2; c) TFA, CH2Cl2 then 
sat aq NaHCO3; d) DAST, CH2Cl2; e) K2CO3, MeOH. 
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A more elegant strategy would be to install the benzoyl protecting group earlier in the 
synthesis of the parent structure before the closure of the B ring by RCM.  Assuming it 
was tolerated through the subsequent transformations this approach would require less 
protecting group manipulations near the end of the synthesis.     102
Chapter 6 - Experimental 
6.1  General experimental 
All non-aqueous reactions were carried out under an inert atmosphere (nitrogen or 
argon) in oven or flame-dried glassware.  Reaction solvents were distilled before use: 
CH2Cl2 and MeOH were distilled over CaH2; THF and Et2O over 
sodium/benzophenone; toluene and hexane over sodium.  All other solvents and 
reagents were used as received.  The enzymes used were kindly donated by the 
manufacturer: Novozym 435® from NovoNordisk A/S and Amano® AK20 Lipase 
from Amano Enzyme Inc.  Column chromatography was carried out using Merck 
Kieselgel 60A (particle size 35-70 microns) unless stated otherwise.  Thin layer 
chromatography was carried out on Merck silica gel 60 F254, visualised under UV 
illumination (254 nm) and stained with potassium permanganate or phosphomolybdic 
acid (PMA).  Both 
1H and 
13C NMR spectra were recorded on either a Bruker AV-300 
spectrometer at 300 MHz and 75 MHz respectively or a Bruker DPX-400 spectrometer 
at 400 MHz and 100 MHz respectively in CDCl3 or acetone-d6 at 300 K.  Chemical 
shifts for proton and carbon spectra are reported on the δ scale in ppm and were 
referenced to residual solvent (CDCl3: 7.27 ppm for 
1H and 77.0 ppm for 
13C; acetone-
d6: 2.05 ppm for 
1H and 29.92 ppm for 
13C).  
19F NMR spectra were recorded on a 
Bruker AV-300 spectrometer at 282 MHz in CDCl3 at 300 K (decoupled) and were 
referenced to C6F6 (−162.9 ppm).  Infrared data were collected on a Thermo Nicolet 380 
FT-IR spectrometer with a Smart Orbit Goldengate attachment using OMNIC software.  
The IR spectra are reported in wavenumbers (cm
−1).  Absorption peaks are reported as 
either: weak (w), medium (m), strong (s) or broad (br).  Optical rotations were collected 
on an Optical Activity PolAAr 2001 machine.  Melting points were collected on a 
Gallenkamp Electrothermal® melting point apparatus and are uncorrected.  All 
electrospray low resolution mass spectra were recorded on a Waters ZMD quadrupole 
spectrometer.  EI and CI low resolution mass spectroscopic data were collected on a 
ThermoQuest TraceMS single quadrupole GC-MS.  High resolution mass spectroscopic 
data were collected on a Bruker Apex III FT-ICR-MS.  Yields for the resin coupling 
reactions describe the mass increase of the resin and are calculated from the theoretical 
mass gain using the loading of the unfunctionalised resin and the observed mass gain of 
the product resin.  In some cases these yields are >100% which may be due to     103
inaccuracies in the resin loading quoted by the supplier (Novabiochem) or to traces of 
reagent or solvent molecules in the resin matrix due to incomplete washing and/or 
drying of the product resin. 
 
6.2  Experimental detail 
6-Phenylhexanoic acid methyl ester (2.02)  
 
 
 
 
C13H18O2 
Mw = 206.28 gmol
−1 
Colourless oil 
 
Following the procedure of Hanessian et al.,
59 to a solution of 6-phenylhexanoic acid 
(2.01, 0.50 mL, 2.6 mmol) in MeOH (15 mL) at 0 °C was added TMSCl (1.30 mL, 10.4 
mmol).  The solution was stirred for 4 h at rt before it was quenched with water (2 mL) 
and concentrated in vacuo.  The residue was dissolved in CH2Cl2, dried over MgSO4 
and concentrated in vacuo.  The residue was purified by column chromatography 
(eluent 0-10% EtOAc/hexane) to give a colourless oil (550 mg, 2.6 mmol, 100%).   
Spectroscopic data were in agreement with those published in the literature.
59 
 
IR  νmax (neat) 3026 (w), 2933 (w), 2857 (w), 1736 (s), 1170 (m), 698 (s) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.32-7.25 (2H, m, CArH ortho to CH2), 7.22-7.15 
(3H, m, CArH meta and para to CH2), 3.67 (3H, s, C(O)OCH3), 2.63 
(2H, t, J = 7.7 Hz, CArCH2), 2.32 (2H, t, J = 7.5 Hz, C(O)CH2), 1.73-
1.60 (4H, m, C(O)CH2CH2CH2CH2), 1.44-1.32 (2H, m, 
C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3) δ 174.2 (C(O)OCH3), 142.5 (CArCH2), 128.4 (CArH 
meta to alkyl group), 127.9 (CArH ortho to alkyl group), 125.6 (CArH 
para to alkyl group), 51.4 (OCH3), 35.7 (CArCH2), 34.0 (C(O)CH2), 
31.0 (C(O)CH2CH2CH2), 28.7 (C(O)CH2CH2), 24.8 (CArCH2CH2).     104
LRMS
  (EI) 206 (M
+•, 12%), 174 ([M − MeOH]
+, 49%), 91 ([M − CH2C6H5]
+, 
100%). 
 
 
6-(4-Chlorosulfonyl-phenyl) hexanoic acid methyl ester (2.03) 
 
 
 
C13H17ClO4S 
Mw = 304.79 gmol
−1 
Colourless oil 
 
To a solution of methyl ester 2.02 (6.55 g, 31.8 mmol) in CH2Cl2 (60 mL) at 0 °C was 
added ClSO2OH (6.40 mL, 95.3 mmol).  The solution was allowed to slowly warm to rt 
and was stirred for 17.5 h.  The reaction mixture was concentrated in vacuo and the 
residue was dissolved in EtOAc (50 mL) and quenched with water.  The organic layer 
was separated and the aqueous layer was extracted with EtOAc (3 x 20 mL).  The 
combined organic layers were dried over MgSO4 and concentrated in vacuo.  The 
residue was dissolved in CH2Cl2 (40 mL) and cooled to 0 °C.  MeOH (20 mL) and AcCl 
(1.2 mL, 15.9 mmol) were added and the solution was stirred for 3.25 h.  The reaction 
mixture was concentrated in vacuo and the residue was purified by column 
chromatography (eluent 10-50% EtOAc/hexane) to give the title compound as a 
colourless oil (6.57 g, 21.6 mmol, 68%). 
 
IR  νmax (neat) 2943 (w), 2861 (w), 1735 (m), 1375 (m), 1174 (s), 573 (m) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.95 (2H, d, J = 8.6 Hz, CArH ortho to SO2Cl), 
7.42 (2H, d, J = 8.6 Hz, CArH meta to SO2Cl), 3.67 (3H, s, C(O)OCH3), 
2.75 (2H, t, J = 7.7 Hz, CArCH2), 2.33 (2H, t, J = 7.5 Hz, C(O)CH2), 
1.75-1.63 (4H, m, C(O)CH2CH2CH2CH2), 1.45-1.34 (2H, m, 
C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 173.9 (C(O)OCH3), 151.2 (CArCH2), 142.0 
(CArSO2Cl), 129.6 (CArH meta to SO2Cl), 127.1 (CArH ortho to SO2Cl),     105
51.5 (OCH3), 35.8 (CArCH2), 33.8 (C(O)CH2), 30.5 (C(O)CH2CH2CH2), 
28.6 (C(O)CH2CH2), 24.6 (CArCH2CH2). 
 
LRMS
  (ES+) m/z 305 [M + H]
+, 307 (
37Cl isotope peak), 322 [M + NH4]
+, 324 
(
37Cl isotope peak), 327 [M + Na]
+, 329 (
37Cl isotope peak). 
 
HRMS  (ES+) calcd for C13H17O4S
35ClNa [M + Na]
+ 327.0428, found 327.0427. 
 
 
6-[4-(2,2-Dimethyl-propoxysulfonyl) phenyl] hexanoic acid methyl ester (2.04) 
 
 
 
C18H28O5S 
Mw = 356.48 gmol
−1 
Colourless oil 
 
To a solution of neopentyl alcohol (12 mg, 0.14 mmol) in THF (2 mL) at rt was added 
NaHMDS (1.0 M sol in THF, 0.14 mL, 0.14 mmol).  A solution of sulfonyl chloride 
2.03 (43 mg, 0.14 mmol) in THF (1 mL) was added and the mixture was stirred for 5 h.  
The reaction mixture was diluted with EtOAc (5 mL) and washed with sat aq NH4Cl (2 
x 5 mL), water (2 x 5 mL) and sat aq NaCO3H (1 x 5 mL), dried over MgSO4 and 
concentrated in vacuo.  The residue was purified by column chromatography (eluent 5-
20% EtOAc/hexane) to give the title compound as a colourless oil (4 mg, 0.01 mmol, 
7%). 
 
IR  νmax (neat) 2956 (w), 2866 (w), 1736 (m), 1359 (m), 1176 (s), 967 (m) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.81 (2H, d, J = 8.4 Hz, CArH ortho to SO2O), 7.35 
(2H, d, J = 8.4 Hz, CArH meta to SO2O), 3.70 (2H, s, SO2OCH2), 3.67 
(3H, s, C(O)OCH3), 2.72 (2H, t, J = 7.9 Hz, CArCH2), 2.33 (2H, t, J = 
7.5 Hz, C(O)CH2), 1.68 (4H, quin, J = 7.5 Hz, C(O)CH2CH2CH2CH2), 
1.44-1.32 (2H, m, C(O)CH2CH2CH2), 0.90 (9H, s, C(CH3)3). 
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13C NMR  (100 MHz, CDCl3)  δ 174.0 (C(O)OCH3), 149.0 (CArCH2), 133.5 
(CArSO2O), 129.1 (CArH meta to SO2O), 128.0 (CArH ortho to SO2O), 
79.5 (SO2OCH2), 51.5 (OCH3), 35.6 (CArCH2), 33.8 (C(O)CH2), 31.7 
(C(CH3)3), 30.6 (C(O)CH2CH2CH2), 28.6 (C(O)CH2CH2), 26.0 
(C(CH3)3), 24.6 (CArCH2CH2). 
 
LRMS
  (ES+) m/z 379 [M + Na]
+, 735 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C18H28O5SNa [M + Na]
+ 379.1550, found 379.1555. 
 
 
6-[4-(3-Phenyl propoxysulfonyl) phenyl] hexanoic acid methyl ester (2.06) 
 
C22H28O5S 
Mw = 404.52 gmol
−1 
Colourless oil 
 
To a solution of 3-phenyl propan-1-ol (0.062 mL, 0.46 mmol) in CH2Cl2 (1 mL) was 
added Et3N (0.16 mL, 1.15 mmol) and sulfonyl chloride 2.03 (279 mg, 0.92 mmol) in 
CH2Cl2 (2 mL) and the solution was heated to reflux for 7 h.  The reaction mixture was 
diluted with CH2Cl2 (5 mL), washed with 2N HCl (1 x 10 mL), brine (1 x 10 mL) and 
water (1 x 10 mL), dried over MgSO4 and concentrated in vacuo.  The residue was 
purified by column chromatography (eluent 5-15% EtOAc/hexane) to give the title 
compound as a colourless oil (152 mg, 0.38 mmol, 82%) and recovered sulfonyl 
chloride 2.03 (32 mg, 0.11 mmol, 11%). 
 
IR  νmax (neat) 2935 (w), 2860 (w), 1735 (m), 1360 (m), 1174 (s), 928 (m) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) 7.82 (2H, d, J = 8.4 Hz, CArH ortho to SO2O), 7.35 
(2H, d, J = 8.4 Hz, CArH meta to SO2O), 7.29-7.13 (3H, m, CArH meta 
& para to CH2), 7.18 (2H, d, J = 6.6 Hz, CArH ortho to CH2), 4.06 (2H, 
t, J = 6.3 Hz, SO2OCH2), 3.69 (3H, s, C(O)OCH3), 2.75-2.63 (4H, m, 2     107
x CArCH2), 2.33 (2H, t, J = 7.4 Hz, C(O)CH2), 2.03-1.90 (2H, m, 
SO3CH2CH2), 1.74-1.62 (4H, m, C(O)CH2CH2CH2CH2), 1.45-1.32 (2H, 
m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 174.0 (C(O)OCH3), 149.1 (CArCH2), 140.4 
(CArCH2CH2CH2O), 133.5 (CArSO2O), 129.2 (CArH meta to SO2O), 
128.5 (CArH meta to CH2), 128.4 (CArH ortho to CH2), 128.0 (CArH 
ortho  to SO2O), 126.1 (CArH  para to CH2), 69.6 (SO2OCH2), 52.0 
(C(O)OCH3), 35.7 (CArCH2), 33.9 (C(O)CH2), 31.5 (SO2OCH2CH2), 
30.6 (C(O)CH2CH2CH2), 30.5 (SO2OCH2CH2CH2), 28.6 
(C(O)CH2CH2), 24.6 (CArCH2CH2). 
  
LRMS
  (ES+) m/z 405 [M + H]
+, 422 [M + NH4]
+, 427 [M + Na]
+, 831 [2M + 
Na]
+. 
 
HRMS  (ES+) calcd for C22H28O5SNa [M + Na]
+ 427.1550, found 427.1549. 
 
 
6-[4-(Phenyl propoxysulfonyl) phenyl] hexanoic acid (2.07) 
 
C21H26O5S 
Mw = 390.49 gmol
−1 
Colourless oil 
 
To a suspension of Novozym 435® (260 mg) in an aq phosphate buffer (pH 7, 1 mL) 
was added a solution of methyl ester 2.06 (262 mg, 0.65 mmol) in CH2Cl2/acetone/Et2O 
(3:1:1, 2.5 mL) and the mixture was stirred at 50 °C for 23.5 h.  The cold suspension 
was filtered through Celite®, the pad was washed with CHCl3 and EtOAc and the 
organic phase was concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 10-50% EtOAc/hexane) to give the title compound as a 
colourless oil (125 mg, 0.32 mmol, 49%) and recovered methyl ester 2.06 (46 mg, 0.11 
mmol, 22%). 
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IR  νmax (neat) 3028 (w), 2935 (br), 2860 (w),  1705 (s), 1358 (m), 1174 (s), 
926 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.83 (2H, d, J = 8.4 Hz, CArH ortho to SO2O), 7.36 
(2H, d, J = 8.4 Hz, CArH meta to SO2O), 7.28-7.14 (3H, m, CArH meta 
& para to CH2), 7.18 (2H, d, J = 6.6 Hz, CArH ortho to CH2), 4.08 (2H, 
t, J = 6.2 Hz, SO2OCH2), 2.76-2.62 (4H, m, 2 x CArCH2), 2.37 (2H, t, J 
= 7.3 Hz, C(O)CH2), 2.03-1.92 (2H, m, SO2OCH2CH2), 1.75-1.63 (4H, 
m, C(O)CH2CH2CH2CH2), 1.47-1.36 (2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 179.4 (C(O)OH), 149.1 (CArCH2), 140.4 
(CArCH2CH2CH2O), 133.5 (CArSO2O), 129.2 (CArH meta to SO2O), 
128.5 (CArH meta to CH2), 128.4 (CArH ortho to CH2), 128.0 (CH ortho 
to SO2O), 126.1 (CArH para to CH2), 69.6 (SO2OCH2),  35.6 (CArCH2), 
33.7 (C(O)CH2), 31.5 (SO2OCH2CH2), 30.6 (C(O)CH2CH2CH2), 30.5 
(SO2OCH2CH2CH2), 28.5 (C(O)CH2CH2), 24.3 (CArCH2CH2). 
  
LRMS
  (ES+) m/z 413 [M + Na]
+, 803 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C21H26O5SNa [M + Na]
+ 413.1393, found 413.1399. 
 
 
4-(5-Benzylcarbamoyl phenyl) benzenesulfonic acid 3-phenyl propyl ester (2.08) 
 
N
H
O
S
O O
O
C28H33NO4S 
Mw = 479.63 gmol
−1 
Colourless oil 
 
Carboxylic acid 2.07 (43 mg, 0.11 mmol) and HOBt (14 mg, 0.11 mmol) were 
dissolved in CH2Cl2 (1 mL) and stirred for 10 min at rt.  DIC (0.02 mL, 0.11 mmol) was 
added and the solution was stirred for 1.5 h.  Benzylamine (0.12 mL, 0.11 mmol) was 
added and the solution was stirred for 21 h.  The reaction mixture was diluted with     109
EtOAc (5 mL), washed with sat aq NaCO3H (1 x 10 mL), water (1 x 10 mL) and brine 
(1 x 10 mL), dried over MgSO4 and concentrated in vacuo.  The residue was purified by 
column chromatography (eluent 20-50% EtOAc/hexane) to give the title compound as a 
colourless oil (17 mg, 0.36 mmol, 33%). 
 
IR  νmax (neat) 3297 (br), 3063 (w), 3029 (w), 2932 (w), 2859 (w), 1647 
(m), 1540 (w),  1360 (m), 1174 (s), 929 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.81 (2H, d, J = 8.4 Hz, CArH ortho to SO2O), 
7.39-7.15 (10H, m, CArH), 7.09 (2H, d, J = 8.2 Hz, CArH), 5.65 (1H, s, 
NH) 4.45 (2H, d, J = 5.7 Hz, CH2NH), 4.06 (2H, t, J = 6.2 Hz, 
SO2OCH2), 2.75-2.62 (4H, m, 2 x CArCH2), 2.21 (2H, t, J = 7.5 Hz, 
C(O)CH2), 2.05-1.92 (2H, m, SO2OCH2CH2), 1.78-1.63 (4H, m, 
C(O)CH2CH2CH2CH2), 1.45-1.37 (2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 172.5 (C(O)NH), 149.2 (CArCH2), 140.4 
(CArCH2CH2CH2O), 138.3 (CArCH2NH), 133.4 (CArSO2O), 129.2 (CArH 
meta  to SO2O), 128.7 (CArH meta to CH2NH), 128.5 (CArH meta to 
CH2), 128.4 (CArH ortho to CH2), 127.9 (CArH ortho to SO2O), 127.8 
(CArH ortho to CH2NH), 127.5 (CArH para to CH2NH), 126.1 (CArH 
para to CH2), 69.6 (SO2OCH2), 43.6 (CH2NH), 36.5 (CArCH2), 35.6 
(C(O)CH2), 31.4 (SO2OCH2CH2), 30.7 (C(O)CH2CH2CH2), 30.4 
(SO2OCH2CH2CH2), 28.7 (C(O)CH2CH2), 25.3 (CArCH2CH2). 
  
LRMS
  (ES+) m/z 480 [M + H]
+, 502 [M + Na]
+, 981 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C28H34NO4S [M + H]
+ 480.2203, found 480.2197. 
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Solid supported 6-[4-(phenyl propoxysulfonyl) phenyl] hexanoic acid (2.09) 
 
 
Theoretical loading = 0.90 
mmolg
−1 
Resin beads 
 
To a solution of HOBt (65 mg, 0.48 mmol) and DIC (0.08 mL, 0.48 mmol) in 
DMF/CH2Cl2 (2:3, 1 mL) was added carboxylic acid 2.07 (120 mg, 0.25 mmol) in 
CH2Cl2 (1 mL) and amino methyl polystyrene resin (107 mg, loading 1.5 mmolg
−1, 0.16 
mmol).  The mixture was stirred at rt for 19 h after which time a ninhydrin test 
performed on a small sample of the resin beads was negative, indicating that all of the 
amino groups had reacted.  The resin was removed by filtration, washed with CH2Cl2 (3 
x 10 mL), MeOH (3 x 10 mL) and Et2O (3 x 10 mL) and dried in vacuo at 40 °C for 50 
h to give the product resin (177 mg, theoretical loading 0.90 mmolg
−1, 117%). 
 
IR  νmax (neat) 2924 (w), 1738 (s), 1366 (m), 1217 (m), 696 (m) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 7.87 (s, CArH ortho to SO2O), 7.40-7.10 (m, 
CArH meta to SO2O & CArH ortho, meta & para to CH2), 6.66 (amino 
methyl resin), 5.50 (s, NH), 4.45 (CH2NH), 4.11 (s, OCH2), 2.77-2.70 
(m, 2 x CArCH2), 2.26 (s, C(O)CH2), 2.02 (SO2OCH2CH2), 1.75 (s, 
C(O)CH2CH2CH2CH2), 1.46 (s, C(O)CH2CH2CH2). 
 
13C NMR  MAS (100 MHz, CDCl3)  δ 172.6 (C(O)NH), 149.3 (CArCH2), 145.3 
(amino methyl resin), 140.4 (CArCH2), 133.5 (CArSO2O), 129.3 (CArH 
meta to SO2O), 128.5 (CArH meta to CH2), 128.1 (CArH ortho to CH2), 
126.2 (CArH ortho to SO2O), 125.8 (CArH  para to CH2), 69.8 
(SO2OCH2), 43.4 (NCH2), 40.5 (amino methyl resin), 36.5 (CArCH2), 
35.8 (C(O)CH2), 31.5 (SO2OCH2CH2), 30.8 (C(O)CH2CH2CH2), 30.5 
(CArCH2), 28.9 (C(O)CH2CH2), 25.5 (CArCH2CH2). 
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6-(4-Chlorosulfonyl phenyl) hexanoic acid (2.10) 
 
HO
O
S
Cl O
O
 
C12H15ClO4S 
Mw = 290.76 gmol
−1 
Colourless oil 
 
To a solution of 6-phenylhexanoic acid (2.01, 150 mg, 0.78 mmol) in CHCl3 (2 mL) at 
0 °C was added ClSO2OH (0.16 mL, 2.34 mmol).  The reaction was slowly allowed to 
warm to rt and stirred for 17 h.  The reaction mixture was diluted with CHCl3 (5 mL) 
and poured onto an excess of ice.  The organic layer was separated and the aqueous 
layer was extracted with CHCl3 (2 x 10 mL).  The combined organic layers were 
washed with 2 N HCl (1 x 10 mL), dried over MgSO4 and concentrated in vacuo.  The 
residue was purified by column chromatography (eluent 20-50% EtOAc/hexane) to give 
a colourless oil (123 mg, 0.42 mmol, 54%). 
 
IR  νmax (neat) 2939 (br), 2860 (w), 1706 (s), 1593 (w), 1375 (m), 1174 (s), 
573 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.96 (2H, d, J = 8.6 Hz, CArH ortho to SO2Cl), 
7.42 (2H, d, J = 8.6 Hz, CArH meta to SO2Cl), 2.76 (2H, d, J = 7.7 Hz, 
CArCH2), 2.38 (2H, t, J = 7.3 Hz, C(O)CH2), 1.79-1.64 (4H, m, 
C(O)CH2CH2CH2CH2), 1.48-1.36 (2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 179.0 (C(O)OH), 151.0 (CArCH2), 142.0 
(CArSO2Cl), 129.6 (CArH meta to SO2Cl), 127.2 (CArH ortho to SO2Cl), 
35.7 (CArCH2), 33.6 (C(O)CH2), 30.4 (C(O)CH2CH2CH2), 28.4 
(C(O)CH2CH2), 24.3 (CArCH2CH2). 
  
LRMS
  (ES+) m/z 313 [M + Na]
+, 315 (
37Cl isotope peak). 
 
HRMS  (ES+) calcd for C12H15
35ClO4SNa [M + Na]
+ 313.0272, found 313.0271. 
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6-(4-(2-[4-(tert-Butoxycarbonyl phenyl amino) butoxy] sulfonyl) phenyl) hexanoic 
acid methyl ester (2.15) 
 
C28H39NO7S 
Mw = 533.68 gmol
−1 
Orange oil 
 
A solution of sulfonyl chloride 2.03 (5.94 g, 19.5 mmol), (4-hydroxy butyl) phenyl 
carbamic acid tert-butyl ester (2.14, 4.31 g, 16.3 mmol), Et3N (6.8 mL, 49.0 mmol) and 
DMAP (500 mg, 4.1 mmol) in CH2Cl2 (100 mL) was stirred at rt for 3.25 h.  The 
reaction mixture was diluted with CH2Cl2 (50 mL), washed with 2 N HCl (1 x 100 mL), 
water (1 x 100 mL) and brine (1 x 100 mL), dried over MgSO4 and concentrated in 
vacuo.  The residue was purified by column chromatography (eluent 10-60% 
EtOAc/hexane) to give the title compound as an orange oil (7.08 g, 13.3 mmol, 81%). 
 
IR  νmax (neat) 2935 (w), 2862 (w), 1736 (m), 1693 (s), 1597 (w), 1363 (m), 
1172 (s), 1146 (m) cm
−1. 
 
1H NMR  (400 MHz, CDCl3) δ 7.78 (2H, d, J = 8.5 Hz, CArH ortho to SO2O), 
7.37-7.30 (4H, m, CArH meta to SO2O & meta to N), 7.22 (1H, t, J = 7.5 
Hz, CArH para to N), 7.12 (2H, d, J = 7.5 Hz, CArH ortho to N), 4.03 
(2H, t, J = 6.5 Hz, SO2OCH2), 3.67 (3H, s, C(O)OCH3), 3.60 (2H, t, J = 
7.2 Hz, NCH2), 2.70 (2H, t, J = 7.8 Hz, CArCH2), 2.32 (2H, t, J = 7.4 Hz, 
C(O)CH2), 1.72-1.63 (6H, m, C(O)CH2CH2CH2CH2 & SO2OCH2CH2), 
1.60-1.52 (2H, m, NCH2CH2) 1.43-1.34 (11H, m, C(O)OC(CH3)3 & 
C(O)CH2CH2CH2). 
 
13C NMR  (100 MHz, CDCl3) δ 174.0 (C(O)OCH3), 154.7 (C(O)OC(CH3)3), 149.1 
(CArCH2), 142.2 (CArN), 133.4 (CArSO2O), 129.1 (CArH meta to SO2O), 
128.8 (CArH ortho to N), 127.9 (CArH ortho to SO2O), 127.1 (CArH meta 
to N), 126.1 (CArH para to N), 80.2 (C(O)OC(CH3)3), 70.1 (SO2OCH2), 
51.5 (C(O)CH3), 49.0 (CH2N), 35.6 (CArCH2), 33.8 (C(O)CH2), 30.6     113
(C(O)CH2CH2CH2),  28.6 (C(O)CH2CH2), 28.2 (C(O)OC(CH3)3), 26.1 
(SO2OCH2CH2), 24.6 (CArCH2CH2), 24.1 (CH2CH2N). 
  
LRMS
  (ES+) m/z 556 [M + Na]
+. 
 
HRMS  (ES+) calcd for C28H39NO7SNa [M + Na]
+ 556.2339, found 556.2330. 
 
 
General procedure A for sulfonate ester formation as part of the solution model 
studies 
 
To a solution of the sulfonyl chloride (2 eq) and the alcohol (1 eq) in CH2Cl2 was added 
Et3N (2.5 eq) and the solution was heated under reflux at 50 °C.  The cooled reaction 
mixture was diluted with CH2Cl2, washed with 2 N HCl, water, and brine, dried over 
MgSO4 and concentrated in  vacuo.  The residue was purified by column 
chromatography (eluent 5-40% EtOAc/hexane) to give the title compound. 
 
6-(4-(2-[4-(tert-Butoxycarbonyl phenyl amino) butoxy] sulfonyl) phenyl) hexanoic 
acid methyl ester (2.15) 
 
C28H39NO7S 
Mw = 533.68 gmol
−1 
Orange oil 
 
Sulfonyl chloride 2.03 (500 mg, 1.64 mmol) and alcohol 2.14 (218 mg, 0.82 mmol) 
were used in general procedure A and the reaction was stirred for 16 h to give the title 
compound as orange oil (155 mg, 0.29 mmol, 35%).  Spectroscopic data were consistent 
with those previously collected. 
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6-(4-(2-[4-(tert-Butoxycarbonyl phenyl amino) butoxy] sulfonyl) phenyl) hexanoic 
acid (2.16) 
 
C27H37NO7S 
Mw = 519.65 gmol
−1 
Colourless oil 
 
To a suspension of Novozym 435® (200 mg) in an aq phosphate buffer (pH 7, 4 mL) 
was added methyl ester 2.15 (197 mg, 0.37 mmol) in CH2Cl2/acetone (2:1, 1.5 mL) and 
the mixture was heated at 50 °C for 18 h.  The cooled suspension was filtered through 
Celite® and the pad was washed with CH2Cl2 (3 x 10 mL) and EtOAc (3 x 10 mL).  
The filtrate was concentrated in vacuo and the residue was purified by column 
chromatography (eluent 10-100% EtOAc/hexane) to give the title compound as a 
colourless oil (113 mg, 0.22 mmol, 59%) and recovered methyl ester 2.15 (22 mg, 0.04 
mmol, 11%). 
 
IR  νmax (neat) 2934 (br), 2862 (w), 1705 (w), 1693 (m), 1597 (w), 1364 
(m), 1172 (s) 1148 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.77 (2H, d, J = 8.4 Hz, CArH ortho to SO2O), 
7.37-7.28 (4H, m, CArH meta to SO2O & meta to N), 7.20 (1H, t, J = 7.3 
Hz, CArH para to N), 7.12 (2H, d, J = 7.3 Hz, CArH ortho to N), 4.02 
(2H, t, J = 6.3 Hz, SO2OCH2), 3.59 (2H, t, J = 7.0 Hz, NCH2), 2.70 (2H, 
t, J = 7.6 Hz, CArCH2), 2.35 (2H, t, J = 7.3 Hz, C(O)CH2), 1.74-1.60 
(6H, m, C(O)CH2CH2CH2CH2 & SO2OCH2CH2), 1.60-1.49 (2H, m, 
NCH2CH2) 1.45-1.33 (11H, m, C(O)OC(CH3)3 & C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 178.9 (C(O)OH), 154.8 (C(O)OC(CH3)3), 149.0 
(CArCH2), 142.1 (CArN), 133.3 (CArSO2O), 129.1 (CArH meta to SO2O), 
128.7 (CArH ortho to N), 127.9 (CArH ortho to SO2O), 127.0 (CArH meta 
to N), 126.2 (CArH para to N), 80.3 (C(O)OC(CH3)3), 70.1 (SO2OCH2), 
49.0 (CH2N), 35.6 (CArCH2), 33.7 (C(O)CH2), 30.5 (C(O)CH2CH2CH2),      115
28.4 (C(O)CH2CH2), 28.2 (C(O)OC(CH3)3), 26.0 (SO2OCH2CH2), 24.3 
(CArCH2CH2 & CH2CH2N). 
  
LRMS
  (ES+) m/z 542 [M + Na]
+. 
 
HRMS  (ES+) calcd for C27H37NO7SNa [M + Na]
+ 542.2183, found 542.2176. 
 
 
Solid supported 6-(4-(2-[4-(tert-butoxycarbonyl phenyl amino) butoxy] sulfonyl) 
phenyl) hexanoic acid (2.17) 
 
 
Loading = 0.80 mmolg
−1 
Resin beads 
 
To a solution of HOBt (53 mg, 0.39 mmol) and DIC (0.06 mL, 0.39 mmol) in DMF (0.6 
mL) was added carboxylic acid 2.16 (100 mg, 0.19 mmol) in CH2Cl2 (1.4 mL) and 
amino methyl polystyrene resin (87 mg, loading 1.5 mmolg
−1, 0.13 mmol).  The mixture 
was stirred at rt for 17 h after which time a ninhydrin test performed on a small sample 
of the resin beads was negative, indicating that all of the amino groups had reacted.  The 
resin was removed by filtration, washed with CH2Cl2 (3 x 10 mL), MeOH (3 x 10 mL) 
and Et2O (3 x 10 mL) and dried in vacuo at 40 °C for 24 h to give the product resin (157 
mg, theoretical loading 0.83 mmolg
−1, actual loading (S elemental analysis) 0.80 
mmolg
−1, 108%). 
 
IR  νmax (neat) 2970 (w), 1739 (m), 1365 (m) 1217 (m), 669 (m) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 7.77 (s, CArH ortho to SO2O), 7.32 (s, CArH 
meta to SO2O & ortho to N), 7.20 (s, CArH para to N), 7.12 (s, CArH 
meta  to N), 6.66 (amino methyl resin), 4.02 (s, SO2OCH2), 3.59 (s, 
NCH2), 2.70 (s, CArCH2), 2.35 (s, C(O)CH2), 1.70 (s, 
C(O)CH2CH2CH2CH2 & SO2OCH2CH2), 1.55 (s, NCH2CH2), 1.38 (s,     116
C(O)OC(CH3)3 & C(O)CH2CH2CH2). 
 
13C NMR  MAS (100 MHz, CDCl3) δ 172.8 (C(O)NH), 154.8 (C(O)OC(CH3)3), 
149.4 (CArCH2), 145.3 (amino methyl resin), 142.3 (CArN), 133.4 
(CArSO2O), 129.4 (CArH meta to SO2O), 129.0 (CArH ortho to N), 128.0 
(CArH ortho to SO2O), 127.2 (CArH meta to N), 126.3 (CArH para to N), 
80.3 (C(O)OC(CH3)3), 70.3 (SO2OCH2), 49.1 (CH2N), 43.3 (amino 
methyl resin), 40.6 (amino methyl resin), 36.4 (CArCH2), 35.4 
(C(O)CH2), 30.8 (C(O)CH2CH2CH2),  28.9 (C(O)CH2CH2), 28.4 
(C(O)OC(CH3)3), 26.2 (SO2OCH2CH2), 25.6 (CArCH2CH2), 24.6 
(CH2CH2N). 
  
 
(4-Fluoro butyl) phenyl carbamic acid tert-butyl ester (2.18) 
 
F
N O
O
 
C15H22FNO2 
Mw = 267.34 gmol
−1 
Colourless oil 
 
Solution Phase Method: A solution of sulfonate ester 2.15 (181 mg, 0.34 mmol), KF (24 
mg, 0.41 mmol) and 1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo [8.8.8] hexacosan (154 
mg, 0.41 mmol) in MeCN (7 mL) was heated under reflux for 15 min.  The cooled 
reaction mixture was concentrated in vacuo and the residue was dissolved in CH2Cl2 
and was washed with water.  The aqueous phase was re-extracted with CH2Cl2 (3 x 20 
mL) and the combined organic layers were washed with brine (1 x 20 mL), dried over 
Na2SO4 and concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 5-10% EtOAc/hexane) to give a colourless oil (47 mg, 0.18 
mmol, 52%). 
 
Solid Phase Method – General Procedure B: A suspension of the resin (1.0 eq), KF (1.2 
eq) and 1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo [8.8.8] hexacosan (1.2 eq) in MeCN 
(1 mL/40 μmol of resin) was heated to reflux for 30 min.  The resin was removed from 
the cooled suspension by filtration and was washed with CH2Cl2 (10 mL/40 μmol of     117
resin).  The filtrate was concentrated in vacuo and the residue was purified by column 
chromatography (eluent 20% EtOAc/hexane) to give the title compound as a colourless 
oil. 
 
Resin 2.17 (84 mg, 0.80 mmolg
−1, 67 μmol) was used in general procedure B to give the 
title compound (5 mg, 19 μmol, 28%). 
 
Resin 2.24 (95 mg, 0.81 mmolg
−1, 77 μmol) was used in general procedure B to give the 
title compound (6 mg, 22 μmol, 28%). 
 
Resin 2.30 (100 mg, 0.95 mmolg
−1, 95 μmol) was used in general procedure B to give 
the title compound (7 mg, 26 μmol, 27%). 
 
Resin 2.45 (50 mg, 0.58 mmolg
−1, 29 μmol) was used in general procedure B to give the 
title compound (1 mg, 3.7 μmol, 13%). 
 
IR  νmax (neat) 2970 (w), 1738 (w), 1694 (s), 1391 (m), 1366 (m), 1147 (m), 
698 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.45-7.29 (2H, m, CArH meta to N), 7.26-7.11 (3H, 
m, CArH ortho & para to N), 4.44 (2H, dt, 
2JHF = 47.4, J = 5.7 Hz, 
FCH2), 3.68 (2H, t, J = 7.0 Hz, NCH2), 1.82-1.64 (4H, m, 
FCH2CH2CH2), 1.43 (9H, s, C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 154.7 (C(O)C(CH3)3), 142.3 (CArN), 128.8 (CArH 
ortho to N), 127.1 (CArH meta to N), 126.1 (CArH para to N), 83.7 (d, J 
= 164.8 Hz, FCH2), 80.1 (C(O)OC(CH3)3), 49.4 (NCH2), 28.3 
(C(O)OC(CH3)3), 27.3 (d, J = 19.9 Hz, FCH2CH2), 24.3 (d, J = 4.4 Hz, 
NCH2CH2). 
 
19F NMR  (282 MHz, CDCl3) δ −218.4 (FCH2). 
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LRMS
  (ES+) m/z 290 [M + Na]
+, 557 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C15H22FNO2Na [M + Na]
+ 290.1527, found 290.1521. 
 
 
General procedure C for the solution phase fluoridative cleavage to give (4-fluoro 
butyl) phenyl carbamic acid tert-butyl ester (2.18) 
 
F
N O
O
 
C15H22FNO2 
Mw = 267.34 gmol
−1 
Colourless oil 
 
A solution of the sulfonate ester (1 eq), KF (1.2 eq) and Kryptofix 2.2.2 (1.2 eq) in 
MeCN was heated under reflux at 80 °C.  The cooled reaction mixture was concentrated 
in vacuo and the residue was dissolved in CH2Cl2, washed with water and the aqueous 
phase extracted was with CH2Cl2.  The combined organic layers were washed with 
brine, dried over Na2SO4 and concentrated in  vacuo.  The residue was purified by 
column chromatography (eluent 10% EtOAc/hexane) to give the title compound as a 
colourless oil.  Spectroscopic data were consistent with those previously collected. 
 
Sulfonate ester 2.31 (140 mg, 0.33 mmol) was used in general procedure C and the 
reaction was stirred for 45 min to give the title compound (56 mg, 0.21 mmol, 64%). 
 
Sulfonate ester 2.32 (149 mg, 0.33 mmol) was used in general procedure C and the 
reaction was stirred for 30 min to give the title compound (55 mg, 0.21 mmol, 62%). 
 
Sulfonate ester 2.33 (113 mg, 0.33 mmol) was used in general procedure C and the 
reaction was stirred for 3.5 h to give the title compound (66 mg, 0.25 mmol, 75%). 
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4-Phenyl butyric acid methyl ester (2.20) 
 
 
C11H14O2 
Mw = 178.23 gmol
−1 
Colourless liquid 
 
Following the procedure of Hanessian et al.,
59 to a solution of 4-phenyl-butyric acid 
(2.19, 5.00 g, 30.5 mmol) in MeOH (80 mL) at 0 ºC was added TMSCl (15.50 mL, 
121.8 mmol) and the solution was stirred for 1.5 h.  The reaction mixture was quenched 
with water (6 mL) and concentrated in vacuo.  The residue was dissolved in CH2Cl2, 
dried over MgSO4 and concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 20% EtOAc/ hexane) to give the title compound as a colourless 
liquid (4.17 g, 23.4 mmol, 77%).  Spectroscopic data were in agreement with those 
published in the literature.
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IR  νmax (neat) 3027 (w), 2950 (w), 1733 (s), 1454 (m), 1435 (m), 1201 (m), 
1143 (m), 745 (m), 699 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.37 (2H, m CArH ortho to CH2), 7.30-7.23 (3H, m, 
CArH meta & para to CH2), 3.74 (3H, s, OCH3), 2.73 (2H, t, J = 7.5 Hz, 
CArCH2), 2.41 (2H, t, J = 7.5 Hz, C(O)CH2), 2.04 (2H, quin, J = 7.5 Hz, 
C(O)CH2CH2). 
 
13C NMR  (75 MHz, CDCl3) δ 173.9 (C(O)OCH3), 141.3 (CArCH2),  128.5 (CArH 
meta to CH2), 128.4 (CArH ortho to CH2), 126.0 (CArH para to CH2), 
51.5 (C(O)CH3), 35.1 (CArCH2), 33.4 (C(O)CH2), 26.5 (C(O)CH2CH2). 
  
LRMS
  (EI) 178 (M
+•, 30%), 104 (C6H5CH2CH2CH
+, 89%), 91 (C6H5CH2
+, 
100%). 
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4-(4-Chlorosulfonyl phenyl) butyric acid methyl ester (2.21) 
 
 
C11H13ClO4S 
Mw = 276.74 gmol
−1 
Colourless oil 
 
To a solution of methyl ester 2.20 (3.10 g, 17.4 mmol) in CH2Cl2 (60 mL) at 0 ºC was 
added ClSO2OH (3.50 mL, 52.2 mmol).  The solution was allowed to slowly warm up 
to rt and it was stirred for 19 h.  The reaction mixture was concentrated in vacuo and the 
residue dissolved in Et2O (40 mL).  The solution was quenched with ice and the 
aqueous was layer separated and extracted with Et2O (2 x 20 mL).  The combined 
organic layers were dried over MgSO4 and concentrated in vacuo.  The residue was 
dissolved in CH2Cl2 (40 mL) and cooled to 0 ºC before MeOH (1 mL) and acetyl 
chloride (0.60 mL, 8.0 mmol) was added and the solution was stirred for 1 h.  Further 
MeOH (5 mL) and acetyl chloride (0.30 mL, 4.0 mmol) were added and the solution 
stirred for an additional 1 h.  The reaction mixture was concentrated in vacuo and the 
residue was purified by column chromatography (eluent 10% EtOAc/hexane) to give 
the title compound as a colourless oil (2.90 g, 10.5 mmol, 60%). 
 
IR  νmax (neat) 2952 (w), 1732 (m), 1593 (w), 1374(m), 1172 (s), 571 (s) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.97 (2H, d, J = 8.4 Hz, CArH ortho to SO2Cl), 
7.44 (2H, d, J = 8.4 Hz, CArH meta to SO2Cl), 3.69 (3H, s, OCH3), 2.80 
(2H, t, J = 7.5 Hz, CArCH2), 2.38 (2H, t, J = 7.5 Hz, C(O)CH2), 2.01 
(2H, quin, J = 7.5 Hz, C(O)CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 173.3 (C(O)OCH3), 150.1 (CArCH2), 142.2 
(CArSO2Cl), 129.7 (CArH meta to SO2Cl), 127.2 (CArH ortho to SO2Cl), 
51.7 (OCH3), 35.1 (CArCH2), 33.1 (C(O)CH2), 25.9 (C(O)CH2CH2). 
  
LRMS
  (ES+) m/z 299 [M + Na]
+, 301 (
37Cl isotope peak). 
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HRMS  (ES+) calcd for C11H13
35ClO4SNa [M + Na]
+ 299.0115, found 299.0115. 
 
 
4-(4-[4-(tert-Butoxycarbonyl phenyl amino) butoxysulfonyl] phenyl) butyric acid 
methyl ester (2.22) 
 
C26H35NO7S 
Mw = 505.62 gmol
−1 
Colourless oil 
 
A solution of sulfonyl chloride 2.21 (2.22 g, 8.0 mmol), (4-hydroxy butyl) phenyl 
carbamic acid tert-butyl ester (2.14, 1.78 g, 6.7 mmol), Et3N (2.30 mL, 16.8 mmol) and 
DMAP (208 mg, 1.7 mmol) in CH2Cl2 (30 mL) was stirred at rt for 2.5 h.  The reaction 
mixture was diluted with CH2Cl2 (10 mL), washed with 2 N HCl (1 x 30 mL), water (1 
x 30 mL) and brine (1 x 30 mL), dried over MgSO4 and concentrated in vacuo.  The 
residue was purified by column chromatography (eluent 20-40% EtOAc/hexane) to give 
the title compound as a colourless oil (2.92 g, 5.8 mmol, 86%). 
 
IR  νmax (neat) 2952 (w), 1736 (m), 1694 (s), 1597 (w), 1364 (m), 1175 (s) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.80 (2H, d, J = 8.3 Hz, CArH ortho to SO2O), 
7.38-7.30 (4H, m, CArH meta to SO2O & meta to N), 7.20 (1H, tt, J = 
7.5, 2.1 Hz, CArH para to N), 7.13 (2H, d, J = 7.5 Hz, CArH ortho to N), 
4.02 (2H, t, J = 6.2 Hz, SO2OCH2), 3.69 (3H, s, OCH3), 3.60 (2H, t, J = 
7.0 Hz, NCH2), 2.74 (2H, t, J = 7.5 Hz, CArCH2), 2.36 (2H, t, J = 7.3 Hz, 
C(O)CH2), 1.98 (2H, tt, J = 7.5, 7.3 Hz, C(O)CH2CH2), 1.71-1.53 (4H, 
m, SO2OCH2CH2CH2), 1.51 (9H, s, C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3)  δ 176.1 (C(O)CH3), 154.7 (NC(O)O), 148.0 
(CArCH2), 138.6 (CArN), 133.8 (CArSO2O),  129.3 (CArH meta to SO2O), 
128.8 (CArH ortho to N), 128.0 (CArH ortho to SO2O), 127.1 (CArH meta     122
to N), 126.2 (CArH para to N), 80.2 (C(O)OC(CH3)3), 70.1 (SO2OCH2), 
51.6 (OCH3), 49.0 (CH2N),  35.0 (CArCH2), 33.2 (C(O)CH2), 28.3 
(C(O)OC(CH3)3), 26.2 (SO2OCH2CH2),  26.0 (C(O)CH2CH2), 24.5 
(CH2CH2N). 
 
LRMS
  (ES+) m/z 528 [M + Na]
+, 1034 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C26H35NO7SNa [M + Na]
+ 528.2026, found 528.2027. 
 
 
4-(4-[4-(tert-Butoxycarbonyl phenyl amino) butoxysulfonyl] phenyl) butyric acid 
(2.23) 
 
HO
O
S
O O
O
N
O
O
C25H33NO7S 
Mw = 491.60 gmol
−1 
Colourless oil 
 
To a suspension of Novozym 435® (250 mg) in aq phosphate buffer (pH 7, 5 mL) was 
added methyl ester 2.22 (228 mg, 0.45 mmol) in CH2Cl2/acetone (4:3, 3.5 mL) and the 
mixture was stirred at 50 °C for 22 h.  Further Novozym 435® (100 mg) was added and 
the suspension stirred for an additional 7 h.  The cooled reaction mixture was filtered 
through a pad of Celite® and the pad was washed with CH2Cl2 (20 mL).  The filtrate 
was acidified with 2N HCl, the organic layer separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL).  The combined organic layers were dried over 
MgSO4 and concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 20-40% EtOAc/hexane) to give the title compound as a 
colourless oil (128 mg, 0.26 mmol, 58%). 
 
IR  νmax (neat) 2974 (w), 2934 (w), 1733 (w), 1693 (m), 1597(w), 1363 (m), 
1173 (s), 935 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.80 (2H, d, J = 8.2 Hz, CArH ortho to SO2O),     123
7.39-7.31 (4H, m, CArH meta to SO2O & meta to N), 7.21 (1H, t, J = 7.5 
Hz, CArH para to N), 7.12 (2H, d, J = 7.5 Hz, CArH ortho to N), 4.05 
(2H, t, J = 6.3 Hz, SO2OCH2), 3.60 (2H, t, J = 7.1 Hz, NCH2), 2.77 (2H, 
t, J = 7.3 Hz, CArCH2), 2.40 (2H, t, J = 7.3 Hz, C(O)CH2), 2.00 (2H, 
quin, J = 7.3 Hz, C(O)CH2CH2), 1.72-1.50 (4H, m, SO2OCH2CH2CH2), 
1.40 (9H, s, C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 178.2 (C(O)OH), 154.8 (NC(O)O), 147.8 (CArCH2), 
142.1 (CArN), 133.8 (CArSO2O),  129.3 (CArH meta to SO2O), 128.8 
(CArH meta to CN), 128.0 (CArH ortho to SO2O), 127.1 (CArH meta to 
N), 126.2 (CArH para to N), 80.3 (C(O)OC(CH3)3), 70.2 (SO2OCH2), 
48.9 (CH2N),  34.9 (CArCH2), 33.0 (C(O)CH2), 28.3 (C(O)OC(CH3)3), 
26.2 (SO2OCH2CH2),  25.6 (C(O)CH2CH2), 24.3 (CH2CH2N). 
 
LRMS
  (ES+) m/z 514 [M + Na]
+, 1006 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C25H33NO7SNa [M + Na]
+ 514.1870, found 514.1877. 
 
 
Solid supported 4-(4-[4-(tert-butoxycarbonyl phenyl amino) butoxysulfonyl] 
phenyl) butyric acid (2.24) 
 
 
Loading = 0.81 mmolg
−1 
Resin beads 
 
To a solution of HOBt (97 mg, 0.72 mmol) in DMF (1.2 mL) was added carboxylic acid 
2.23 (119 mg, 0.24 mmol) in CH2Cl2 (2.8 mL) and the solution was stirred at rt for 10 
min.  DIC (0.11 mL, 0.72 mmol) was added and the solution was stirred for a further 10 
min.  Amino methyl polystyrene resin (110 mg, 1.5 mmolg
−1, 0.16 mmol) was added 
and the suspension was stirred for 18 h after which time a ninhydrin test on a sample of 
resin beads was negative.  The resin was removed by filtration, washed with CH2Cl2 (3 
x 10 mL), MeOH (3 x 10 mL) and Et2O (3 x 10 mL) and dried in vacuo at 40 ºC for 35     124
h to give the product resin (174 mg, theoretical loading 0.92 mmolg
−1, actual loading (S 
elemental analysis) 0.81 mmolg
−1, 84%). 
 
IR  νmax (neat) 3360 (br), 3023 (w), 2924 (w), 1694 (m), 1598 (w), 1493 
(m), 1363 (m), 1173 (m), 697 (s) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 7.76 (s, CArH ortho to SO2O), 7.30 (s, CArH 
meta to SO2O), 7.18 (s, CArH ortho to N), 7.11 (s, CArH para to N), 7.10 
(s, CArH meta to N), 6.54 (amino methyl resin), 4.28 (amino methyl 
resin), 4.01 (s, SO2OCH2), 3.58 (s, NCH2), 2.71 (s, CArCH2), 2.16 (s, 
NC(O)CH2), 1.98 (s, NC(O)CH2CH2), 1.82 (amino methyl resin), 1.64 
(s, CH2CH2N), 1.54 (s, SO3CH2CH2), 1.39 (s, C(O)OC(CH3)3). 
 
13C NMR  MAS (100 MHz, CDCl3) δ 172.3 (NC(O)CH2), 155.1 (NC(O)O), 148.7 
(CArCH2), 145.5 (amino methyl resin), 142.5 (CArN), 134.1 (CArSO2O),  
129.8 (CArH meta to SO2O), 129.3 (CArH ortho to N), 128.4 (CArH ortho 
to SO2O), 127.5 (CArH meta to N), 126.6 (CArH para to N), 80.6 
(C(O)OC(CH3)3), 70.7 (SO2OCH2), 49.4 (CH2N), 43.8 (amino methyl 
resin), 40.8 (amino methyl resin), 35.8 (CArCH2), 35.5 NC(O)CH2), 28.7 
(C(O)OC(CH3)3), 27.0 (SO2OCH2CH2),  26.5 (C(O)CH2CH2), 24.9 
(CH2CH2N). 
  
 
Phenyl acetic acid methyl ester (2.26) 
 
 
C9H10O2 
Mw = 150.17 gmol
−1 
Pale yellow liquid 
 
Following the procedure of Hanessian et al.,
59 to a solution of phenyl acetic acid (2.25, 
20.00 g, 146.9 mmol) in MeOH (200 mL) at 0 ºC was added TMSCl (19.00 mL, 146.9 
mmol) and the solution was stirred for 2.25 h.  The solvent was removed and the residue 
was diluted with ether (150 mL) and washed with sat aq NaCO3H (1 x 50 mL).  The     125
aqueous layer was extracted with ether (2 x 50 mL).  The combined organic layers were 
dried over MgSO4 and concentrated in vacuo to give the crude product as a pale yellow 
liquid (21.14 g, 140.8 mmol, 96%).  The crude product was used in subsequent 
reactions without further purification.  Spectroscopic data were in agreement with those 
published in the literature.
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IR  νmax (neat) 3031 (w), 2952 (w), 1733 (s), 1435 (m), 1252 (m), 1139 (m), 
696 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.40-7.25 (5H, m, CArH), 3.71 (3H, s, OCH3), 3.65 
(2H, s, C(O)CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 172.0 (C(O)CH3), 134.0 (CArCH2), 129.2 (CArH 
ortho to CH2), 128.8 (CArH meta to CH2), 127.1 (CArH para to CH2), 
52.0 (OCH3), 41.2 (C(O)CH2). 
 
LRMS
  (ES+) m/z 173 [M + Na]
+. 
 
 
(4-Chlorosulfonyl phenyl) acetic acid methyl ester (2.27) 
 
 
C9H9ClO4S 
Mw = 248.68 gmol
−1 
Colourless liquid 
 
To a solution of methyl ester 2.26 (1.93g, 12.8 mmol) in CH2Cl2 (40 mL) at 0 °C was 
added ClSO2OH (2.60 mL, 38.4 mmol) and the solution was allowed to slowly warm to 
rt.  Further ClSO2OH (0.90 mL, 12.8 mmol) was added after 17 h and the solution was 
stirred for a total of 21 h.  The reaction mixture was concentrated in vacuo and the 
residue was dissolved in Et2O (40 mL) and quenched with water (30 mL).  The aqueous 
layer was separated and extracted with Et2O (2 x 30 mL).  The combined organic layers 
were dried over MgSO4 and concentrated in vacuo.  The residue was dissolved in 
CH2Cl2 (30 mL) and cooled to 0 °C.  MeOH (5 mL) and AcCl (0.70 mL, 9.6 mmol)     126
were added and the solution was stirred for 1.5 h.  The reaction mixture was 
concentrated in vacuo and the residue was purified by column chromatography (eluent 
10% EtOAc/hexane) to give the title compound as a colourless liquid (1.08 g, 4.3 mmol, 
34%). 
 
IR  νmax (neat) 2954 (w), 1733 (m), 1372 (m), 1164 (s), 567 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.01 (2H, d, J = 8.5 Hz, CArH ortho to SO2Cl), 
7.55 (2H, d, J = 8.5 Hz, CArH meta to SO2Cl), 3.77 (2H, s, C(O)CH2), 
3.75 (3H, s, OCH3). 
 
13C NMR  (75 MHz, CDCl3)  δ 170.3 (C(O)CH3), 142.0 (CArCH2), 135.4 
(CArSO2Cl), 130.7 (CArH meta to SO2Cl), 127.3 (CArH ortho to SO2Cl), 
52.5 (OCH3), 40.9 (C(O)CH2). 
 
LRMS
  (ES+) m/z 271 [M + Na]
+, 273 (
37Cl isotope peak). 
 
HRMS  (ES+) calcd for C9H9
35ClO4SNa [M + Na]
+ 270.9802, found 270.9804. 
 
 
(4-[4-(tert-Butoxycarbonyl phenyl amino) butoxysulfonyl] phenyl) acetic acid 
methyl ester (2.28) 
 
C24H31NO7S 
Mw = 477.57 gmol
−1 
Orange oil 
 
To a solution of sulfonyl chloride 2.27 (3.76 g, 15.1 mmol) and (4-hydroxy butyl) 
phenyl carbamic acid tert-butyl ester (2.14, 2.00 g, 7.5 mmol) in CH2Cl2 (50 mL) was 
added Et3N (2.60 mL, 18.8 mmol) and the mixture was stirred at 50 ºC for 3 h to give a 
yellow/green solution.  The cooled reaction mixture was diluted with CH2Cl2, washed 
with 2N HCl (1 x 50 mL), water (1 x 50 mL) and brine (1 x 50 mL), dried over MgSO4 
and concentrated in vacuo.  The residue was purified by column chromatography     127
(eluent 10-40% EtOAc/hexane) to give the title compound as an orange oil (2.94 g, 6.2 
mmol, 83%).   
 
IR  νmax (neat) 2976 (w), 1737 (m), 1690 (s), 1364 (m), 1145 (s), 729 (m), 
697 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.82 (2H, d, J = 8.4 Hz, CArH ortho to SO2O), 7.46 
(2H, d, J = 8.4 Hz, CArH meta to SO2O), 7.32 (2H, t, J = 7.5 Hz, CArH 
meta to N), 7.20 (1H, t, J = 7.5 Hz, CArH para to N), 7.13 (2H, d, J = 7.5 
Hz, CArH ortho to N), 4.03 (2H, t, J = 6.2 Hz, SO2OCH2), 3.73 (5H, s, 
CH3OC(O)CH2), 3.60 (2H, t, J = 7.0 Hz, NCH2), 1.70-1.50 (4H, m, 
SO3CH2CH2CH2), 1.40 (9H, s, C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3)  δ 170.7 (C(O)OCH3), 154.7 (NC(O)O), 142.1 
(CArCH2), 140.1 (CArN), 134.8 (CArSO2O),  130.2 (CArH meta to SO2O), 
128.8 (CArH ortho to N), 128.0 (CArH ortho to SO2O), 127.0 (CArH meta 
to N), 126.1 (CArH para to N), 80.2 (C(O)OC(CH3)3), 70.3 (SO2OCH2), 
52.3 (OCH3), 48.9 (CH2N), 40.8 (C(O)CH2), 28.2 (C(O)OC(CH3)3), 
26.1 (SO2OCH2CH2),  24.4 (CH2CH2N). 
 
LRMS
  (ES+) m/z 500 [M + Na]
+. 
 
HRMS  (ES+) calcd for C24H31NO7SNa [M + Na]
+ 500.1713, found 500.1721. 
 
 
(4-[4-(tert-Butoxycarbonyl phenyl amino) butoxysulfonyl] phenyl)acetic acid (2.29) 
 
 
C23H29NO7S 
Mw = 463.54 gmol
−1 
Colourless oil 
 
To a suspension of Novozym 435® (2.80 g) in aq phosphate buffer (pH 7, 60 mL) was 
added methyl ester 2.28 (2.84 g, 6.0 mmol) in CH2Cl2/acetone (4:3, 46 mL) and the     128
solution was stirred at 50 °C for 23 h.  Further Novozym 435® (1.00 g) was added and 
the suspension stirred for a further 24 h.  The cooled reaction mixture was filtered 
through a pad of Celite® and the pad was washed with CH2Cl2.  The filtrate was 
acidified with 2N HCl, the organic layer separated and the aqueous layer was extracted 
with CH2Cl2 (4 x 100 mL).  The combined organic layers were dried over MgSO4 and 
concentrated in vacuo.  The residue was purified by column chromatography (eluent 20-
60% EtOAc/hexane) to give the title compound as a colourless oil (1.25 g, 2.7 mmol, 
45%) and recovered methyl ester 2.28 (522 mg, 1.0 mmol, 17%). 
 
IR  νmax (neat) 2970 (w), 1738 (m), 1625 (m), 1365 (m), 1174 (m), 912 (m), 
726 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.85 (2H, d, J = 8.4 Hz, CArH ortho to SO2O), 7.47 
(2H, d, J = 8.4 Hz, CArH meta to SO2), 7.33 (2H, t, J = 7.3 Hz, CArH 
meta to N), 7.22 (1H, t, J = 7.3 Hz, CArH para to N), 7.12 (2H, d, J = 7.3 
Hz, CArH ortho to N), 4.04 (2H, t, J = 6.2 Hz, SO2OCH2), 3.74 (2H, s, 
C(O)CH2), 3.59 (2H, t, J = 7.1 Hz, NCH2), 1.75-1.46 (4H, m, 
SO2OCH2CH2CH2), 1.40 (9H, s, C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 174.5 (C(O)OH), 154.8 (NC(O)O), 142.2 (CArCH2), 
139.6 (CArN), 135.2 (CArSO2O),  130.3 (CArH meta to SO2O), 128.8 
(CArH ortho to N), 128.1 (CArH ortho to SO2O), 127.1 (CArH meta to 
N), 126.2 (CArH para to N), 80.4 (C(O)OC(CH3)3), 70.4 (SO2OCH2), 
49.0 (CH2N), 40.6 (C(O)CH2), 28.3 (C(O)OC(CH3)3), 26.1 
(SO2OCH2CH2),  24.4 (CH2CH2N). 
 
LRMS
  (ES+) m/z 486 [M + Na]
+, 950 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C23H29NO7S [M + Na]
+ 486.1557, found 486.1560. 
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Solid supported (4-[4-(tert-butoxycarbonyl phenyl amino) butoxysulfonyl] phenyl) 
acetic acid (2.30) 
 
 
Loading = 0.95 mmolg
−1 
Resin beads 
 
To a solution of HOBt (703 mg, 5.2 mmol) in DMF (12 mL) was added carboxylic acid 
2.29 (1.23 g, 2.6 mmol) in CH2Cl2 (28 mL) and the solution was stirred at rt for 10 min.  
DIC (0.80 mL, 5.2 mmol) was added and the solution was stirred for a further 10 min.  
Amino methyl polystyrene resin (1.13 g, 1.5 mmolg
−1, 1.7 mmol) was added and the 
suspension was stirred for 21 h after which time a ninhydrin test on a small sample of 
resin beads was negative, indicating that all of the amino groups had reacted.  The resin 
was removed by filtration, washed with CH2Cl2 (3 x 100 mL), MeOH (3 x 100 mL) and 
Et2O (3 x 100 mL) and dried in vacuo at 40 ºC for 35 h to give the product resin (1.98 g, 
theoretical loading 0.86 mmolg
−1, actual loading (S elemental analysis) 0.95 mmolg
−1, 
112%). 
 
IR  νmax (neat) 3308 (br), 3025 (w), 2923 (w), 1684 (m), 1598 (w), 1493 
(m), 1363 (m), 1173 (m), 696 (s) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 7.83 (s, CArH ortho to SO2O), 7.45 (s, CArH 
meta to SO2O), 7.35 (s, CArH ortho to N), 7.22 (s, CArH para to N), 7.17 
(s, CArH meta to N), 6.63 (amino methyl resin), 4.05 (s, SO2OCH2), 3.63 
(s, CH2N), 3.52 (s, NC(O)CH2), 1.68 (s, SO2OCH2CH2), 1.60 (s, 
CH2CH2N), 1.44 (s, C(O)OC(CH3)3). 
 
13C NMR  MAS (100 MHz, CDCl3) δ 169.1 (NC(O)CH2), 154.8 (NC(O)O), 145.2 
(amino methyl resin), 142.2 (CArCH2), 141.7 (CArN),  134.7 (CArSO2O), 
130.2 (CArH meta to SO2O), 128.9 (CArH ortho to N), 128.1 (CArH ortho 
to SO2O), 127.2 (CArH meta to N), 126.3 (CArH para to N), 80.3 
(C(O)OC(CH3)3), 70.5 (SO2OCH2), 49.1 (CH2N), 43.1 (amino methyl     130
resin), 40.8 (NC(O)CH2), 28.4 (C(O)OC(CH3)3), 26.2 (SO2OCH2CH2),  
24.5 (CH2CH2N). 
  
 
Toluene-4-sulfonic acid 4-(tert-butoxycarbonyl phenyl amino) butyl ester (2.31) 
 
 
C22H29NO5S 
Mw = 419.53 gmol
−1 
Colourless oil 
 
Toluene sulfonyl chloride (500 mg, 2.62 mmol) and alcohol 2.14 were used general 
procedure A and the reaction was stirred for 16 h to give the title compound as a 
colourless oil (261 mg, 0.62 mmol, 47%). 
 
IR  νmax (neat) 2975 (w), 1692 (s), 1597 (m), 1495 (m), 1363 (s), 1174 (s), 
935 (m), 663 (m), 554 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.75 (2H, d, J = 8.2 Hz, CArH ortho to SO2O), 
7.37-7.29 (4H, m, CArH meta to SO2O & meta to N), 7.20 (1H, t, J = 7.3 
Hz, CArH para to N), 7.12 (2H, d, J = 7.3 Hz, CArH ortho to N), 4.04 
(2H, t, J = 6.2 Hz, SO2OCH2), 3.60 (2H, t, J = 7.1 Hz, NCH2), 2.45 (3H, 
s, CArCH3), 1.75-1.49 (4H, 2 x m, SO2OCH2CH2CH2), 1.40 (9H, s, 
C(O)OC(CH3)3. 
 
13C NMR  (75 MHz, CDCl3)  δ 154.7 (C(O)OC(CH3)3), 144.7 (CArCH3), 142.2 
(CArN), 133.1 (CArSO2O), 129.8 (CArH meta to SO2O), 128.8 (CArH 
ortho to N), 127.8 (CArH ortho to SO2O), 127.1 (CArH meta to N), 126.1 
(CArH para to N), 80.2 (C(O)OC(CH3)3), 70.1 (SO2OCH2), 49.0 
(NCH2), 28.3 (C(O)OC(CH3)3), 26.1 (SO2OCH2CH2), 24.4 (NCH2CH2), 
21.6 (CArCH3). 
 
LRMS
  (ES+) m/z 442 [M + Na]
+, 862 [2M + Na]
+.     131
HRMS  (ES+) calcd for C22H29NO5SNa [M + Na]
+ 442.1659, found 442.1652. 
 
 
4-Nitro benzenesulfonic acid 4-(tert-butoxycarbonyl phenyl amino) butyl ester 
(2.32) 
 
 
C21H26N2O7S 
Mw = 450.51 gmol
−1 
Orange oil 
 
4-Nitrobenzene sulfonyl chloride (500 mg, 2.26 mmol) and alcohol 2.14 (300 mg, 1.13 
mmol) were used general procedure A and the reaction was stirred for 1.5 h to give the 
title compound as an orange oil (248 mg, 0.55  mmol, 49%). 
 
IR  νmax (neat) 2977 (w), 1692 (s), 1533 (s), 1366 (s), 1185 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.39 (2H, d, J = 8.8 Hz, CArH ortho to SO2O), 8.08 
(2H, d, J = 8.8 Hz, CArH meta to SO2O), 7.33 (2H, t, J = 7.3 Hz, CArH 
meta to N), 7.22 (1H, tt, J = 7.3, 2.0 Hz, CArH para to N), 7.11 (2H, d, J 
= 7.3 Hz, CArH ortho to N), 4.15 (2H, t, J = 7.0 Hz, SO2OCH2), 3.62 
(2H, t, J = 7.0 Hz, NCH2), 1.75-1.67 (2H, m, NCH2CH2), 1.58-1.51 (2H, 
m, SO2OCH2CH2), 1.39 (9H, s, C(O)OC(CH3)3. 
 
13C NMR  (75 MHz, CDCl3)  δ 154.7 (C(O)OC(CH3)3), 150.7 (CArNO2), 142.1 
(CArN), 141.9 (CArSO2O), 129.2 (CArH ortho  to SO2O), 128.9 (CArH 
ortho to N), 127.1 (CArH meta to N), 126.2 (CArH para to N), 124.4 
(CArH meta to SO2O), 80.3 (C(O)OC(CH3)3), 71.3 (SO2OCH2), 48.8 
(NCH2), 28.3 (C(O)OC(CH3)3), 26.1 (SO2OCH2CH2), 24.3 (NCH2CH2). 
 
LRMS
  (ES+) m/z 473 [M + Na]
+, 924 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C21H26 N2O7SNa [M + Na]
+ 473.1353, found 473.1349. 
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Methanesulfonic acid 4-(tert-butoxycarbonyl phenyl amino) butyl ester (2.33) 
 
 
C16H25NO5S 
Mw = 343.44 gmol
−1 
Colourless oil 
 
Methanesulfonyl chloride (0.34 ml, 3.46 mmol) and alcohol 2.14 (459 mg, 1.73 mmol) 
were used in general procedure A and the reaction was stirred for 1.5 h to give the title 
compound as a colourless oil (410 mg, 1.19 mmol, 69%). 
 
IR  νmax (neat) 2975 (w), 1689 (s), 1597 (w), 1352 (s), 1170 (s), 936 (m), 
699 (m), 528 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.35 (2H, t, J = 7.5 Hz, CArH meta to N), 7.22 (1H, 
t, J = 7.5 Hz, CArH para to N), 7.17 (2H, d, J = 7.5 Hz, CArH ortho to 
N), 4.23 (2H, t, J = 6.2 Hz, SO2OCH2), 3.69 (2H, t, J = 7.1 Hz, NCH2), 
3.00 (3H, s, CH3SO2O), 1.83-1.71 (2H, m, NCH2CH2), 1.70-1.60 (2H, 
m, SO2OCH2CH2), 1.42 (9H, s, C(O)OC(CH3)3. 
 
13C NMR  (75 MHz, CDCl3) δ 154.7 (C(O)OC(CH3)3), 142.1 (CArN), 128.8 (CArH 
ortho to N), 127.1 (CArH meta to N), 126.2 (CArH para to N), 80.2 
(C(O)OC(CH3)3), 69.5 (SO2OCH2), 48.9 (NCH2), 37.3 (CH3SO2O),  
28.3 (C(O)OC(CH3)3), 26.3 (SO2OCH2CH2), 24.4 (NCH2CH2). 
 
LRMS
  (ES+) m/z 366 [M + Na]
+. 
 
HRMS  (ES+) calcd for C16H25NO5SNa [M + Na]
+ 366.1346, found 366.1346. 
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6-Aminocaproic acid methyl ester (2.37)  
 
 
C7H16ClNO2 
Mw = 181.66 gmol
−1 
White solid 
 
Following the procedure of Lin et al.,
68 a colourless solution of SOCl2 (12.50 mL, 167.6 
mmol) in MeOH (80 mL) was stirred at 0 °C for 10 min.  6-Aminohexanoic acid (2.36, 
10.00 g, 76.2 mmol) was added to give a cloudy white mixture which was stirred at rt 
and turned colourless after 15 min.  The solution was stirred for a further 4 h and was 
then concentrated in vacuo to give the title compound as a cream solid (13.69 g, 75.4 
mmol, 99%) which was sufficiently pure (
1H NMR) to be used in subsequent reactions 
without further purification.  Spectroscopic data were in agreement with those published 
in the literature.
68 
 
MP  124-127 °C (lit 120.0-121.0 °C).
68 
 
IR  νmax (neat) 3440 (br), 2931 (m), 2896 (m), 2868 (m), 1728 (s), 1621 (w), 
1581 (w), 1517 (m), 1175 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.25 (3H, broad s, NH3), 3.67 (3H, s, OCH3), 3.02 
(2H, t, J = 7.5 Hz, CH2NH3), 2.34 (2H, t, J = 7.3 Hz, C(O)CH2), 1.82 
(2H, tt, J = 7.7, 7.5 Hz, CH2CH2NH3), 1.68 (2H, tt, J = 7.7, 7.3 Hz, 
C(O)CH2CH2), 1.48-1.43 (2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3) δ 173.9 (C(O)OCH3), 51.6 (OCH3), 39.7 (CH2NH3), 
33.6 (C(O)CH2), 27.2 (CH2CH2NH3), 25.9 (C(O)CH2CH2), 24.2 
(C(O)CH2CH2CH2). 
 
LRMS
  (ES+) m/z 146 [M – 
35Cl]
+. 
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5-Chloro-2-nitrobenzoyl chloride (2.38) 
 
 
C7H3Cl2NO3 
Mw = 220.01 gmol
−1 
Orange oil 
 
To a suspension of 5-chloro-2-nitrobenzoic acid (2.35, 10.00 g, 48.2 mmol) in benzene 
(150 mL) was added SOCl2 (7.00 mL, 96.4 mmol) and the solution was heated under 
reflux for 3 h.  The cooled reaction mixture was concentrated in vacuo and the residue 
was dissolved in CH2Cl2 (50 mL), washed with water (1 x 50 mL) and sat aq NaCO3H 
(1 x 50 mL), dried over MgSO4 and concentrated in vacuo.  The residue was dissolved 
in hot CH2Cl2 and filtered to remove the solid impurities.  Removal of the solvent 
afforded the title compound as an orange oil (9.60 g, 43.6 mmol, 91%).  
 
IR  νmax (neat) 3103 (w), 1783 (m), 1530 (s), 1339 (s), 1194 (s), 916 (m), 
842 (s), 736 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.10 (1H, d, J = 8.6 Hz, CArH ortho to NO2), 7.69 
(1H, dd, J = 8.6, 2.2 Hz, CArH ortho to Cl), 7.66 (1H, d, J = 2.2 Hz, 
CArH ortho to C(O)Cl). 
 
13C NMR  (75 MHz, CDCl3) δ 164.5 (C(O)Cl), 143.1 (CArNO2), 141.0 (CArCl), 
133.9 (CArC(O)Cl), 132.4 (CArH ortho to C(O)Cl), 128.0 (CArH ortho to 
Cl), 126.1 (CArH ortho to NO2). 
 
 
Methyl 6-(5-chloro-2-nitrobenzamido)hexanoate (2.39) 
 
N
H
O
O2N
Cl MeO
O
 
C14H17ClN2O5 
Mw = 328.75 gmol
−1 
Cream solid 
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Method 1: To a solution of methyl ester 2.37 (5.20 g, 28.6 mmol) and acid chloride 2.38 
(6.29 g, 28.6 mmol) in dioxane (90 mL) was added DIPEA (10.00 mL, 57.2 mmol) and 
the solution was stirred at 70 ºC for 3.5 h.  The cooled reaction mixture was 
concentrated in vacuo and the residue was dissolved in CH2Cl2 (100 mL), washed with 
2 N HCl (1 x 75 mL) and brine (1 x 50 mL), dried over MgSO4 and concentrated in 
vacuo.  The residue was by recrystallisation from hot CH2Cl2 to give the title compound 
as a cream solid (8.41 g, 25.6 mmol, 89%). 
 
Method 2: A solution of HOBt (67 mg, 4.96 mmol) in DMF (12 mL) and 5-chloro-2-
nitrobenzoic acid (1.00 g, 4.96 mmol) in CH2Cl2 (28 mL) was stirred at rt before DIC 
(0.77 mL, 4.96 mmol) was added and the solution was stirred for 5 min.  Methyl ester 
2.37 (900 mg, 4.96 mmol) and DIPEA (2.6 mL, 14.88 mmol) were added and the 
solution was stirred for 19 h.  The reaction mixture was diluted with CH2Cl2, washed 
with 2 N HCl (1 x 100 mL) and brine (1 x 50 mL), dried over MgSO4 and concentrated 
in vacuo.  The residue was purified by column chromatography (eluent 20% 
EtOAc/hexane) to give the product as a white solid (1.32 g, 4.00 mmol, 81%). 
 
MP  82-84 ºC. 
 
IR  νmax (neat) 3272 (br), 3079 (w), 2944 (w), 2863 (w), 1732 (m), 1643 
(m), 1527 (s), 1342 (s), 1304 (m), 1163 (m), 839 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.02 (1H, d, J = 8.8 Hz, CArH ortho to NO2), 7.52 
(1H, dd, J = 8.8, 2.2 Hz, CArH ortho to Cl), 7.48 (1H, d, J = 2.2 Hz, 
CArH ortho to C(O)NH), 6.12 (1H, br m, NH), 3.66 (3H, s, OCH3), 3.45 
(2H, apt q, J = 7.0 Hz, CH2NH), 2.34 (2H, t, J = 7.3 Hz, C(O)CH2), 
1.75-1.59 (4H, m, C(O)CH2CH2CH2CH2), 1.51-1.35 (2H, m, 
C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 174.1 (C(O)OCH3), 165.1 (C(O)NH), 144.5 
(CArNO2), 140.3 (CArCl), 134.6 (CArC(O)NH), 130.3 (CArH ortho to Cl), 
129.0 (CArH ortho to C(O)NH), 126.0 (CArH ortho to NO2), 51.5 
(OCH3), 40.0 (CH2NH), 33.7 (C(O)CH2), 28.6 (CH2CH2NH), 26.2     136
(C(O)CH2CH2), 24.2 (C(O)CH2CH2CH2). 
 
LRMS
  (ES+) m/z 351 [M + Na]
+, 353 (
37Cl isotope peak), 679 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C14H17
35Cl N2O5Na [M + Na]
+ 351.0718, found 
351.0718. 
 
 
Methyl 6-(5-methylthio-2-nitrobenzamido) hexanoate (2.40) 
 
 
C15H20N2O5S 
Mw = 340.39 gmol
−1 
Pale yellow solid 
 
To a solution of chloride 2.39 (1.13 g, 3.4 mmol) in CH2Cl2/water (1:1, 54 mL) was 
added Bu4NCl (47 mg, 0.2 mmol) followed by NaSMe (2.10 mL, 6.8 mmol) and the 
solution was stirred vigorously at 30-35 ºC.  Further Bu4NCl (77 mg, 0.3 mmol)/NaSMe 
(1.00 mL, 3.4 mmol) were added after 7 h followed by the addition of Bu4NCl (47 mg, 
0.2 mmol)/NaSMe (2.00 mL, 6.8 mmol) after 23 h.  The solution was stirred for a total 
reaction time of 25 h.  The reaction mixture was partitioned between CH2Cl2 and water, 
the organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 x 
25 mL).  The combined organic layers were washed with brine (1 x 50 mL), dried over 
MgSO4 and concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 20-60% EtOAc/hexane) to give the title compound as a pale 
yellow solid (834 mg, 2.5 mmol, 74%). 
 
MP  100-102 ºC. 
 
IR  νmax (neat) 3271 (br), 3078 (w), 2944 (w), 2862 (w), 1736 (s), 1644 (m), 
1566 (m), 1519 (s), 1337 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.02 (1H, d, J = 8.8 Hz, CArH ortho to NO2), 7.29 
(1H, dd, J = 8.8, 2.2 Hz, CArH ortho to SCH3), 7.22 (1H, d, J = 2.2 Hz,     137
CArH ortho to C(O)NH), 5.91 (1H, br m, NH), 3.66 (3H, s, OCH3), 3.45 
(2H, td, J = 7.0, 6.2 Hz, CH2NH), 2.56 (3H, s, SCH3), 2.35 (2H, t, J = 
7.3 Hz, C(O)CH2), 1.75-1.58 (4H, m, C(O)CH2CH2CH2CH2), 1.50-1.35 
(2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 174.1 (C(O)OCH3), 166.5 (C(O)NH), 148.6 
(CArSMe), 142.2 (CArNO2), 133.8 (CArC(O)NH), 125.7 (CArH ortho to 
SCH3), 125.0 (CArH ortho to C(O)NH), 124.4 (CArH ortho to NO2), 51.5 
(OCH3), 40.0 (CH2NH), 33.8 (C(O)CH2), 28.7 (CH2CH2NH), 26.2 
(C(O)CH2CH2), 24.3 (C(O)CH2CH2CH2), 14.8 (SCH3). 
 
LRMS
  (ES+) m/z 363 [M + Na]
+, 703 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C15H20N2O5SNa [M + Na]
+ 363.0985, found 363.0986. 
 
 
Methyl 6-(5-benzylthio-2-nitrobenzamido) hexanoate (2.41) 
 
C21H24N2O5S 
Mw = 416.49 gmol
−1 
Pale yellow solid 
 
To a solution of chloride 2.39 (6.50 g, 19.8 mmol) in CH2Cl2/water (1:1, 240 mL) was 
added NaOH (1.58 g, 39.6 mmol), Bu4NCl (550 mg, 2.0 mmol) and benzyl mercaptan 
(4.70 mL, 39.6 mmol).  The solution was stirred vigorously at 30-35 ºC for 70 h.  A 
solution of NaOH (792 mg, 19.8 mmol), Bu4NCl (275 mg, 1.0 mmol) and benzyl 
mercaptan (2.3 mmol, 19.8 mmol) in water (5 mL) was added, the temperature was 
increased to 55 ºC and the mixture was stirred vigorously for 5 h after which time 
further Bu4NCl (275 mg, 1.0 mmol) was added.  After a total of 97 h the reaction 
mixture was partitioned between CH2Cl2 and water, the organic layer was separated and 
the aqueous layer was extracted with CH2Cl2 (2 x 25 mL).  The combined organic 
layers were washed with brine (1 x 50 mL), dried over MgSO4 and concentrated in 
vacuo.  The residue was dissolved in CH2Cl2 (30 mL), added to a solution of NaOH     138
(792 mg, 19.8 mmol), Bu4NCl (550 mg, 2.0 mmol) and benzyl mercaptan (2.33 mL, 
19.8 mmol) in water (25 mL) and the mixture was stirred vigorously at 30-35 ºC for 20 
h.    The reaction mixture was worked up as before and the residue was purified by 
column chromatography (eluent 20-50% EtOAc/hexane) to give the title compound as a 
pale yellow solid (6.91 g, 16.6 mmol, 84%). 
 
MP  83-85 ºC. 
 
IR  νmax (neat) 3273 (br), 3066 (w), 2942 (w), 2861 (w), 1732 (m), 1643 
(m), 1564 (m), 1518 (m), 1336 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.96 (1H, d, J = 8.8 Hz, CArH ortho to NO2), 7.45-
7.19 (7H, m, CArH ortho to SCH2, CArH ortho to C(O)NH & benzyl 
CArH), 5.83 (1H, br m, NH), 4.25 (2H, s, SCH2), 3.66 (3H, s, OCH3), 
3.44 (2H, apt q, J = 6.8 Hz, CH2NH), 2.35 (2H, t, J = 7.3 Hz, C(O)CH2), 
1.76-1.57 (4H, m, C(O)CH2CH2CH2CH2), 1.50-1.37 (2H, m, 
C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 174.1 (C(O)OCH3), 166.2 (C(O)NH), 146.8 
(CArSCH2), 142.8 (CArNO2), 135.1 (CArCH2), 133.7 (CArC(O)NH), 
128.9 & 128.8 (CArH ortho & meta to CH2), 127.9 (CArH para to CH2), 
127.3 (CArH ortho to SCH2), 126.1 (CArH ortho to C(O)NH), 125.0 
(CArH ortho to NO2), 51.5 (OCH3), 39.9 (CH2NH), 37.0 (SCH2), 33.8 
(C(O)CH2), 28.8 (CH2CH2NH), 26.2 (C(O)CH2CH2), 24.3 (C(O)CH-
2CH2CH2). 
 
LRMS
  (ES+) m/z 439 [M + Na]
+, 855 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C21H24N2O5SNa [M + Na]
+ 439.1298, found 439.1288. 
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Methyl 6-(5-chlorosulfonyl-2-nitrobenzamido) hexanoate (2.42) 
 
 
C14H17ClN2O7S 
Mw = 392.81 gmol
−1 
White solid 
 
Benzyl sulfide 2.41 (5.53 g, 13.3 mmol) was dissolved in glacial acetic acid (40 mL) 
and molecular chlorine was bubbled through the solution for 1 h, during which time the 
temperature of solution was maintained below 30 ºC with an ice-water bath.  The 
reaction mixture was concentrated in vacuo and the residue was purified by column 
chromatography (eluent 35% EtOAc/hexane) to give the title compound as a white solid 
(3.27 g, 8.3 mmol, 62%). 
 
MP  100-103 ºC. 
 
IR  νmax (neat) 3292 (m), 3083 (w), 2948 (w), 2864 (w), 1736 (s), 1646 (s), 
1541 (m), 1379 (m), 1182 (m), 628 (m), 545 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.25-8.15 (3H, m, CArH), 6.39 (1H, br m, NH), 
3.66 (3H, s, OCH3), 3.50 (2H, apt q, J = 6.7 Hz, CH2NH), 2.36 (2H, t, J 
= 7.1 Hz, C(O)CH2), 1.77-1.60 (4H, m, C(O)CH2CH2CH2CH2), 1.54-
1.39 (2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 174.2 (C(O)OCH3), 163.5 (C(O)NH), 150.3 
(CArSO2Cl), 147.3 (CArNO2), 134.4 (CArC(O)NH), 129.1 (CArH ortho to 
SO2Cl), 127.6 (CArH ortho to C(O)NH), 126.0 (CArH ortho to NO2), 
51.6 (OCH3), 40.1 (CH2NH), 33.6 (C(O)CH2), 28.5 (CH2CH2NH), 26.0 
(C(O)CH2CH2), 24.0 (C(O)CH2CH2CH2). 
 
LRMS
  (ES+) m/z 415 [M + Na]
+, 417 (
37Cl isotope peak), 807 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C14H17
35ClN2O7SNa [M + Na]
+ 415.0337, found 
415.0341.     140
6-(5-[4-(tert-Butoxycarbonyl phenyl amino) butoxysulfonyl]-2-nitro benzoylamino) 
hexanoic acid methyl ester (2.43) 
 
C29H39N3O10S 
Mw = 621.70 gmol
−1 
Orange oil 
 
To a solution of sulfonyl chloride 2.42 (1.30 g, 3.3 mmol), (4-hydroxy butyl) phenyl 
carbamic acid tert-butyl ester (2.14, 732 mg, 2.8 mmol) and DMAP (84 mg, 0.7 mmol) 
in CH2Cl2 (20 mL) was added Et3N (0.96 mL, 6.9 mmol).  The solution was stirred at rt 
for 2.5 h.  The reaction mixture was diluted with CH2Cl2 (20 mL), washed with 2 N HCl 
(1 x 40 mL), water (1 x 20 mL) and brine (1 x 20 mL), dried over MgSO4 and 
concentrated in vacuo.  The residue was purified by column chromatography (eluent 10-
35% EtOAc/petroleum ether) to give the title compound as an orange oil (1.28 g, 2.1 
mmol, 75%). 
 
IR  νmax (neat) 3298 (br), 2970 (w), 2940 (w), 2866 (w), 1736 (m), 1692 (s), 
1670 (s), 1536 (m), 1366 (s), 1165 (s), 698 (w) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.15 (1H, d, J = 8.9 Hz, CArH ortho to NO2), 8.08-
8.03 (2H, m, CArH ortho to C(O)NH & ortho to SO2O), 7.33 (2H, td, J = 
7.4, 1.9 Hz, CArH meta to N), 7.22 (1H, tt, J = 7.4, 1.9 Hz, CArH para to 
N), 7.09 (2H, d, J = 7.4 Hz, CArH ortho to N), 6.81 (1H, br m, NH), 4.18 
(2H, t, J = 6.4 Hz, SO2OCH2 ), 3.66 (3H, s, OCH3), 3.56 (2H, t, J = 6.8 
Hz, CH2NC(O)O), 3.46 (2H, apt q, J = 7.0 Hz, CH2NH), 2.35 (2H, t, J = 
7.0 Hz, C(O)CH2), 1.73-1.38 (10H, 2 x m, C(O)CH2CH2CH2CH2 & 
SO2OCH2CH2CH2), 1.34 (9H, s, C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3)  δ 174.0 (C(O)OCH3), 164.4 (C(O)NH), 154.8 
(NC(O)O), 149.4 (CArNO2), 140.7 (CArN), 134.1 (CArC(O)NH), 130.7 
(CArSO2O), 129.6 (CArH ortho to SO2O), 128.9 (CArH ortho to N), 128.5 
(CArH ortho to C(O)NH), 126.8 (CArH meta to N), 126.5 (CArH para to     141
N), 125.4 (CArH ortho to NO2), 80.4 (OC(CH3)3), 71.6 (SO2OCH2), 51.6 
(OCH3), 49.0 (CH2NC(O)O), 40.0 (CH2NH), 33.7 (C(O)CH2), 28.7 
(CH2CH2NH), 28.2 (OC(CH3)3), 26.2 (SO2OCH2C2), 25.7 
(C(O)CH2CH2), 24.2 (CH2CH2NC(O)O), 23.7 (C(O)CH2CH2CH2). 
 
LRMS
  (ES+) m/z 644 [M + Na]
+. 
 
HRMS  (ES+) calcd for C29H39N3O10SNa [M + Na]
+ 644.2248, found 644.2240. 
 
 
6-(5-[4-(tert-Butoxycarbonyl phenyl amino) butoxysulfonyl]-2-nitro benzoylamino) 
hexanoic acid (2.44) 
 
C28H37N3O10S 
Mw = 607.67 gmol
−1 
Orange oil 
 
To a solution of methyl ester 2.43 (222 mg, 0.36 mmol) in CH2Cl2/acetone (4:1, 10 mL) 
was added aq phosphate buffer (pH 7, 15 mL) followed by Novozym 435® (300 mg) 
and the suspension was stirred vigorously at 50 ºC.  Further Novozym 435® (300 mg) 
was added after 23 and 28 h, and the reaction was stirred for a total of 48 h.  The cooled 
reaction mixture was acidified with HCl and filtered through a pad of Celite®.  The pad 
was washed with CH2Cl2 (20 mL) and MeOH (20 mL).  The organic phase of the 
filtrate was separated and the aqueous phase was extracted with CH2Cl2 (2 x 10 mL).  
The combined organic phases were dried over MgSO4 and concentrated in vacuo.  The 
residue was purified by column chromatography (eluent 60-100% EtOAc/hexane then 
10% MeOH/CH2Cl2) to give the title compound as an orange oil (54 mg, 0.089 mmol, 
25%) and recovered methyl ester 2.43 (128 mg, 0.21 mmol, 57%). 
 
IR  νmax (neat) 3292 (br), 3078 (w), 2931 (m), 2866 (w), 1652 (s), 1538 (s), 
1366 (s), 1188 (s), 1152 (s), 934 (m) cm
−1.
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1H NMR  (300 MHz, CDCl3) δ 8.13 (1H, d, J = 9.1 Hz, CArH ortho to NO2), 8.08-
8.01 (2H, m, CArH ortho to C(O)NH & ortho to SO2O), 7.33 (2H, td, J = 
7.3, 1.7 Hz, CArH meta to N), 7.21 (1H, tt, J = 7.3, 1.7 Hz, CArH para to 
N), 7.09 (2H, d, J = 7.3 Hz, CArH ortho to N), 6.92 (1H, br s, NH), 4.17 
(2H, t, J = 6.4 Hz, SO2OCH2), 3.56 (2H, t, J = 7.0 Hz, CH2NC(O)O), 
3.51-3.38 (2H, m, CH2NH), 2.38 (2H, t, J = 7.0 Hz, C(O)CH2), 1.76-
1.37 (10H, 2 x m, C(O)CH2CH2CH2CH2 & SO2OCH2CH2CH2), 1.34 
(9H, s, C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3)  δ 177.8 (C(O)OH), 164.4 (C(O)NH), 155.0 
(NC(O)O), 149.5 (CArNO2), 141.7 (CArSO2O), 140.6 (CArN), 134.0 
(CArC(O)NH), 129.7 (CArH ortho to SO2O), 128.9 (CArH ortho to N), 
128.4 (CArH ortho to C(O)NH), 127.0 (CArH meta to N), 126.4 (CArH 
para  to N), 125.5 (CArH ortho to NO2), 80.5 (OC(CH3)3), 71.7 
(SO2CH2), 40.0 (CH2NH), 33.5 (C(O)CH2), 30.9 (CH2NC(O)O), 28.5 
(CH2CH2NH), 28.2 (OC(CH3)3), 26.1 (SO2OCH2CH2), 25.6 
(C(O)CH2CH2), 24.0 (CH2CH2NC(O)O), 23.7 (C(O)CH2CH2CH2). 
 
LRMS
  (ES−) m/z 606 [M − H]
+. 
 
HRMS  (ES+) calcd for C28H37N3O10SNa [M + Na]
+ 630.2092, found 630.2098. 
 
 
Solid supported 6-(5-[4-(tert-butoxycarbonyl phenyl amino) butoxysulfonyl]-2-
nitro benzoylamino) hexanoic acid (2.45) 
 
 
 
Loading = 0.58 
mmolg
−1 
Resin beads 
 
A solution of HOBt (174 mg, 1.29 mmol) and carboxylic acid 2.44 (312 mg, 0.51 
mmol) in CH2Cl2/DMF (7:3, 10 mL) was stirred at rt for 10 min.  DIC (0.20 mL, 1.29     143
mmol) was added and the solution was stirred for 10 min.  Amino methyl polystyrene 
resin (360mg, 1.20 mmolg
−1, 0.43 mmol) was added and the resin was stirred gently.  A 
ninhydrin test on a small sample of resin beads after 18 h was negative, indicating that 
all of the amino groups had reacted.  The resin was removed by filtration, washed with 
CH2Cl2 (50 mL), MeOH (50 mL) and Et2O (50 mL) and dried in vacuo to give the 
product resin (574 mg, theoretical loading 0.75 mmolg
−1, actual loading (S elemental 
analysis) 0.58 mmolg
−1, 84%). 
 
IR  νmax (neat) 3307 (br), 3025 (w), 2992 (w), 2855 (w), 1651 (w), 1531 (m), 
756 (m), 696 (s) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 8.03-7.83 (m, CArH ortho to NO2, ortho to 
C(O)NH & ortho to SO2O), 7.30 (s, CArH ortho to N), 7.26 (s, CArH 
para to N), 7.10 (s, CArH meta to N), 6.59 (amino methyl resin), 4.11 (s, 
SO2OCH2), 3.65 (s, CH2NC(O)O), 3.56 (s, CH2NH), 1.97 (s, C(O)CH2), 
1.87-1.41 (m, C(O)CH2CH2CH2CH2 & SO2OCH2CH2CH2), 1.35 (s, 
NC(O)OC(CH3)3). 
 
13C NMR  MAS - not acquired due to low resin loading. 
 
 
3-(2-Naphthylenoxy)-1-propanol (2.48)  
 
 
C13H14O2 
Mw = 202.25 gmol
−1 
Off white solid 
 
Following the procedure of Shi et al.,
77 to a suspension of 2-naphthol (3.00 g, 20.8 
mmol) in water (60 mL) was added NaOH (2.00 g, 50.0 mmol) and the solution was 
stirred for 30 min until clear.  3-Bromo-1-propanol (2.90 mL, 20.8 mmol) was added 
and the solution was stirred at rt for 72 h.  The reaction mixture was extracted with 
CH2Cl2 (3 x 100mL) and the combined organic layers were washed with water (1 x 100     144
mL) and concentrated in vacuo.  The residue was recrystallised from hot EtOAc to give 
the title compound as an off white solid (2.79g, 13.8 mmol, 66%).  
 
MP  102-104 ºC (lit 99-100 °C).
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IR  νmax (neat) 3272 (br), 2955 (w), 2931 (w), 2878 (w), 1629 (m), 1600 
(m), 1509 (m), 1467 (m), 1390 (w), 1260 (m), 1217 (m), 1184, (m), 
1054 (m), 1038 (s), 837 (s), 750 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.81-7.70 (3H, m, H4, H5 & H8), 7.45 (1H, ddd, J 
= 8.1, 6.9, 1.2 Hz, H6), 7.35 (1H, ddd J = 8.1, 6.9, 1.2 Hz, H7), 7.19-7.12 
(2H, m, H1 & H3), 4.26 (2H, t, J = 6.1 Hz, CArOCH2), 3.93 (2H, t, J = 
5.8 Hz, CH2OH), 2.13 (2H, tt, J = 6.1, 5.8 Hz, CH2CH2OH). 
 
13C NMR  (75 MHz, CDCl3) δ 156.5 (CArOCH2), 134.5 (C10), 129.4 (C9), 129.1 
(C5), 127.6 (C4), 126.7 (C7), 126.4 (C8), 123.7 (C6), 118.8 (C3), 106.6 
(C1), 65.7 (CArOCH2), 60.6 (CH2OH), 31.9 (CH2CH2OH). 
 
LRMS
  (ES+) m/z 225 [M + Na]
+. 
 
HRMS  (ES+) calcd for C13H14O2Na [M + Na]
+ 255.0886, found 225.0890 
 
 
6-(4-[3-(2-Naphthalenyloxy) propoxysulfonyl] phenyl) hexanoic acid methyl ester 
(2.49) 
 
C26H30O6S 
Mw = 470.58 gmol
−1 
Orange oil 
 
To a solution of sulfonyl chloride 2.03 (1.36 g, 4.5 mmol), alcohol 2.48 (750 mg, 3.7 
mmol) and DMAP (113 mg, 0.9 mmol) in CH2Cl2 (20 mL) was added Et3N (1.30 mL, 
9.3 mmol) and the solution was stirred at rt for 1.5 h.  The reaction mixture was diluted     145
with CH2Cl2 (5 mL), washed with 2 N HCl (1 x 20 mL), water (1 x 10 mL) and brine (1 
x 10 mL), dried over MgSO4 and concentrated in vacuo to give an orange oil (1.73 g, 
3.7 mmol, 100%) which was used in subsequent reactions without further purification. 
 
IR  νmax (neat) 3057 (w), 2938 (w), 2859 (w), 1733 (m), 1359 (m), 1216 (m) 
1174 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.80-7.68 (5H, m, CArH ortho to SO2O, H4, H5 & 
H8), 7.45 (1H, td, J = 8.0, 1.2 Hz, H6), 7.35 (1H, td, J = 8.0, 1.2 Hz, H7), 
7.19 (2 H, d, J = 8.3 Hz, CArH meta to SO2O), 7.04-6.98 (2H, m, H1 & 
H3), 4.31 (2H, t, J = 6.1 Hz, CH2OCAr), 4.08 (2H, t, J = 5.8 Hz, 
SO2OCH2), 3.68 (3H, s, OCH3), 2.52 (2H, t, J = 7.7 Hz, CH2CAr), 2.30 
(2H, t, J = 7.4 Hz, C(O)CH2), 2.20 (2H, tt, J = 6.1, 5.8 Hz, 
SO2OCH2CH2), 1.70-1.50 (4H, m, C(O)CH2CH2CH2CH2), 1.45-1.20 
(2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3) δ 174.0 (C(O)OCH3), 156.3 (C2), 149.2 (CArCH2), 
134.4 (C10), 133.0 (CArSO2O), 129.3 (C9), 129.1 (CArH meta to SO2O), 
129.0 (C5), 127.8 (CArH ortho to SO2O), 127.6 (C4), 126.7 (C7), 126.4 
(C8), 123.7 (C6), 118.6 (C3), 106.5 (C1), 67.1 (SO2OCH2), 63.0 
(CH2OC), 51.5 (OCH3), 35.4 (CH2CAr), 33.8 (C(O)CH2), 30.4 
(C(O)CH2CH2CH2), 28.8 (SO2OCH2CH2), 28.6 (C(O)CH2CH2), 24.6 
(CH2CH2CAr). 
 
LRMS
  (ES−) m/z 493 [M + Na]
+, 963 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C26H30O6SNa [M + Na]
+ 493.1655, found 493.1645. 
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6-(4-[3-(2-Naphthalenyloxy) propoxysulfonyl] phenyl) hexanoic acid (2.50) 
 
C25H28O6S 
Mw = 456.55 gmol
−1 
Pale yellow solid 
 
To a suspension of Novozym 435® (2.00 g) in aq phosphate buffer (pH 7, 100 mL) was 
added a solution of methyl ester 2.49 (1.73 g, 3.7 mmol) in CH2Cl2/acetone (4:1, 50 
mL) and the suspension was stirred vigorously at 50 °C for 46 h.  The cooled reaction 
mixture was filtered through a pad of Celite® and the pad was washed with CH2Cl2 (30 
mL) and MeOH (30 mL).  The aqueous layer was separated and extracted with CH2Cl2 
(2 x 25 mL).  The combined organic layers were dried over MgSO4 and concentrated in 
vacuo.  The residue was purified by column chromatography (eluent 10-70% 
EtOAc/petroleum ether) to give the title compound as a pale yellow solid (1.21 g, 2.7 
mmol, 73%). 
 
MP  85-88 ºC. 
 
IR  νmax (neat) 3056 (w), 2936 (w), 2860 (w), 1704 (m), 1356 (m), 1174 (s) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.81-7.67 (5H, m, CArH ortho to SO2O, H4, H5 & 
H8), 7.45 (1H, td, J = 8.0, 1.2 Hz, H6), 7.35 (1H, td, J = 8.0, 1.2 Hz, H7), 
7.19 (2 H, d, J = 8.3 Hz, CArH meta to SO2O), 7.04-6.95 (2H, m, H1 & 
H3), 4.31 (2H, t, J = 6.1 Hz, CH2OCAr), 4.07 (2H, t, J = 5.8 Hz, 
SO2OCH2), 2.51 (2H, t, J = 7.7 Hz, CH2CAr), 2.35 (2H, t, J = 7.4 Hz, 
C(O)CH2), 2.20 (2H, tt, J = 6.1, 5.8 Hz, SO2OCH2CH2), 1.72-1.48 (4H, 
m, C(O)CH2CH2CH2CH2), 1.40-1.22 (2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3) δ 179.0 (C(O)OH), 156.3 (C2), 149.1 (CArCH2), 134.4 
(C10), 133.0 (CArSO2O), 129.3 (C9), 129.1 (CArH meta to SO2O), 128.9 
(C5), 127.9 (CArH ortho to SO2O), 127.6 (C4), 126.7 (C7), 126.4 (C8), 
123.7 (C6), 118.6 (C3), 106.6 (C1), 67.1 (SO2OCH2), 63.0 (CH2OCAr),     147
35.4 (CH2CAr), 33.7 (C(O)CH2), 30.3 (C(O)CH2CH2CH2), 28.8 
(SO2OCH2CH2), 28.5 (C(O)CH2CH2), 24.3 (C(O)CH2CH2CH2). 
 
LRMS
  (ES+) m/z 479 [M + Na]
+, 935 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C25H28O6SNa [M + Na]
+ 479.1499, found 479.1499. 
 
 
Solid supported 6-(4-[3-(2-naphthalenyloxy) propoxysulfonyl] phenyl) hexanoic 
acid (2.51) 
 
 
Loading = 0.67 
mmolg
−1 
Resin beads 
 
To a solution of N-hydroxysuccinimide (543 mg, 4.72 mmol) in DMF (10 mL) was 
added  carboxylic acid 2.50 (1.08 g, 2.36 mmol) in CH2Cl2 (35 mL) and the solution 
was stirred at rt for 10 min.  DIC (0.73 mL, 4.72 mmol) was added and the solution was 
stirred for a further 10 min.  Amino methyl polystyrene resin (1.05 g, 1.5 mmolg
−1, 1.57 
mmol) was added and the suspension was stirred gently.  A ninhydrin test carried out on 
a small sample of the resin after 68 h was negative, indicating that all of the amino 
groups had reacted.  The resin was removed by filtration, washed with CH2Cl2 (3 x 100 
mL), MeOH (3 x 100 mL) and Et2O (3 x 100 mL) and dried in vacuo to give the 
product resin (1.62 g, theoretical loading 0.97 mmolg
−1, actual loading (S elemental 
analysis) 0.67 mmolg
−1, 83%). 
 
IR  νmax (neat) 3306 (br), 3025 (w), 2923 (w), 1738 (s), 1651 (w), 1365 (m), 
1216 (m), 697 (s) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 7.72-7.63 (m, CArH ortho to SO2O, H4, H5 & 
H8), 7.36 (s, H6), 7.26 (s, H7), 7.11 (s, CArH meta to SO2O), 7.02-6.95 
(m, H1 & H3), 6.55 (amino methyl resin), 4.23 (s, CH2OCAr), 3.97 (s, 
SO2OCH2), 2.44 (s, CH2CAr), 2.08 (s, C(O)CH2 & SO2OCH2CH2), 1.57-    148
1.47 (m, C(O)CH2CH2CH2CH2), 1.27 (s, C(O)CH2CH2CH2). 
 
13C NMR  MAS (100 MHz, CDCl3) δ 172.5 (C(O)N), 156.3 (C2), 149.2 (CArCH2), 
145.2 (amino methyl resin), 135.4 (amino methyl resin), 134.4 (C10), 
133.0 (CArSO2O), 129.1 (C9), 129.0 (CArH meta to SO2O), 127.8 (C5), 
127.6 (CArH ortho to SO2O), 126.7 (C4), 126.4 (C7), 125.7 (C8), 123.7 
(C6), 118.7 (C3), 106.6 (C1), 67.2 (SO2OCH2), 63.0 (CH2OCAr), 43.3 
(amino methyl resin), 40.3 (amino methyl resin), 36.4 (CH2CAr), 35.4 
(C(O)CH2), 30.5 (C(O)CH2CH2CH2), 28.8 (SO2OCH2CH2 & 
C(O)OCH2CH2), 25.4 (CH2CH2CAr). 
 
 
6-(5-[3-(2-Naphthalenyloxy) propoxysulfonyl]-2-nitro benzolyamino) hexanoic acid 
methyl ester (2.52) 
 
C27H30N2O9S 
Mw = 558.60 gmol
−1 
Cream solid 
 
To a solution of sulfonyl chloride 2.42 (500 mg, 1.27 mmol), alcohol 2.38 (215 mg, 
1.06 mmol) and DMAP (33 mg, 0.27 mmol) in CH2Cl2 (10 mL) was added Et3N (0.37 
mL, 2.65 mmol) and the solution was stirred at rt for 3 h.  The reaction mixture was 
diluted with CH2Cl2 (10 mL), washed with 2 N HCl (1 x 10 mL), water (1 x 10 mL) and 
brine (1 x 10 mL), dried over MgSO4 and concentrated in vacuo.  The residue was 
purified by column chromatography (eluent 10-70% EtOAc/petroleum ether) to give the 
title compound as a cream solid (384 mg, 0.69 mmol, 65%). 
 
MP  106-109 ºC. 
 
IR  νmax (neat) 3308 (br), 3063 (w), 2941 (w), 2865 (w), 1735 (m), 1653 
(m), 1539 (s), 1366 (m), 1188 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.01-7.89 (3H, m, CArH ortho to NO2, ortho to     149
C(O)NH & ortho to SO2O), 7.77 (1H, d, J = 8.0 Hz, H5), 7.70 (1H, d, J 
= 8.0 Hz, H8), 7.69 (1 H, d, J = 9.0 Hz, H4), 7.45 (1H, ddd, J = 8.0, 7.1, 
1.2 Hz, H6), 7.36 (1H, ddd, J = 8.0, 7.1, 1.2 Hz, H7), 7.02 (1H, d, J = 2.7 
Hz, H1), 6.89 (1H, dd, J = 9.0, 2.7, H3), 5.90 (1H, br t, J = 5.8 Hz, NH), 
4.40 (2H, t, J = 5.8 Hz, CH2OCAr), 4.07 (2H, t, J = 5.5 Hz, SO2OCH2), 
3.66 (3H, s, OCH3), 3.30-3.20 (2H, m, CH2NH), 2.32 (2H, t, J = 7.4 Hz, 
C(O)CH2), 2.22 (2H, tt, J = 5.8, 5.5 Hz, SO2OCH2CH2), 1.63 (2H, tt, J = 
7.7, 7.4 Hz, C(O)CH2CH2), 1.55-1.43 (2H, m, CH2CH2NH), 1.30-1.27 
(2H, m, C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3) δ 174.1 (C(O)OCH3), 164.1 (C(O)NH), 156.0 (C2), 
149.2 (CArNO2), 140.2 (CArSO2O), 134.2 (C10), 133.9 (CArC(O)N), 
129.7 (C9), 129.6 (CArH ortho to SO2O), 129.0 (C5), 128.3 (CArH ortho 
to C(O)NH), 127.7 (C4), 126.7 (C7), 126.6 (C8), 125.3 (CArH ortho to 
NO2), 124.0 (C6), 118.3 (C3), 106.3 (C1), 68.4 (SO2OCH2), 62.4 
(CH2OCAr), 51.5 (OCH3), 39.9 (CH2NH), 33.7 (C(O)CH2), 28.48 
(SO2OCH2CH2), 28.45 (CH2CH2NH), 26.1 (C(O)CH2CH2), 24.2 
(C(O)CH2CH2CH2). 
 
LRMS
  (ES+) m/z 581 [M + Na]
+, 1139 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C27H30N2O9SNa [M + Na]
+ 581.1564, found 581.1578. 
 
 
6-(5-[3-(2-Naphthalenyloxy) propoxysulfonyl]-2-nitro benzolyamino) hexanoic acid 
(2.53) 
 
C26H28N2O9S 
Mw = 544.57 gmol
−1 
Cream solid 
 
To a solution of methyl ester 2.52 (285 mg, 0.51 mmol) in CH2Cl2/acetone (4:1, 10 mL) 
was added aq phosphate buffer (pH 7, 15 mL) followed by Novozym 435® (300 mg)     150
and the suspension was stirred vigorously at 50 °C for 48 h.  The cooled suspension was 
filtered through a pad of Celite® and the pad was washed with CH2Cl2 (20 mL).  The 
filtrate was acidified with HCl and the aqueous phase was extracted with CH2Cl2 (2 x 
10 mL).  The combined organic phases were dried over MgSO4 and concentrated in 
vacuo.  The residue was purified by column chromatography (eluent 20-60% 
EtOAc/hexane) to give the title compound as a cream solid (152 mg, 0.28 mmol, 55%) 
and recovered methyl ester 2.52 (64 mg, 0.11 mmol, 22%). 
 
MP  118-120 ºC. 
 
IR  νmax (neat) 3271 (br), 3066 (w), 2937 (w), 2865 (w), 1708 (m), 1642 (s), 
1630 (s), 1536 (s), 1346 (m), 1182 (s), 840 (m) cm
−1. 
 
1H NMR  (300 MHz, acetone-d6) δ 8.24-8.03 (3H, m, CArH ortho to NO2, ortho to 
C(O)NH & ortho to SO2O), 7.84-7.75 (3H, m, H4, H5 & H8), 7.44 (1H, 
ddd, J = 8.1, 7.0, 1.1 Hz, H6), 7.34 (1H, ddd, J = 8.1, 7.0, 1.1 Hz, H7), 
7.25 (1H, d, J = 2.6 Hz, H1), 7.05 (1H, dd, J = 9.0, 2.6, H3), 4.48 (2H, t, 
J = 6.1 Hz, CH2OCAr), 4.19 (2H, t, J = 6.0 Hz, SO2OCH2), 3.44-3.31 
(2H, m, CH2NH), 2.39-2.20 (4H, m, C(O)CH2 & SO2OCH2CH2), 1.75-
1.55 (4H, m, C(O)CH2CH2CH2CH2), 1.54-1.37 (2H, m, 
C(O)CH2CH2CH2).  NH not observed. 
 
13C NMR  (75 MHz, acetone-d6)  δ 174.7 (C(O)OCH3), 164.5 (C(O)NH), 157.4 
(C2), 140.8 (CArSO2O), 139.7 (CArNO2), 135.6 (C10), 134.7 (CArC(O)N), 
131.0 (C9), 130.3 (CArH ortho to SO2O), 129.8 (C5), 128.2 (CArH ortho 
to C(O)NH), 128.5 (C4), 127.7 (C7), 127.3 (C8), 126.5 (CArH ortho to 
NO2), 124.6 (C6), 119.5 (C3), 107.6 (C1), 70.0 (SO2OCH2), 64.1 
(CH2OCAr), 40.4 (CH2NH), 34.2 (C(O)CH2), 30.7 (SO2OCH2CH2), 29.1 
(CH2CH2NH), 27.1 (C(O)CH2CH2), 25.3 (C(O)CH2CH2CH2). 
 
LRMS
  (ES−) m/z 543 [M − H]
+. 
 
HRMS  (ES+) calcd for C26H28N2O9SNa [M + Na]
+ 567.1408, found 567.1394.     151
Solid supported 6-(5-[3-(2-naphthalenyloxy) propoxysulfonyl]-2-nitro 
benzolyamino) hexanoic acid (2.54) 
 
 
Loading = 0.66 
mmolg
−1 
Resin beads 
 
A solution of HOBt (101 mg, 0.75 mmol) and carboxylic acid 2.53 (167 mg, 0.30 
mmol) in CH2Cl2/DMF (7:3, 10 mL) was stirred at rt for 10 min.  DIC (0.12 mL, 0.75 
mmol) was added and the solution was stirred for 5 min.  Amino methyl polystyrene 
resin (208 mg, 1.20 mmolg
−1, 0.25 mmol) was added and the suspension was stirred 
gently.  A ninhydrin test carried out on a small sample of the resin after 22 h was 
negative, indicating that all of the amino groups had reacted.  The resin was removed 
from the suspension by filtration and was washed with CH2Cl2 (50 mL), MeOH (50 
mL) and Et2O (50 mL) and dried in vacuo to give the title resin (324 mg, theoretical 
loading 0.77 mmolg
−1, actual loading (S elemental analysis) 0.66 mmolg
−1, 88%). 
 
IR  νmax (neat) 3306 (br), 3025 (w), 2922 (w), 2852 (w), 1651 (w), 1532 (m), 
1452 (m), 755 (m), 696 (s) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 8.01 (s, CArH ortho to NO2, ortho to C(O)NH 
& ortho to SO2O), 7.83-7.66 (m, H4, H5 & H8), 7.40 (s, H6), 7.26 (s, 
H7),7.06 (amino methyl resin),  7.00 (s, H1), 6.93 (s, H3), 6.59 (amino 
methyl resin), 4.33 (s, CH2OCAr), 4.01 (s, SO2OCH2), 3.29 (s, CH2NH), 
2.13 (s, C(O)CH2 & SO2OCH2CH2), 1.56 (s, C(O)CH2CH2CH2CH2), 
1.27 (s, C(O)CH2CH2CH2). 
 
13C NMR  MAS (100 MHz, CDCl3) δ 172.5 (C(O)NH), 166.0 (CArC(O)NH), 156.5 
(C2), 149.7 (CArNO2), 145.7 (amino methyl resin), 140.4 (CArSO2O), 
134.7 (C10 & CArC(O)N), 130.0 (C9), 129.4 (CArH ortho to SO2O), 
128.4 (C5 & C4), 127.1 (CArH ortho to C(O)NH), 126.1 (C7, C8 & CArH 
ortho to NO2), 124.4 (C6), 118.8 (C3), 106.9 (C1), 66.2 (SO2OCH2), 63.0 
(CH2OCAr), 44.2 (amino methyl resin), 42.3 (amino methyl resin), 40.8     152
(CH2NH), 36.4 (C(O)CH2 & SO2OCH2CH2), 28.9 (CH2CH2NH), 26.6 
(C(O)CH2CH2), 25.0 (C(O)CH2CH2CH2). 
 
 
2-(3-Fluoropropoxy) naphthalene (2.57) 
 
 
C13H13FO 
Mw = 204.24 gmol
−1 
Colourless oil 
 
Solid Phase Method – General Procedure D: A suspension of the resin (1 eq), KF (1.2 
eq) and 1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo [8.8.8] hexacosan (1.2 eq) in MeCN 
(1 mL/40 μmol of resin) was heated under reflux for 30 min.  The resin was removed 
from the cooled suspension by filtration and was washed with CH2Cl2 (10 mL/40 μmol 
of resin).  The filtrate was concentrated in vacuo and the residue was purified by column 
chromatography (eluent 20% EtOAc/hexane) to give the title compound as a colourless 
oil.  Spectroscopic data were in agreement with those published in the literature.
74 
 
Resin 2.51 (100 mg, 0.67 mmolg
−1, 67 μmol) was used in general procedure D to give 
the title compound (5 mg, 25 μmol, 37%). 
 
Resin 2.54 (50 mg, 0.66 mmolg
−1, 33 μmol) was used in general procedure D to give 
the title compound (1.5 mg, 7.3 μmol, 22%). 
 
IR  νmax (neat) 3057 (w), 2967 (w), 1629 (m), 1600 (m), 1510 (m), 1464 
(m), 1389 (m), 1257 (s), 1215 (s), 1181 (s), 1051 (m), 837 (s), 746 (m), 
472 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.80-7.71 (3H, m, H4, H5 & H8), 7.45 (1H, td, J = 
8.0, 1.2 Hz, H6), 7.35 (1H, td, J = 8.0, 1.2 Hz, H7), 7.12-7.18 (2H, m, H1 
& H3), 4.71 (2H, dt, 
2JHF = 47.2, J = 5.8 Hz, FCH2), 4.24 (2H, t, J = 6.1 
Hz, CH2O), 2.25 (2H, dtt, 
3JHF = 26.0, J = 6.1, 5.8 Hz, FCH2CH2). 
     153
13C NMR  (100 MHz, CDCl3) δ 156.7 (CArOCH2), 134.3 (C10), 129.4 (C9), 129.0 
(C5), 127.6 (C4), 126.7 (C7), 126.4 (C8), 123.7 (C6), 118.8 (C3), 106.7 
(C1), 80.8 (d, J = 164.3 Hz, FCH2), 63.6 (d, J = 4.9 Hz, CArOCH2), 30.4 
(d, J = 19.4 Hz, FCH2CH2). 
 
19F NMR  (282 MHz, CDCl3) δ −222.4 (FCH2). 
 
LRMS
  (EI) 204 (M
+•, 67%), 144 ([M − FC3H5]
+, 100%), 115 ([M − FC4H6O]
+, 
89%). 
 
 
Benzyl Fluoride (3.02) 
 
 
C7H7F 
Mw = 110.13 gmol
−1 
Colourless liquid 
 
To a stirred solution of KF (674 mg, 11.60 mmol) in MeCN (4 mL) was added benzyl 
bromide (3.01, 0.70 mL, 5.89 mmol).  The solution was heated using microwave 
irradiation at 150 °C for 2 h.  The reaction mixture was partitioned between water and 
ether and the aqueous layer was extracted with ether (1 x 5 mL).  The combined organic 
layers were washed with water (1 x 10 mL) and brine (1 x 10 mL), dried over MgSO4 
and the solvent was carefully removed in vacuo.  The residue was purified by column 
chromatography (eluent 100% pentane) to give the title compound as a colourless liquid 
(114 mg, 1.04 mmol, 18%).  Spectroscopic data were in agreement with those published 
in the literature.
81,156 
 
IR  νmax (neat) 3017 (w), 2970 (w), 1738 (s), 1434 (w), 1366 (m), 1217 (m) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.53-7.29 (5H, m, CArH), 5.40 (2H, d, 
2JHF = 47.9 
Hz, CH2F). 
     154
13C NMR  (75 MHz, CDCl3) δ 136.3 (CArCH2), 128.7 (d, J = 3.3 Hz, CArH meta to 
CH2), 128.6 (CArH para to CH2), 127.5 (d, J = 5.5 Hz, CArH ortho to 
CH2), 84.6 (d, J = 165.9 Hz, CH2F). 
 
19F NMR  (282 MHz, CDCl3) δ −207.9 (FCH2). 
 
LRMS
  (EI) 110 (M
+•, 52%), 109 ([M − H]
+, 100%). 
 
 
(S)-(+)-2-tert-Butoxycarbonylamino-3-[4-(2-hydroxy ethoxy) phenyl] propionic 
acid tert-butyl ester (4.07) 
 
 
C20H31NO6 
Mw = 381.46 gmol
−1 
White solid 
 
Method 1: A solution of phenol 4.09 (3.85 g, 11.4 mmol) and BTEAC (5.20 g, 22.8 
mmol) in DMF (50 mL) was warmed at 50 °C for 10 min.  K2CO3 (4.45 g, 34.2 mmol) 
was added and the solution was stirred for 30 min.  Bromoethanol (0.90 mL, 12.5 
mmol) was added dropwise and the solution was stirred.  After 48 h, bromoethanol 
(0.45 mL, 6.3 mmol) was added dropwise and the solution was stirred for a further 24 h.  
The cooled reaction mixture was diluted with CH2Cl2 (100 mL), washed with water (1 x 
150 mL) and brine (1 x 150 mL), dried over MgSO4 and concentrated in vacuo.  The 
residue was purified by column chromatography (eluent 40% EtOAc/hexane) to give 
the title compound as a white solid (3.17 g, 8.3 mmol, 73%) and recovered phenol 4.09 
(364 mg, 1.1 mmol, 9%). 
 
Method 2: Benzoic ester 4.12 (265 mg, 0.55 mmol) was stirred in a 1% aq solution of 
NaOH/MeOH (25 mL) at rt for 4 h.  The reaction was added to water (10 mL) and 
extracted with CH2Cl2 (3 x 25 mL).  The combined organic layers were dried over 
MgSO2 and concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 30% EtOAc/hexane) to give the title compound as a colourless 
oil (139 mg, 0.36 mmol, 66%).     155
 
MP  87-90 °C. 
 
[α]D  +17.8 (c 1.06, CHCl3, 23 °C). 
 
IR  νmax (neat) 3435 (br), 2977 (w), 2932 (w), 1701 (m), 1510 (m), 1366 
(m), 1246 (m), 1151 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.09 (2H, d, J = 8.7 Hz, CArH meta to OCH2), 6.85 
(2H, d, J = 8.7 Hz, CArH ortho to OCH2), 4.98 (1H, br d, J = 7.7 Hz, 
NH), 4.41 (1H, ddd, J = 7.7, 6.4, 6.0 Hz, C(O)CH), 4.07 (2H, t, J = 4.0 
Hz, OCH2CH2OH,), 3.95 (2H, t, J = 4.0 Hz, OCH2CH2OH), 3.10-2.86 
(2H, m, CArCH2), 2.09 (1H, br s, OH), 1.43 & 1.42 (18H, 2 x s, 2 x 
C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3)  δ 171.0 (CHC(O)OC(CH3)3), 157.6 
(NHC(O)OC(CH3)3) , 155.1 (CArOCH2), 130.6 (CArH meta to OCH2), 
128.9 (CArCH2), 114.4 (CArH ortho to OCH2), 82.0 & 79.6 (2 x 
OC(CH3)3), 69.2 (OCH2CH2OH), 61.4 (OCH2CH2OH), 54.9 (C(O)CH), 
37.5 (CArCH2), 28.3 & 27.9 (2 x OC(CH3)3). 
 
LRMS
  (ES+) m/z 404 [M + Na]
+, 785 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C20H31NO6Na [M + Na]
+ 404.2044, found 404.2044. 
 
 
 
 
 
 
 
     156
(S)-(+)-2-tert-Butoxycarbonylamino-3-(4-hydroxy phenyl) propionic acid tert-butyl 
ester (4.09)  
 
 
C18H27NO5 
Mw = 337.41 gmol
−1 
Cream solid 
 
Following a modified procedure to that described by Chevallet et al.,
97 to a solution of 
N-(tert-butoxycarbonyl)-L-tyrosine (4.08, 2.0 g, 7.1 mmol), BTEAC (1.6 g, 7.1 mmol) 
and K2CO3 (24.0 g, 185.0 mmol) in DMAC (22 mL) was added 2-bromo-2-methyl 
propane (38.0 mL, 340.0 mmol) and the solution was stirred at 55 °C for 48 h.  The 
cooled reaction mixture was poured onto water and the aqueous layer was extracted 
with EtOAc (2 x 100 mL).  The combined organic layers were dried over MgSO4 and 
concentrated in vacuo.  The residue was purified by column chromatography (eluent 10-
50% EtOAc/hexane) to give the title compound as a cream solid (2.2 g, 6.5 mmol, 
92%).  Spectroscopic data were in agreement with those published in the literature.
157 
 
MP  117-120 °C (lit 112.8-113.0 °C).
157 
 
[α]D  +36.2 (c 1.00, CHCl3, 24 °C) (lit +8.0 (c 1.00, EtOH, 20 °C).
157 
 
IR  νmax (neat) 3351 (br), 2978 (w), 2932 (w), 1716 (shoulder), 1686 (m), 
1515 (m), 1366 (m), 1159 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.03 (2H, d, J = 8.1 Hz, CArH meta to OH), 6.74 
(2H, d, J = 8.1 Hz, CArH ortho to OH), 5.43 (1H, s, OH), 5.01 (1H, br d, 
J = 7.9 Hz, NH), 4.43-4.37 (1H, m, C(O)CH),  3.00-2.94 (2H, m, 
CArCH2), 1.43 & 1.42 (18H, 2 x s, 2 x C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3)  δ 171.1 (CHC(O)OC(CH3)3), 155.2 
(NHC(O)OC(CH3)3) , 154.7 (CArOH), 130.6 (CArH meta to OH), 128.2 
(CArCH2), 115.2 (CArH ortho to OH), 82.1 & 79.8 (2 x OC(CH3)3), 55.0 
(C(O)CH), 37.7 (CArCH2), 28.3 & 28.0 (2 x OC(CH3)3).     157
LRMS
  (ES+) m/z 360 [M + Na]
+, 697 [2M + Na]
+. 
 
 
(S)-2-tert-Butoxycarbonylamino-3-(4-ethoxycarbonylmethoxy phenyl) propionic 
acid tert-butyl ester (4.10)  
 
 
C22H33NO7 
Mw = 423.50 gmol
−1 
Colourless oil 
 
Following the procedure of Thompson et al.,
103 a vigorously stirred solution of phenol 
4.09 (120 mg, 0.36 mmol) and Cs2CO3 (352 mg, 1.08 mmol) in dioxane (5 mL) was 
aged at rt for 19 h.  To this solution was added ethyl bromoacetate (1.80 mL, 16.20 
mmol) and the reaction mixture was heated to 80 °C for 6.5 h.  The cooled reaction 
mixture was diluted with CHCl3 (5 mL), filtered and the filtrate was concentrated in 
vacuo.  The residue was purified by column chromatography (eluent 5-40% 
EtOAc/hexane) to give the title compound as a colourless oil (72 mg, 0.17 mmol, 47%). 
 
IR  νmax (neat) 3388 (br), 2978 (w), 2933 (w), 1712 (m), 1511 (m), 1366 
(m), 1152 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.10 (2H, d, J = 8.8 Hz, CArH meta to OCH2), 6.84 
(2H, d, J = 8.8 Hz, CArH ortho to OCH2), 4.97 (1H, br d, J = 7.1 Hz, 
NH), 4.60 (2H, s, OCH2C(O)O), 4.42-4.38 (1H, m, C(O)CH), 4.26 (2H, 
q, J = 7.1 Hz, C(O)OCH2), 3.02-2.99 (2H, m, CArCH2), 1.43 & 1.41 
(18H, 2 x s, 2 x C(O)OC(CH3)3), 1.30 (3H, t, J = 7.1 Hz, 
C(O)OCH2CH3). 
 
13C NMR  (75 MHz, CDCl3) δ 170.9 (CHC(O)OC(CH3)3), 168.9 (C(O)OCH2CH3), 
156.8 (NHC(O)OC(CH3)3)  , 155.0 (CArOCH2), 130.6 (CArH meta to 
OCH2), 129.6 (CArCH2), 114.6 (CArH ortho to OCH2), 82.0 & 79.6 (2 x 
OC(CH3)3), 65.6 (OCH2C(O)O), 61.3 (C(O)OCH2CH3), 54.9     158
(C(O)CH), 37.6 (CArCH2), 28.3 & 27.9 (2 x OC(CH3)3), 14.1 
(C(O)OCH2CH3). 
 
LRMS
  (ES+) m/z 446 [M + Na]
+, 870 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C22H33NO7Na [M + Na]
+ 446.2149, found 446.2143. 
 
 
(S)-Benzoic acid 2-[4-(2-tert-butoxycarbonyl-2-tert-butoxycarbonylamino ethyl) 
phenoxy] ethyl ester (4.12) 
 
O
O
O
O
O
NHBoc
 
C27H35NO7 
Mw = 485.57 gmol
−1 
White solid 
 
Following the general procedure of Chen et al.,
105 to a solution of phenol 4.09 (431 mg, 
1.30 mmol), alcohol 4.13 (216 mg, 1.30 mmol) and tri-n-butylphosphine (0.65 mL, 2.60 
mmol) in CH2Cl2 (30 mL) at 0 °C was added dropwise a solution of ADDP (656 mg, 
2.60 mmol) in THF (10 mL).  The solution was stirred at 0 °C for 1 h and then allowed 
to warm to rt and was stirred for a further 18 h.  The reaction mixture was concentrated 
in vacuo and the residue was purified by column chromatography (eluent 5-30% 
EtOAc/hexane) to give the title compound as a white solid (265 mg, 0.55 mmol, 42%). 
 
MP  65-70 °C. 
 
IR  νmax (neat) 3369 (br), 2977 (w), 2890 (w), 1713 (s), 1511 (m), 1366 (m), 
1243 (s), 1150 (s), 712 cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.06 (2H, d, J = 7.8 Hz, CArH ortho to C(O)O), 
7.58 (1H, t, J = 7.4 Hz, CArH para to C(O)O), 7.45 (2H, dd, J = 7.8, 7.4 
Hz, CArH meta to C(O)O), 7.10 (2H, d, J = 8.6 Hz, CArH meta to OCH2), 
6.87 (2H, d, J = 8.6 Hz, CArH ortho to OCH2), 4.97 (1H, br d, J = 7.5     159
Hz, NH), 4.70-4.62 (2H, m, C(O)OCH2), 4.42-4.38 (1H, m, C(O)CH), 
4.32-4.27 (2H, m, C(O)OCH2CH2), 3.02-2.99 (2H, m, CArCH2), 1.43 & 
1.42 (18H, 2 x s, 2 x C(O)OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 171.0 (CHC(O)OC(CH3)3), 166.5 (C(O)CAr), 157.5 
(NHC(O)OC(CH3)3) , 155.1 (CArOCH2), 133.1 (CAr H para to C(O)O), 
130.6 (CArH meta to OCH2), 129.7 (CArH ortho to C(O)O), 129.0 
(CArCH2), 128.3 (CArC(O)O), 128.2 (CArH meta to C(O)O), 114.6 
(CArH ortho to OCH2), 82.0 & 79.6 (2 x OC(CH3)3), 66.0 (C(O)OCH2), 
63.3 (C(O)OCH2CH2), 54.9 (C(O)CH), 37.5 (CArCH2), 28.3 & 28.0 (2 x 
OC(CH3)3). 
 
LRMS
  (ES+) m/z 508 [M + Na]
+, 994 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C27H35NO7Na [M + Na]
+ 508.2306, found 508.2305. 
 
 
Benzoic acid 2-hydroxy ethyl ester (4.13)  
 
 
C9H10O3 
Mw = 166.17 gmol
−1 
Colourless liquid 
 
Following the procedure of Wiseman et al.,
104 to a solution of ethylene glycol (1.70 mL, 
30.0 mmol) and pyridine (0.90 mL, 11.0 mmol) in CH2Cl2 (10 mL) at 0 °C was slowly 
added benzoyl chloride (1.16 mL, 10.0 mmol).  The reaction mixture was allowed to 
warm to rt and was stirred for 20.5 h.  The reaction mixture was diluted with EtOAc (10 
mL), washed with water (2 x 25 mL) and brine (1 x 50 mL), dried over Na2SO4 and 
concentrated in vacuo.  The residue was purified by column chromatography (eluent 5-
50% EtOAc/hexane) to give the title compound as a colourless liquid (1.31 g, 7.9 mmol, 
79%).  Spectroscopic data were in agreement with those published in the literature.
104 
 
IR  νmax (neat) 3413 (br), 2952 (w), 2890 (w), 1699 (m), 1269 (s), 1068 (m),     160
708 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 8.10-8.04 (2H, m, CArH ortho to C(O)O), 7.57 
(1H, tt, J = 7.4, 1.4 Hz, CArH para to C(O)O), 7.45 (2H, dd, J = 7.7, 7.3 
Hz, CArH meta to C(O)O), 4.50-4.45 (2H, m, C(O)OCH2), 4.00-3.95 
(2H, m, C(O)OCH2CH2), 2.39 (1H, br s, OH). 
 
13C NMR  (75 MHz, CDCl3) δ 166.9 (C(O)O), 133.2 (CArH para to C(O)O), 129.8 
(CArC(O)O), 129.7 (CArH ortho to C(O)O), 128.4 (CArH meta to 
C(O)O), 66.6 (C(O)OCH2), 61.4 (C(O)OCH2CH2). 
 
LRMS
  (ES+) m/z 189 [M + Na]
+. 
 
 
(S)-(+)-6-(4-(2-[4-(2-tert-Butoxycarbonyl-2-tert-butoxycarbonylamino ethyl) 
phenoxy] ethoxysulfonyl) phenyl) hexanoic acid methyl ester (4.14) 
 
O
O
O
O
NHBoc
S
O
O
MeO
O
 
C33H47NO10S 
Mw = 649.79 gmol
−1 
Colourless oil 
 
To a solution of alcohol 4.07 (1.53 g, 4.0 mmol), sulfonyl chloride 2.03 (1.46 g, 4.8 
mmol) and DMAP (122 mg, 1.0 mmol) in CH2Cl2 (25 mL) was added Et3N (1.40 mL, 
10.0 mmol) and the solution was stirred at rt for 1.75 h.  The reaction mixture was 
diluted with CH2Cl2 (20 mL), washed with 2 N HCl (1 x 40 mL), water (1 x 40 mL) and 
brine (1 x 40 mL), dried over MgSO4 and concentrated in vacuo.  The residue was 
purified by column chromatography (eluent 30% EtOAc/hexane) to give the title 
compound as a colourless oil (2.15 g, 3.3 mmol, 83%). 
 
[α]D  +7.2 (c 1.10, CHCl3, 24 °C). 
 
IR  νmax (neat) 3393 (br), 2977 (w), 2935 (w), 1735 (m), 1716 (m), 1512     161
(m), 1365 (m), 1249 (m), 1176 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.85 (2H, d, J = 8.3 Hz, CArH ortho to SO2O), 7.35 
(2H, d, J = 8.3 Hz, CArH meta to SO2O), 7.06 (2H, d, J = 8.6 Hz, CArH 
meta to OCH2), 6.72 (2H, d, J = 8.6 Hz, CArH ortho to OCH2), 4.97 (1H, 
br d, J = 7.1 Hz, NH), 4.40-4.33 (3H, m, SO2OCH2 & CHC(O)), 4.17-
4.09 (2H, m, SO2OCH2CH2), 3.67 (3H, s, C(O)OCH3), 3.09-2.89 (2H, 
m, CArCH2CH), 2.71 (2H, t, J = 7.7 Hz, CArCH2CH2), 2.32 (2H, t, J = 
7.4 Hz, C(O)CH2), 1.76-1.61 (4H, m, C(O)CH2CH2CH2CH2), 1.53-1.31 
(20H, m, 2 x C(O)OC(CH3)3 & C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3)  δ 174.0 (C(O)OCH3), 170.9 (CHC(O)OC(CH3)3) , 
157.0 (NHC(O)OC(CH3)3) , 155.0 (CArOCH2), 149.4 (CArCH2), 139.0 
(CArH meta to SO2O), 133.2 (CArSO2O), 130.6 (CArH meta to OCH2), 
129.2 (CArCH2CH), 128.1 (CArH ortho to SO2O),  114.4 (CArH ortho to 
OCH2), 82.0 & 79.6 (2 x OC(CH3)3), 68.1 (SO2OCH2), 65.5 
(SO2CH2CH2), 54.9 (C(O)CH), 51.5 (C(O)CH3), 37.6 (CArCH2CH), 
35.7 (CArCH2CH2), 34.8 (C(O)CH2), 30.6 (C(O)CH2CH2CH2),  28.6 
(C(O)CH2CH2), 28.3 & 28.0 (2 x OC(CH3)3), 24.6 (CArCH2CH2). 
 
LRMS
  (ES+) m/z 672 [M + Na]
+. 
 
HRMS  (ES+) calcd for C33H47NO10SNa [M + Na]
+ 672.2813, found 672.2826. 
 
 
(S)-(+)-2-tert-Butoxycarbonylamino-3-[4-(2-fluoro  ethoxy) phenyl] propionic acid 
tert-butyl ester (4.15) 
 
 
C20H30FNO5 
Mw = 383.45 gmol
−1 
Colourless oil 
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Solution Phase Method: A solution of sulfonyl ester 4.14 (16 mg, 0.025 mmol), KF (2 
mg, 0.030 mmol) and 1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo [8.8.8] hexacosan (11 
mg, 0.030 mmol) in MeCN (1 mL) was heated under reflux for 1 h.  The cooled 
reaction mixture was concentrated in vacuo and the residue was dissolved in CH2Cl2 
and was washed with water.  The aqueous phase was extracted with CH2Cl2 (3 x 2 mL) 
and the combined organic layers were dried over Na2SO4 and concentrated in vacuo.  
The residue was purified by column chromatography (eluent 2-40% EtOAc/hexane ) to 
give the title compound as a colourless oil (4 mg, 0.012 mmol, 48%). 
 
Solid Phase Method: Resin 4.17 (100 mg, 0.78 mmolg
−1, 0.078 mmol), KF (5 mg, 0.084 
mmol) and 1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo [8.8.8] hexacosan (32 mg, 0.084 
mmol) were heated under reflux in MeCN (2 mL) for 45 min.  The resin was removed 
by filtration and was washed with CH2Cl2 (10 mL).  The filtrate was concentrated in 
vacuo and the residue was purified by column chromatography (eluent 40% 
EtOAc/hexane) to give the title compound as a colourless oil (15 mg, 0.039 mmol, 
50%). 
 
[α]D  +4.0 (c 0.70, CHCl3, 23 °C) 
 
IR  νmax (neat) 3367 (br), 2978 (w), 1708 (m), 1511 (m), 1366 (m), 1248 
(m), 1150 (s), 1953 (m), 801 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.10 (2H, d, J = 8.6 Hz, CArH meta to OCH2), 6.86 
(2H, d, J = 8.6 Hz, CArH ortho to OCH2), 4.97 (1H, br d, J = 7.7 Hz, 
NH), 4.75 (2H, dt, 
2JHF = 47.4, J = 4.2 Hz, FCH2), 4.41 (1H, dt, J = 7.7, 
6.2 Hz, C(O)CH), 4.20 (2H, dt, 
3JHF = 27.8, J = 4.2 Hz, FCH2CH2), 
3.05-3.95 (2H, m, CArCH2), 1.43 & 1.42 (18H, 2 x s, 2 x 
C(O)OC(CH3)3). 
 
13C NMR  (100 MHz, CDCl3)  δ 171.0 (CHC(O)OC(CH3), 157.4 
(NHC(O)OC(CH3)3) , 155.1 (CArOCH2), 130.6 (CArH meta to OCH2), 
129.1 (CArCH2), 114.5 (CArH ortho to OCH2), 81.98 (OC(CH3)3), 81.95 
(d,  J = 170.0 Hz, FCH2), 81.1 (OC(CH3)3),  67.2 (d, J = 20.4 Hz,     163
FCH2CH2), 54.9 (C(O)CH), 37.6 (CArCH2), 28.3 & 28.0 (2 x 
OC(CH3)3). 
 
19F NMR  (282 MHz, CDCl3) δ −225.1 (FCH2). 
 
LRMS
  (ES+) m/z 406 [M + Na]
+, 790 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C20H30FNO5Na [M + Na]
+ 406.2000, found 406.1994. 
 
 
(S)-(+)-6-(4-[2-[4-(2-tert-Butoxycarbonyl-2-tert-butoxycarbonylamino ethyl) 
phenoxy] ethoxysulfonyl] phenyl) hexanoic acid (4.16) 
 
O
O
O
O
NHBoc
S
O
O
HO
O
C32H45NO10S 
Mw = 635.77 gmol
−1 
Colourless oil 
 
A solution of methyl ester 4.14 (1.92 g, 3.0 mmol) and Novozym 435® (2.00 g) in 
CH2Cl2/acetone (5:1, 30 mL) and aq phosphate buffer (pH 7, 80 mL) was heated at 50 ° 
C for 28 h.  Further Novozym 435® (1.00 g) was added and the reaction mixture was 
stirred for an additional for 24 h.  The cooled reaction mixture was filtered through 
Celite® and the pad was washed with CH2Cl2.  The filtrate was acidified with HCl, the 
organic layer was separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 
mL).  The combined organic layers were washed with brine (1 x 100 mL), dried over 
MgSO4 and concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 40% EtOAc/hexane) to give the title compound as a colourless 
oil (969 mg, 1.5 mmol, 50%) and recovered methyl ester 4.14 (475 mg, 0.7 mmol, 
23%). 
 
[α]D  +6.8 (c 1.12, CHCl3, 24 °C). 
 
IR  νmax (neat) 3395 (br), 2977 (w), 2933 (w), 1708 (m), 1512 (m), 1365     164
(m), 1248 (m), 1174 (s), 1153 (s), 927 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.84 (2H, d, J = 8.2 Hz, CArH ortho to SO2O), 7.35 
(2H, d, J = 8.2 Hz, CArH meta to SO2O), 7.06 (2H, d, J = 8.3 Hz, CArH 
meta to OCH2), 6.70 (2H, d, J = 8.3 Hz, CArH ortho to OCH2), 5.01 (1H, 
br d, J = 7.9 Hz, NH), 4.54-4.24 (3H, m, SO2OCH2 & CArCH2CH), 
4.23-3.92 (2H, m, SO2OCH2CH2), 3.02-2.93 (2H, m, CArCH2CH), 2.71 
(2H, t, J = 7.6, CArCH2CH2), 2.36 (2H, t, J = 7.3 Hz, C(O)CH2), 1.88-
1.55 (4H, m, C(O)CH2CH2CH2CH2), 1.52-1.29 (20H, m, 2 x 
C(O)OC(CH3)3 & C(O)CH2CH2CH2). 
 
13C NMR  (75 MHz, CDCl3) δ 178.6 (C(O)OH), 171.0 (CHC(O)OC(CH3)3), 157.0 
(NHC(O)OC(CH3)3), 155.1 (CArOCH2), 149.3 (CArCH2CH2), 133.2 
(CArSO2O), 130.5 (CArH meta to OCH2), 129.2 (CArH meta to SO2O), 
129.2 (CArCH2CH), 128.1 (CArH ortho to SO2O),  114.4 (CArH ortho to 
OCH2), 82.0 & 79.7 (2 x OC(CH3)3), 68.2 (SO2OCH2), 65.4 
(SO2OCH2CH2), 54.9 (C(O)CH), 37.6 (CArCH2CH), 35.6 (CArCH2CH2), 
33.7 (C(O)CH2), 30.5 (C(O)CH2CH2CH2),  28.5 (C(O)CH2CH2), 28.3 & 
27.9 (2 x OC(CH3)3), 24.4 (CArCH2CH2). 
 
LRMS
  (ES+) m/z 658 [M + Na]
+. 
 
HRMS  (ES+) calcd for C32H45NO10SNa [M + Na]
+ 658.2656, found 658.2640. 
 
 
Solid supported (S)-6-(4-[2-[4-(2-tert-butoxycarbonyl-2-tert-butoxycarbonylamino 
ethyl) phenoxy] ethoxysulfonyl] phenyl) hexanoic acid (4.17) 
 
 
Loading = 0.78 
mmolg
−1 
Resin beads 
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To a solution of HOBt (523 mg, 3.87 mmol) and DIC (0.60 mL, 3.87 mmol) in DMF (5 
mL) was added carboxylic acid 4.16 (823 mg, 1.29 mmol) in CH2Cl2 (20 mL) and 
amino methyl polystyrene resin (573 mg, 1.5 mmolg
−1, 0.86 mmol).  The reaction 
mixture was stirred at rt for 18 h after which time a ninhydrin test carried out on a small 
sample of the resin was negative.  The resin was removed by filtration, washed with 
CH2Cl2 (3 x 100 mL), MeOH (3 x 100 mL) and Et2O (3 x 100 mL) and dried in vacuo 
at 40 °C for 24 h to give the product resin (1.22 g, theoretical loading 0.70 mmolg
−1, 
actual loading (S elemental analysis) 0.78 mmolg
−1, 122%). 
 
IR  νmax (neat) 3399 (w), 2927 (w), 1708 (m), 1361 (m), 1175 (m), 729 (s), 
699 (s) cm
−1. 
 
1H NMR  MAS (400 MHz, CDCl3) δ 7.84 (s, CArH ortho to SO2O), 7.34 (s, CArH 
meta to SO2O), 7.07 (d, CArH meta to OCH2), 6.73 (d, CArH ortho to 
OCH2), 6.66 (amino methyl resin), 5.03 (s, NHC(O)O), 4.40 (s, 
CArCH2CH), 4.36 (s, SO2OCH2), 4.12 (s, SO2OCH2CH2), 3.50 (m, 
amino methyl resin), 3.00 (s, CArCH2CH), 2.70 (s, CArCH2CH2), 2.20 (s, 
C(O)CH2), 1.69 (s, C(O)CH2CH2CH2CH2),  1.43 (s, 2 x OC(CH3)3 & 
C(O)CH2CH2CH2). 
 
13C NMR  MAS (100 MHz, CDCl3) δ 172.6 (NHC(O)), 171.0 (CHC(O)O), 157.0 
(NHC(O)O), 155.1 (CArOCH2), 149.5 (CArCH2CH2), 145.3 (amino 
methyl resin), 135.5 (amino methyl resin), 133.2 (CArSO2O), 130.6 
(CArH meta to OCH2), 129.3 (CArH meta to SO2O), 128.1 (CArH ortho 
SO2O & CArCH2CH), 114.5 (CArH ortho to OCH2), 82.0 & 79.7 (2 x 
C(O)OC(CH3)3), 68.3 (SO2OCH2), 65.5 (SO2OCH2CH2), 55.0 
(CArCH2CHC(O)), 43.4 (amino methyl resin), 40.4 (amino methyl resin), 
37.6 (CArCH2CH), 36.4 (CArCH2CH2), 35.7 (C(O)CH2), 30.8 
(C(O)CH2CH2CH2),  28.9 (C(O)CH2CH2), 28.4 & 28.0 (2 x 
C(O)OC(CH3)3), 25.5 (CArCH2CH2). 
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(4aS,6R,8aS)-(−)-4a,5,9,10,11,12-Hexahydro-3-(2’-fluoro ethoxy)-11-methyl-6H-
benzofuro[3a,3,2-ef][2]benzazepin-6-ol ((–)-5.23) 
 
N
O
O
F
OH
H
1
2
3
4
4a
5
6
7
8 9
8a
10 11
12
13
14
1'
2'
 
 
C18H22FNO3 
Mw = 319.37 gmol
−1 
Colourless oil 
 
A solution of diol (–)-5.25 (33 mg, 0.10 mmol), TsF (36 mg, 0.21 mmol), KF (12 mg, 
0.21 mmol) and 1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo [8.8.8] hexacosan (39 mg, 
0.10 mmol) in THF (2.5 mL) was heated under reflux for 43 h.  The reaction mixture 
was concentrated in vacuo and the residue was purified by column chromatography 
(alumina, Brockman grade III, 6% H2O, 50-200 mesh, eluent EtOAc then 4% 
MeOH/CH2Cl2).  MeOH (2mL) was passed through a Isolute SCX-2 cation exchange 
cartridge before the residue from the column was dissolved in MeOH (0.5 mL) and 
loaded onto the cartridge.  The cartridge was washed with MeOH (5 mL) before being 
eluted with NH4/MeOH (2 mL).  The solvent was removed in vacuo to give the title 
compound as a colourless oil (3 mg, 9.4 μmol, 9%). 
 
[α]D  –49.3 (c 0.20, CHCl3, 25 °C). 
 
IR  νmax (neat) 2918 (w), 2027 (w), 1506 (w), 1443 (w), 1286 (w), 1175 (w), 
1043 (m) cm
−1. 
 
1H NMR  (400 MHz, CDCl3) δ 6.70 (1H, d, J = 8.3 Hz, CArH ortho to OCH2), 6.61 
(1H, d, J = 8.3 Hz, CArH ortho to CH2N), 6.07 (1H, d, J = 10.2 Hz, 
CCH=CH), 6.01 (1H, dd, J = 10.2, 5.0 Hz, CCH=CH), 4.73 (2H, dt, J = 
47.4, 4.2 Hz, CH2F), 4.62 (1H, apt br s, CHOCAr), 4.37-4.18 (2H, m, 
CH2CH2F), 4.15 (1H, apt br s, CHOH), 4.09 (1H, d, J = 15.3 Hz, 
NCHH), 3.69 (1H, d, J = 15.3 Hz, NCHH), 3.27 (1H, t, J = 13.3 Hz, 
CH2CHHN), 3.06 (1H, d, J = 14.0 Hz, CH2CHHN), 2.69 (1H, dt, J =     167
15.7, 1.6 Hz, CHHCHOCAr), 2.42 (4H, br s, NCH3 & OH), 2.09 (1H, td, 
J = 13.3, 3.0 Hz, CHHCH2N), 2.02 (1H, ddd, J = 15.7, 5.0, 2.3 Hz, 
CHHCHOCAr), 1.59 (1H, dd, J = 14.0, 2.1 Hz, CHHCH2N).   
 
13C NMR  (100 MHz, CDCl3) δ 146.5 (CArOCH2), 142.7 (CArOCH), 133.6 (CArC), 
130.6 (CArCH2N), 127.7 (CCH=CH), 126.9 (CCH=CH), 122.1 (CArH 
ortho to OCH2), 114.2 (CArH ortho to CH2N), 88.7 (CHOCAr), 82.0 (d, J 
= 171.1 Hz, CH2F), 68.6 (d, J = 21.4 Hz, CH2CH2F), 62.1 (CHOH), 
60.7 (NCH2), 53.9 (CH2CH2N), 48.2 (CCH=CH), 42.4 (NCH3), 33.9 
(CArOCHCH2), 29.9 (CH2CH2N). 
 
19F NMR  (282 MHz, CDCl3) δ −224.8 (FCH2). 
 
LRMS
  (ES+) m/z 320 [M + H]
+, 342 [M + Na]
+. 
 
HRMS  (ES+) calcd for C18H23FNO3 [M + H]
+ 320.1656, found 320.1656. 
 
 
(4aS,6R,8aS)-(−)-4a,5,9,10,11,12-Hexahydro-3-(2’-hydroxy ethoxy)-11-methyl-6H-
benzofuro[3a,3,2-ef][2]benzazepin-6-ol ((–)-5.25) 
 
 
 
C18H23NO4 
Mw = 317.38 gmol
−1 
Colourless oil 
 
Method 1: Bromide 5.49 (13 mg, 0.022 mmol) was dissolved in CH2Cl2 (0.5 mL) and 
was treated with TFA (0.2 mL).  The solution was stirred at rt for 45 min before sat aq 
NaHCO3 (1 mL) was added and stirring was continued for a further 15 min.  The 
organic phase was separated and the aqueous phase was extracted with CH2Cl2 (4 x 5 
mL).  The combined organic phase was dried over MgSO4 and concentrated in vacuo to 
give the title compound as a colourless oil (4 mg, 0.013 mmol, 57%).     168
 
Method 2: Tosylate (+)-5.51 (66 mg, 0.082 mmol) was dissolved in CH2Cl2 (1 mL) and 
was treated with TFA (0.10 mL).  The solution was stirred at rt for 3.5 h before the 
solvent was removed in vacuo.  The residue was dissolved in THF (1 mL), K2CO3 (100 
mg, 0.72 mmol) was added and the colourless opaque solution was stirred at rt for 4 h.  
The reaction mixture was filtered, the filtrate was dried over MgSO4 and concentrated in 
vacuo.  The residue was purified by column chromatography (eluent 4-10% 
MeOH/CH2Cl2) to give the title compound as a colourless oil (17 mg, 0.054 mmol, 
65%). 
 
[α]D  –57.4 (c 0.70, CHCl3, 27 °C). 
 
IR  νmax (neat) 3365 (br), 3027 (w), 2924 (w), 1738 (m), 1680 (m), 1505 
(m), 1444 (m), 1366 (m), 1284 (m), 1202 (s), 1175 (s), 1043 (s), 730 (s) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 6.70 (1H, d, J = 8.4 Hz, CArH ortho to OCH2), 6.61 
(1H, d, J = 8.4 Hz, CArH ortho to CH2N), 6.06 (1H, d, J = 10.2 Hz, 
CCH=CH), 5.99 (1H, dd, J = 10.2, 4.5 Hz, CCH=CH), 4.60 (1H, apt br 
s, CHOCAr), 4.20-4.01 (4H, m, CArOCH2CH2, NCHH & CHOH), 3.92-
3.87 (2H, m, CArOCH2), 3.72 (1H, d, J = 15.3 Hz, NCHH), 3.29 (1H, t, J 
= 13.2 Hz, CH2CHHN), 3.08 (1H, d, J = 14.0 Hz, CH2CHHN), 2.75 
(2H, br s, 2 x OH), 2.70-2.62 (1H, m, CHHCHOCAr), 2.43 (3H, s, 
NCH3), 2.10 (1H, td, J = 13.2, 3.0 Hz, CHHCH2N), 2.00 (1H, ddd, J = 
15.7, 5.0, 2.4 Hz, CHHCHOCAr), 1.60 (1H, dd, J = 14.0, 2.0 Hz, 
CHHCH2N).   
 
13C NMR  (75 MHz, CDCl3) δ 146.5 (CArOCH2), 143.0 (CArOCH), 133.2 (CArC), 
129.6 (CArCH2N), 127.6 (CCH=CH), 126.8 (CCH=CH), 122.2 (CArH 
ortho  to OCH2), 113.9 (CArH ortho to CH2N), 88.4 (CHOCAr), 70.9 
(CArOCH2CH2), 61.8 (CHOH), 61.1 (NCH2), 60.5 (CArOCH2), 53.8 
(CH2CH2N), 48.1 (CCH=CH), 42.0 (NCH3), 33.6 (CArOCHCH2), 29.9 
(CH2CH2N).     169
LRMS
  (ES+) m/z 318 [M + H]
+, 340 [M + Na]
+, 635 [2M + H]
+, 657 [2M + 
Na]
+. 
 
HRMS  (ES+) calcd for C18H24NO4 [M + H]
+ 318.1700, found 318.1699. 
 
 
tert-Butyl 2-bromoethyl carbonate (5.27) 
 
 
C7H13BrO3 
Mw = 225.08 gmol
−1 
Colourless oil 
 
Following a modified procedure to that described by Mejorado et al.,
136 a solution of 
bromoethanol (5.34, 0.73 mL, 9.60 mmol), di-tert-butyldicarbonate (698 mg, 3.20 
mmol), DMAP (39 mg, 0.32 mmol) and DIPEA (0.11 mL, 0.64 mmol) in THF (5 mL) 
was stirred at rt for 5 h.  The reaction mixture was concentrated in vacuo and the residue 
was purified by column chromatography (eluent 10% EtOAc/hexane) to give the title 
compound as a colourless oil (528 mg, 2.35 mmol, 73%). 
 
IR  νmax (neat) 2980 (w), 2937 (w), 1739 (s), 1369 (m), 1272 (s), 1252 (s), 
1154 (s), 1114 (m), 861 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 4.37 (2H, t, J = 6.4 Hz, BrCH2CH2), 3.52 (2H, t, J 
= 6.4 Hz, BrCH2), 1.50 (9H, s, OC(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 152.9 (C(O)O), 82.8 (C(CH3)3), 66.0 (BrCH2CH2), 
28.3 (BrCH2), 27.7 (C(CH3)3). 
 
LRMS
  (EI) 124/126 ([M − Boc + H]
+, 5%), 107/109 ([M − BocOH]
+, 59%), 
93/95 ([M − BocOCH2]
+, 16%), 79/81 (Br
+, 6%), 44 ([CH2CH2O]
+, 
100%). 
 
HRMS  (ES+) calcd for C7H13
79BrO3Na [M + Na]
+ 246.9940, found 246.9939.     170
tert-Butyl-3-hydroxy-2-iodo-(4-ethyl  tert-butyl carbonate)benzylmethylcarbamate 
(5.28) 
 
OH
O
OBoc
I
NBoc
 
 
C20H30INO7 
Mw = 523.36 gmol
−1 
White solid 
 
Aldehyde 5.36 (14.58 g, 35.7 mmol) was dissolved in MeOH (50 mL) and treated with 
MeNH2 (35.71 mL, 2.0 M sol in MeOH, 71.4 mmol) and the yellow solution was stirred 
at rt for 21.5 h.  The solvent was removed in vacuo and the residue was dissolved in 
MeOH (180 mL).  4 Å Molecular sieves (5 g) were added and the reaction was stirred 
for 15 min before the portionwise addition of NaBH4 (1.49 g, 39.3 mmol) over 10 min.  
The reaction mixture was stirred at rt for 3.5 h before the sieves were removed by 
filtration and the solvent was removed in vacuo.  The residue was dissolved in CHCl3 
(80 mL) and sat. aq NaHCO3 (40 mL) and brine (40 mL) were added before di-tert-
butyldicarbonate (7.79 g, 35.2 mmol).  The emulsion was stirred vigorously at 50 ºC for 
16.5 h.  The cooled reaction mixture was separated and the aqueous layer was extracted 
with CHCl3 (1 x 100mL).  The combined organic layers were washed with water (1 x 
150mL) and brine (1 x 150 mL), dried over MgSO4 and concentrated in vacuo.  The 
residue was purified by column chromatography (eluent 20% EtOAc/hexane) to give 
the title compound as a white solid (14.93 g, 28.5 mmol, 80%). 
 
MP  93-95 ºC. 
 
IR  νmax (neat) 3413 (br), 2977 (w), 2932 (w), 1739 (m), 1664 (m), 1479 
(m), 1367 (m), 1276 (s), 1252 (s), 1151 (s), 1064 (m) cm
−1. 
 
1H NMR  (400 MHz, CDCl3) δ 6.81, (1H, d, J = 8.3 Hz, CArH, ortho to OCH2), 
6.63 (1H, br s, CArH ortho to CH2N), 6.56 (1H, s, OH), 4.62-4.33 (4H, 
m, CH2N & CArOCH2CH2), 4.33-4.10 (2H, m, CArOCH2), 2.85 (3H, br     171
s, NCH3), 1.50-1.35 (18H, m, 2 x C(O)OC(CH3)3).  Spectrum exhibited 
broadening of peaks due to restricted rotation. 
 
13C NMR  (100 MHz, CDCl3)  δ 155.9 (NC(O)O), 153.5 (OC(O)O), 146.2 
(CArOCH2), 143.7 (CArOH), 133.4 (CArCH2N), 117.9 (CArH ortho to 
CH2N), 112.1 (CArH ortho to OCH2), 85.8 (CArI), 82.8 
(OC(O)C(CH3)3), 79.7 (NC(O)OC(CH3)3), 68.1 (CArOCH2CH2), 64.7 
(CArOCH2), 57.1 (NCH2), 34.2 (NCH3), 28.4 (NC(O)C(CH3)3), 27.7 
(OC(O)C(CH3)3). 
 
LRMS
  (ES−) m/z 522 [M − H]
+. 
 
HRMS  (ES+) calcd for C20H30INO7Na [M + Na]
+ 546.0959, found 546.0967. 
 
Anal  Calcd for C20H30INO7 C = 45.90, H = 5.78, N = 2.68.  Found C = 46.41, 
H = 5.83, N = 2.54. 
 
(±)-1-Trimethylsilyl hex-5-en-1-yn-3-ol ((±)-5.29) 
 
TMS
OH
 
C9H16OSi 
Mw = 168.31 gmol
−1 
Colourless liquid 
 
Aldehyde 5.38 (8.72 g, 69.1 mmol) in Et2O (7 mL) was added dropwise to a solution of 
allylmagnesium bromide (76 mL, 1.0 M sol in Et2O, 76.0 mmol) at −50 ºC.  The 
reaction was stirred for 2 h over which time it was allowed to warm to −10
 ºC.  The 
reaction was quenched by pouring onto a mixture of a sat aq solution of NH4Cl (300 
mL) and Et2O (60 mL).  The mixture was stirred rapidly for 10 min before it was 
separated and the aqueous layer was extracted with Et2O (3 x 75 mL).  The combined 
organic layers were washed with water (1 x 100 mL) and brine (1 x 100 mL), dried over 
MgSO4 and concentrated in vacuo.  The resulting oil was purified by distillation (110-
120 ºC, 25 mm/Hg) to give the title compound as a colourless liquid (8.82 g, 52.4     172
mmol, 76%).  Spectroscopic data were in agreement with those published in the 
literature.
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IR  νmax (neat) 3336 (br), 3080 (w), 2960 (w), 2901 (w), 2175 (w), 1250 
(m), 1028 (m), 837 (s), 759 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 6.20-5.62 (1H, m, CH=CH2), 5.31-5.07 (2H, m, 
CH=CH2), 4.41 (1H, apt q, J = 6.0 Hz, CH(OH)), 2.48 (2H, br t, J = 6.0 
Hz, CH2), 1.95 (1H, d, J = 6.0 Hz, OH), 0.18 (9H, s, Si(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 132.9 (CH=CH2), 119.0 (CH=CH2), 105.9 (SiC≡C), 
89.8 (SiC≡C), 61.9 (CH(OH), 42.1 (CH2), –0.2 (Si(CH3)3). 
 
LRMS
  (EI) 127 ([M − C3H5]
+, 90%), 99 ([M − C3H5CO]
+, 100%). 
 
 
(R)-(+)-1-Trimethylsilyl hex-5-en-1-yn-3-ol ((+)-5.29) 
 
TMS
OH
 
C9H16OSi 
Mw = 168.31 gmol
−1 
Colourless liquid 
 
Following the procedure of Burova  et al.,
139 acetate (+)-5.39 (3.41 g, 16.2 mmol) was 
dissolved in CH2Cl2 (16 mL) and cooled to −78 ºC before DIBAL-H (28 mL, 1.0 M 
soln in hexanes, 28.0 mmol) was added dropwise.  The resulting pale yellow solution 
was stirred for 30 min before EtOAc (10 mL) was added.  The reaction mixture was 
stirred for a further 20 min at −78 ºC before it was poured onto a sat aq solution of 
Rochelle’s salt (150 mL) and stirred for 1 h at rt.  The layers were separated and the 
aqueous layer was extracted with Et2O (2 x 100 mL) and EtOAc (3 x 75 mL).  The 
combined organic layers were dried over MgSO4 and concentrated in vacuo.  The 
residue was purified by column chromatography (eluent 15% EtOAc/hexane) to give 
the title compound as a colourless liquid (2.648 g, 15.7 mmol, 97%).  Spectroscopic 
data were consistent with those previously collected.     173
[α]D : +43.3 (c 1.05, CHCl3, 24 °C) (lit: +34, c 0.940, rt).
139  
 
(S)-tert-Butyl-3-((S)-1-formyl-4-(trimethylsilyl)but-3-yn-2-yloxy)-2-iodo-(4-ethyl 
tert-butyl carbonate) benzylmethylcarbamate (5.30) 
 
 
 
C28H42INO8Si 
Mw = 675.62 gmol
−1 
Pale yellow oil 
 
Diol (±)-5.42 (6.82 g, 9.6 mmol) was dissolved in acetone (40 mL) and water (20 mL) 
before NaIO4 (4.12 g, 19.3 mmol) was added in one portion.  The mixture was stirred 
vigorously at rt for 2 h during which time it became cloudy.  The solvent was removed 
in vacuo before EtO2 (100 mL) and water (50 mL) were added.  The aqueous layer was 
extracted with EtO2 (3 x 50 mL).  The combined organic layers were washed with water 
(1 x 100 mL) and brine (1 x 100mL), dried over MgSO4 and concentrated in vacuo to 
give the title compound as a pale yellow oil (5.98 g, 8.9 mmol, 93%) which required no 
subsequent purification. 
 
IR  νmax (neat) 2975 (w), 2930 (w), 1741 (m), 1693 (m), 1476 (m), 1391 
(m), 1273 (m), 1250 (s), 1153 (m), 845 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 10.12 (1H, t, J = 2.2 Hz, CHO), 7.03-6.70 (2H, m, 
2 x CArH), 5.71 (1H, br s, CHOCAr), 4.60-4.30 (4H, m, CH2N & 
CArOCH2CH2), 4.22 (2H, t, J = 4.3 Hz  CArOCH2), 2.98 (2H, dd, J = 5.6, 
2.2 Hz, CH2CHOCAr), 2.91-2.69 (3H, m, NCH3), 1.60-1.30 (18H, m, 2 x 
C(O)OC(CH3)3), 0.05 (9H, s, Si(CH3)3).  Spectrum exhibited broadening 
of peaks due to restricted rotation. 
 
13C NMR  (100MHz, CDCl3) δ 200.3 (CHO), 155.9 (NC(O)O), 153.3 (OC(O)O), 
150.0 (CArOCH2), 146.1 (CArOCH), 133.5 (CArCH2N), 123.6 & 122.6     174
(CArH ortho to OCH2), 114.0 & 113.8 (CArH ortho to CH2N), 101.4 
(SiC≡C), 94.5 (SiC≡C), 82.6 (OC(O)C(CH3)3), 79.8 (NC(O)OC(CH3)3), 
67.2 (CArOCH2CH2), 67.1 (CHOCAr), 64.8 (CArOCH2), 57.7 & 56.6 
(NCH2), 48.6 (CH2CHOCAr), 34.2 (NCH3), 28.4 (NC(O)C(CH3)3), 27.7 
(OC(O)C(CH3)3), –0.5 (Si(CH3)3).  No CArI peak observed. 
 
LRMS
  (ES+) m/z 698 [M + Na]
+. 
 
HRMS  (ES+) calcd for C28H42INO8SiNa [M + Na]
+ 698.1617, found 698.1621. 
 
 
(S)-(+)-tert-Butyl-3-((3S,5S)-5-hydroxy-1-(trimethylsilyl)-oct-7-en-1-yn-3-yloxy)-2-
iodo-(4-ethyl tert-butyl carbonate) benzylmethylcarbamate ((+)-5.31) 
 
 
 
C31H48INO8Si 
Mw = 717.70 gmol
−1 
Pale yellow oil 
 
TiCpCl-(R,R)-TADDOL complex ((R,R)-5.43,  3.35 g, 5.6 mmol) was suspended in 
Et2O (80 mL) and cooled to 0 ºC before allyl magnesium bromide (5.60 mL, 1.0 M sol 
in Et2O, 5.6 mmol) was added dropwise.  The brown reaction mixture was stirred for 
1.5 h before it was cooled to −78 ºC and a solution of aldehyde 5.30 (3.16 g, 4.7 mmol) 
in Et2O (10 mL) was added dropwise.  The reaction mixture was stirred for 5.5 h then 
quenched by the addition of water (50 mL).  The reaction mixture was allowed to warm 
to rt and stirred for 16 h.  Filtration through Celite® and concentration in vacuo gave a 
yellow solid which was purified by column chromatography (eluent 15-40% 
EtOAc/hexane) to give the title compound as a pale yellow oil (3.18 g, 4.4 mmol, 94%). 
 
[α]D  +7.1 (c 1.00, CHCl3, 24 °C). 
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IR  νmax (neat) 3463 (br w), 2976 (w), 2930 (w), 1742 (m), 1694 (m), 1476 
(m), 1392 (m), 1273 (m), 1249 (s), 1152 (m), 842 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.01-6.68 (2H, m, 2 x CArH), 5.92 (1H, ddt, J = 
17.2, 10.1, 6.9 Hz, CH=CH2), 5.46 (1H, br s, CHOCAr), 5.24-4.99 (2H, 
m, CH=CH2), 4.57-4.30 (4H, m, CH2N & CArOCH2CH2), 4.27-4.11 
(3H, m, CArOCH2 & CHOH), 2.94-2.66 (4H, m, NCH3 & OH), 2.36 
(2H, t, J = 6.9 Hz, CH2CH=CH2), 2.26-2.05 (2H, m, CH2CHOCAr), 
1.66-1.29 (18H, m, 2 x C(O)OC(CH3)3), 0.03 (9H, s, Si(CH3)3).  
Spectrum exhibited broadening of peaks due to restricted rotation. 
 
13C NMR  (100MHz, CDCl3)  δ 155.9 (NC(O)O), 153.2 (OC(O)O), 149.9 
(CArOCH2), 146.2 (CArOCH), 134.8 (CH=CH2), 133.5 (CArCH2N), 
123.3 & 122.3 (CArH ortho to OCH2), 117.5 (CH=CH2), 113.6 & 113.4 
(CArH ortho to CH2N), 103.1 (SiC≡C), 93.5 (SiC≡C), 82.7 
(OC(O)C(CH3)3), 79.8 (NC(O)OC(CH3)3), 70.8 (CHOH), 68.9 
(CHOCAr), 67.0 (CArOCH2CH2), 64.9 (CArOCH2), 57.6 & 56.5 (NCH2), 
42.5 (CH2CH=CH2), 41.9 (CH2CHOCAr), 34.1 (NCH3), 28.4 
(NC(O)C(CH3)3), 27.7 (OC(O)C(CH3)3), –0.4 (Si(CH3)3).  No CArI peak 
observed. 
 
LRMS
  (ES+) m/z 740 [M + Na]
+. 
 
HRMS  (ES+) calcd for C31H48INO8SiNa [M + Na]
+ 740.2086, found 740.2096. 
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(S)-(–)-tert-Butyl-3-((1S,5S)-5-[(tert-butyldimethylsilyl)oxy]-2-ethenylcyclohex-2-
en-1-yloxy)-2-iodo-4-(ethyl tert-butyl carbonate) benzylmethylcarbamate ((–)-5.32) 
 
 
 
C34H54INO8Si 
Mw = 759.78 gmol
−1 
Orange oil 
 
Enyne (–)-5.46 (5.03 g, 6.6 mmol) was dissolved in CH2Cl2 (140 mL) and degassed for 
5 min.  Grubbs’ I catalyst (5.45, 273 mg, 0.33 mmol, 5 mol %) was added and the 
solution was heated to reflux.  Further Grubb’s I catalyst (5.45, 54 mg, 0.07 mmol, 1 
mol %) was added after 6 h.  After 21 h the reaction mixture was concentrated in vacuo.  
The residue was purified by column chromatography (eluent 10-20% EtOAc/hexane) to 
give the title compound as an orange oil (3.24 g, 4.3 mmol, 65%). 
 
[α]D  –61.8 (c 1.04, CHCl3, 22 °C). 
 
IR  νmax (neat) 2953 (w), 2929 (w), 2856 (w), 1743 (m), 1697 (m), 1474 
(m), 1391 (m), 1276 (s), 1252 (s), 1155 (s), 837 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 6.98-6.66 (2H, m, 2 x CArH), 6.44 (1H, dd, J = 
17.6, 11.2 Hz, CH=CH2), 5.85 (1H, br d, J = 3.7 Hz, CHOCAr), 5.72-
5.45 (2H, m, CH=CH2), 5.05 (1H, d, J = 11.3 Hz, C=CH), 4.52-4.30 
(4H, m, CH2N & CArOCH2CH2), 4.30-4.15 (2H, m, CArOCH2), 3.78 
(1H, tt, J = 9.8, 5.1 Hz, CHOTBS), 3.01-2.63 (3H, br m, NCH3), 2.47-
2.12 (2H, m, C=CHCH2),  2.07-1.82 (2H, m, CH2CHOCAr), 1.65-1.30 
(18H, m, 2 x C(O)OC(CH3)3), 0.84 (9H, s, Si(C(CH3)3)), 0.02 (3H, s, 
SiCH3), 0.00 (3H, s, SiCH3).  Spectrum exhibited broadening of peaks 
due to restricted rotation. 
 
13C NMR  (75 MHz, CDCl3)  δ 155.9 (NC(O)O), 153.3 (OC(O)O), 149.6     177
(CArOCH2), 146.0 (CArOCH), 137.5 (C=CH), 135.8 (CH=CH2), 133.6 
(CArCH2N), 126.2 (C=CH), 122.1 & 121.4 (CArH ortho to OCH2), 114.1 
(CH=CH2), 113.2 & 113.0 (CArH ortho to CH2N), 82.3 
(OC(O)C(CH3)3), 79.7 (NC(O)OC(CH3)3), 76.1 (CHOTBS), 67.1 
(CHOCAr), 66.6 (CArOCH2CH2), 64.8 (CArOCH2), 57.8 (NCH2), 38.9 
(CArOCHCH2), 35.9 (C=CHCH2), 34.3 (NCH3), 28.4 (NC(O)C(CH3)3), 
27.7 (OC(O)C(CH3)3), 25.8 (SiC(CH3)3), 18.1 (SiC(CH3)3), –4.6 
(Si(CH3)2).  No CArI peak observed. 
 
LRMS
  (ES+) m/z 782 [M + Na]
+. 
 
HRMS  (ES+) calcd for C34H54INO8SiNa [M + Na]
+ 782.2556, found 782.2555. 
 
 
2-(4-Formyl-2-hydroxyphenoxy) ethyl tert-butyl carbonate (5.35) 
 
 
 
C14H18O6 
Mw = 282.29 gmol
−1 
White solid 
 
Following the procedure of Nicolaou et al.,
137 NaH (4.54 g, 113.5 mmol, 60% 
dispersion in mineral oil) was added portionwise to a solution of 3,4-
dihydroxybenzaldehyde (5.26, 15.68 g, 113.5 mmol) in DMF (80 mL) at 0 ºC.  The 
solution was stirred for 15 min before a solution of bromide 5.27 (25.55 g, 113.5 mmol) 
in DMF (60 mL) was added.  The ice bath was removed and the solution was warmed at 
40 ºC for 5 days.  Water was added to the cooled reaction mixture and the pH was 
adjusted to pH 5 using 2 N HCl.  The solution was extracted with Et2O (3 x 200 mL).  
The combined organic layers were dried over MgSO4 and concentrated in vacuo.  The 
residue was purified by column chromatography (eluent 20% EtOAc/hexane) to give 
the title compound as a white solid (17.11 g, 60.6 mmol, 53%). 
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MP  93-98 ºC. 
 
IR  νmax (neat) 3415 (br), 2980 (w), 2937 (w), 1738 (m), 1685 (m), 1609 
(m), 1587 (m), 1508 (m), 1271 (s), 1253 (s), 1157 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 9.85 (1H, s, C(O)H), 7.45 (1H, d, J = 1.9 Hz, CArH 
ortho to OH), 7.41 (1H, dd, J = 8.2, 1.9 Hz, CArH ortho to C(O)H), 6.94, 
(1H, d, J = 8.2 Hz, CArH, ortho to OCH2), 6.00 (1H, s, OH), 4.55-4.48 
(2H, m, CArOCH2CH2), 4.38-4.31 (2H, m, CArOCH2), 1.51 (9H, s, 
C(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 190.9 (C(O)H), 153.4 (OC(O)O), 150.6 (CArOCH2), 
146.5 (CArOH), 131.2 (CArC(O)H), 124.0 (CArH ortho to C(O)H), 114.7 
(CArH ortho to OH), 111.2 (CArH ortho to OCH2), 83.1 (C(CH3)3), 67.6 
(CArOCH2CH2), 64.4 (CArOCH2), 27.7 (C(CH3)3). 
 
LRMS
  (ES+) m/z 305 [M + Na]
+. 
 
HRMS  (ES+) calcd for C14H18O6Na [M + Na]
+ 305.0996, found 305.0999. 
 
 
2-(4-Formyl-2-hydroxy-3-iodophenoxy) ethyl tert-butyl carbonate (5.36) 
 
 
 
C14H17IO6 
Mw = 408.19 gmol
−1 
Pale yellow solid 
 
Following the procedure of Markovich et al.,
138 alcohol 5.35 (9.60 g, 34.0 mmol) was 
dissolved in pyridine (20 mL) and cooled to 0 °C before a solution of ICl (1.80 mL, 
35.7 mmol) in dioxane (35 mL) was added.  The solution was stirred for 1 h before the 
ice bath was removed and the solution was allowed to warm to rt and stirred for 5 days.      179
The solvent was removed in vacuo and water (50 mL) was added.  The aqueous phase 
was extracted with EtOAc (3 x 100 mL).  The combined organic phase was washed 
with 5% aq Na2S2O3 (2 x 100 mL), water (2 x 100 mL) and brine (1 x 100 mL), dried 
over MgSO4 and concentrated in vacuo.  The residue was recrystallised from EtOAc to 
give the title compound as a pale yellow solid (6.53g, 16.0 mmol, 47%).  The filtrate 
from the recrystallisation was purified by column chromatography (eluent 10% 
EtOAc/hexane) to give further product (557 mg, 1.4 mmol, 4%). 
 
MP  155-156 ºC. 
 
IR  νmax (neat) 3415 (br), 2979 (w), 2935 (w), 1740 (m), 1681 (m), 1583 
(m), 1277 (s), 1255 (m), 1158 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 10.05 (1H, s, C(O)H), 7.35 (1H, d, J = 8.5 Hz, 
CArH ortho to C(O)H), 6.90, (1H, d, J = 8.5 Hz, CArH, ortho to OCH2), 
6.60 (1H, s, OH), 4.55-4.48 (2H, m, CArOCH2CH2), 4.39-4.32 (2H, m, 
CArOCH2), 1.51 (9H, s, C(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 194.8 (C(O)H), 153.6 (OC(O)O), 149.4 (CArOCH2), 
146.2 (CArOH), 129.3 (CArC(O)H), 123.4 (CArH ortho to C(O)H), 111.0 
(CArH ortho to OCH2), 88.1 (CArI), 83.2 (C(CH3)3), 68.1 
(CArOCH2CH2), 64.3 (CArOCH2), 27.7 (C(CH3)3). 
 
LRMS
  (ES+) m/z 431 [M + Na]
+, 839 [2M + Na]
+. 
 
HRMS  (ES+) calcd for C14H17IO6Na [M + Na]
+ 430.9962, found 430.9969. 
 
 
3-(Trimethylsilyl) propioaldehyde (5.38) 
 
 
C6H10OSi 
Mw = 126.23 gmol
−1 
Yellow oil     180
 
Following the procedure of Journet et al.,
140 TMS acetylene (5.37, 20.50 mL, 145.0 
mmol) was dissolved in Et2O (200 mL) and cooled to −40 ºC before n-BuLi (58 mL, 2.5 
M solution in hexanes, 145.0 mmol) was added dropwise.  The solution was stirred for 
5 min before DMF (21 mL, 261.0 mmol) was added.  The cold bath was removed and 
the reaction was stirred vigorously for 30 min.  The reaction mixture was quenched by 
pouring into a mixture of 10% aq NaH2PO4 (70.0 g, 580.0 mmol) and Et2O (150 mL).  
The mixture was stirred rapidly for 10 min over which time the aqueous layer turned 
bright yellow.  The layers were separated and the organic layer was washed with water 
(100 mL).  The combined aqueous layers were extracted with Et2O (2 x 50 mL).  The 
combined organic layers were dried over MgSO4 and the bulk of the solvent was 
removed by distillation (50 ºC, atm pressure).  The remaining solvent was removed by 
distillation (40 ºC, 25 mm/Hg) to give the title compound as a yellow free flowing oil 
(14.91 g, 118.1 mmol, 81%) which was used in subsequent reactions without further 
purification.  Spectroscopic data were in agreement with those published in the 
literature.
141 
 
IR  νmax (neat) 2964 (w), 2859 (w), 2154 (w), 1666 (s), 1388 (w), 1252 (m), 
995 (s), 839 (s), 760 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 9.17 (1H, s, C(O)H), 0.27 (9H, s, Si(CH3)3). 
 
13C NMR  (75 MHz, CDCl3)  δ 176.7 (C(O)H), 103.0 (SiC≡C), 102.2 (SiC≡C), 
−0.9 (Si(CH3)3). 
 
LRMS
  (EI) 125 ([M − H]
+, 3%), 111 ([M − CH3]
+, 100%). 
 
 
(R)-(+)-1-(Trimethylsilyl) hex-5-en-1-yn-3-acetate ((+)-5.39) 
 
TMS
OAc
 
C11H18O2Si 
Mw = 210.34 gmol
−1 
Colourless oil     181
 
Method 1: Following the procedure of Burova et al.,
139 to a solution of  racemic alcohol 
(±)-5.29 (5.54 g, 32.9 mmol) in hexane (275 mL) was added 4 Å molecular sieves (10 
g), vinyl acetate (11.60 mL, 126.5 mmol) and Amano® AK20 Lipase enzyme (6.50 g).  
The suspension was stirred at rt for 23 h before it was filtered through Celite® and the 
pad was washed with Et2O (2 x 100 mL).  The filtrated was concentrated in vacuo and 
the residue was purified by column chromatography (eluent 9-20% Et2O/hexane) to 
give the title compound as a colourless oil (3.25 g, 15.4 mmol, 47%) and alcohol (–)-
5.29 as a pale yellow oil (2.08 g, 12.4 mmol, 38%).   
 
(+)-5.39 [α]D : +91.7 (c 1.10, CHCl3, 24 °C) (lit: +86, c 0.970, rt, 99% ee).
139  
(–)-5.29 [α]D : –41.4 (c 1.15, CHCl3, 24 °C) (lit: –29, c 0.850, rt, 98% ee).
139  
 
Method 2: Following the procedure of Jin et al.,
142 a solution of alcohol (–)-5.29 (3.77 
g, 22.4 mmol), PPh3 (23.49 g, 89.6 mmol), pyridine (3.62 mL, 44.8 mmol) and acetic 
acid (6.4 mL, 112.0 mmol) in THF (140 mL) at −50 ºC was added DIAD (17.63 mL, 
89.6 mmol).  The solution was stirred for 10 min at −50 ºC and then was warmed to 0 
ºC and stirred for 22 h, during which time it was allowed to warm to rt.  The reaction 
mixture was concentrated in vacuo and the residue was dissolved in Et2O (200 mL) and 
was washed with sat aq NaHCO3 (1 x 200 mL), 2 N HCl (1 x 150 mL) and brine (1 x 
150 mL), dried over MgSO4 and concentrated in vacuo.  The residue was purified by 
column chromatography (eluent 5-10% EtOAc/hexane) to give the title compound as a 
colourless oil (3.58 g, 17.0 mmol, 76%). 
 
(+)-5.39 [α]D : +99.9 (c 1.00, CHCl3, 24 °C) (lit: +86, c 0.970, rt, 99% ee).
139  
 
Spectroscopic data were in agreement with those published in the literature.
139  
 
IR  νmax (neat) 3080 (w), 2960 (w), 2902 (w), 1745 (s), 1371 (w), 1227 (s), 
1021 (m), 841 (s), 760 (m) cm
−1. 
 
1H NMR  (400 MHz, CDCl3) δ 5.82 (1H, ddt, J = 17.2, 10.2, 6.6 Hz, CH=CH2), 
5.43 (1H, t, J = 6.6 Hz, CH(OC(O)CH3)), 5.22-5.08 (2H, m, CH=CH2),     182
2.52 (2H, t, J = 6.6 Hz, CH2), 2.08 (3H, s, C(O)CH3), 0.18 (9H, s, 
Si(CH3)3). 
 
13C NMR  (100 MHz, CDCl3)  δ 169.7 (C(O)CH3), 132.2 (CH=CH2), 118.6 
(CH=CH2), 102.1 (SiC≡C), 90.9 (SiC≡C), 63.6 (CH(OH)), 39.4 (CH2), 
21.0 (C(O)CH3), –0.2 (Si(CH3)3). 
 
LRMS
  (EI) 169 ([M − C3H5]
+, 82%), 43 ([M − C2H3]
+, 100%). 
 
 
General Procedure E for the Preparation of Mosher Esters of Alcohols  
(R)-(+)-1-Trimethylsilyl hex-5-en-1-yn-3-ol ((+)-5.29) and (S)-(−)-1-Trimethylsilyl 
hex-5-en-1-yn-3-ol ((−)-5.29) 
 
Following the procedure of Fos et al.,
145 (R)-(+)-α-methoxy-α-trifluoromethyl phenyl 
acetic acid ((R)-(+)-MTPA, 500 mg, 2.14 mmol) was dissolved in SOCl2 (20 mL) and 
heated to reflux for 4 h.  The excess SOCl2 was removed in vacuo to give the Mosher 
acid chloride ((S)-(+)-MTPA chloride) as an orange liquid which was used without 
further purification.  To a solution of the appropriate alcohol (50 mg, 0.30 mmol) in 
CH2Cl2 (1 mL) was added (S)-(+)-MTPA chloride (150 mg, 0.60 mmol) and pyridine (3 
drops).  The solution was stirred at room temperature for 27 h and then heated to 40 °C 
for a further 3 h (total reaction time 30 h).  The cooled reaction mixture was diluted with 
CH2Cl2 (5 mL), washed with 0.1 N HCl (10 mL), dried over MgSO4 and concentrated 
in vacuo.  The resulting orange liquid was purified by column chromatography (eluent 
5% EtOAc/hexane) to give the Mosher ester as a colourless liquid. 
 
IR  (neat) 3078 (w), 2969 (w), 2850 (w), 1753 (s), 1231 (m), 1169 (s), 844 
(s) cm
−1 
 
LRMS  (ES+) m/z 407 [M + Na]
+, 439 [M + Na + MeOH]
+. 
 
HRMS  (ES+) calcd for C19H23F3O3SiNa [M + Na]
+ 407.1261, found 407.1268. 
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(3R)-(2’R)-(+)-1-(Trimethylsilyl) hex-5-en-1-yn-3-yl 3’,3’,3’-trifluoro-2’-methoxy-
2’-phenylpropanoate ((+)-5.40) 
 
TMS
O
O
MeO
Ph
F3C
 
C19H23F3O3Si 
Mw = 384.46 gmol
−1 
Colourless oil 
 
Alcohol (+)-5.29 was used in general procedure E to give the title compound (73 mg, 
0.19 mmol, 63%). 
 
 [α]D
  +51.0 (c 0.98, CHCl3, 24 °C) 
 
1H NMR  (300 MHz, CDCl3) δ 7.60-7.54 (2H, m, CArH), 7.44-7.36 (3H, m, CArH), 
5.72 (1H, ddt, J = 16.8, 9.7, 6.8 Hz, CH=CH2), 5.62 (1H, t, J = 6.8 Hz, 
CH(O)), 5.17-5.00 (2H, m, CH=CH2), 3.61 (3H, s, OCH3), 2.57 (2H, t, J 
= 6.8 Hz, CH2), 0.20 (9H, s, Si(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 165.5 (C(O)O), 138.9 (CArC), 132.3 (CArC), 131.4 
(CH=CH2), 129.6 (CF3), 128.9 (CAr para to alkyl group), 128.4 (CAr 
ortho to alkyl group), 127.4 (CAr meta to alkyl group), 119.2 (CH=CH2), 
100.6 (SiC≡C), 92.3 (SiC≡C), 65.6 (CH(O)), 55.5 (OCH3), 38.9 (CH2), 
−0.4 (Si(CH3)3). 
 
19F NMR  (282 MHz, CDCl3) δ −72.4 (CF3). 
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(3S)-(2’R)-(−)-1-(Trimethylsilyl) hex-5-en-1-yn-3-yl 3’,3’,3’-trifluoro-2’-methoxy-
2’-phenylpropanoate ((−)-5.40) 
 
TMS
O
O
MeO
Ph
F3C
 
C19H23F3O3Si 
Mw = 384.46 gmol
−1 
Colourless oil 
 
Alcohol (−)-5.29 was used in general procedure E to give the title compound (70 mg, 
0.18 mmol, 61%). 
 
 [α]D
  −5.1 (c 0.97, CHCl3, 24 °C) 
 
1H NMR  (300 MHz, CDCl3) δ 7.59-7.50 (2H, m, CArH), 7.44-7.37 (3H, m, CArH), 
5.81 (1H, ddt, J = 16.9, 10.2, 6.8 Hz, CH=CH2), 5.58 (1H, t, J = 6.8 Hz, 
CH(O)), 5.29-5.06 (2H, m, CH=CH2), 3.57 (3H, s, OCH3), 2.62 (2H, t, J 
= 6.8 Hz, CH2), 0.19 (9H, s, Si(CH3)3). 
 
13C NMR  (75 MHz, CDCl3) δ 165.5 (C(O)O), 139.8 (CArC), 132.0 (CArC), 131.8 
(CH=CH2), 129.6 (CF3), 128.9 (CAr para to alkyl group), 128.3 (CAr 
ortho to alkyl group), 127.5 (CAr meta to alkyl group), 119.2 (CH=CH2), 
100.4 (SiC≡C), 92.1 (SiC≡C), 65.9 (CH(O)), 55.6 (OCH3), 38.9 (CH2), 
−0.4 (Si(CH3)3). 
 
19F NMR  (282 MHz, CDCl3) δ −73.1 (CF3). 
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(S)-(+)-tert-Butyl-3-(1-(trimethylsilyl) hex-5-en-1-yn-3-yloxy)-2-iodo-(4-ethyl tert-
butyl carbonate) benzylmethylcarbamate ((+)-5.41) 
 
 
 
C29H44INO7Si 
Mw = 673.65 gmol
−1 
Pale pink oil 
 
To a solution of alcohol (+)-5.29 (2.37 g, 14.1 mmol) in THF (60 mL) was added a 
solution of phenol 5.28 (7.74 g, 14.8 mmol) and PPh3 (7.39 g, 28.2 mmol) in THF (40 
mL).  The solution was stirred for 5 min before DIAD (5.54 mL, 28.2 mmol) was added 
dropwise to give a dark orange solution.  The solution was heated to 55 ºC for 6 h 
before being cooled to rt and concentrated in vacuo.  The resulting orange oil was 
purified by column chromatography (eluent 10% EtOAc/hexane) to give the title 
compound as a pale pink oil (9.20 g, 13.7 mmol, 97%). 
 
[α]D  +7.7 (c 1.04, CHCl3, 23 °C). 
 
IR  νmax (neat) 3081 (w), 2976 (w), 2932 (w), 1742 (m), 1696 (m), 1476 
(m), 1367 (m), 1274 (m), 1250 (s), 1154 (m), 843 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.13-6.47 (2H, m, 2 x CArH), 6.05 (1H, ddt, J = 
17.1, 10.2, 6.8 Hz, CH=CH2), 5.30-5.03 (3H, m, CHOCAr & CH=CH2), 
4.72-4.31 (4H, m, CH2N & CArOCH2CH2), 4.20 (2H, t, J = 4.6 Hz, 
CArOCH2), 3.14-2.56 (5H, m, CH2CHOCAr & NCH3), 1.55-1.35 (18H, 
m, 2 x C(O)OC(CH3)3), 0.04 (9H, s, Si(CH3)3).  Spectrum exhibited 
broadening of peaks due to restricted rotation. 
 
13C NMR  (75 MHz, CDCl3)  δ 155.9 (NC(O)O), 153.3 (OC(O)O), 150.0 
(CArOCH2), 146.7 (CArOCH), 133.5 (CH=CH2), 133.3 (CArCH2N), 
123.0 & 122.1 (CArH ortho to OCH2), 117.8 (CH=CH2), 113.7 (CArH     186
ortho to CH2N), 103.1 (SiC≡C), 92.7 (SiC≡C), 82.4 (OC(O)C(CH3)3), 
79.7 (NC(O)OC(CH3)3), 72.2 & 71.6 (CHOCAr), 67.0 (CArOCH2CH2), 
64.9 (CArOCH2), 57.7 (NCH2), 40.4 (CH2CHOCAr), 34.1 (NCH3), 28.4 
(NC(O)C(CH3)3), 27.7 (OC(O)C(CH3)3), –0.4 (Si(CH3)3).  No CArI peak 
observed. 
 
LRMS
  (ES+) m/z 696 [M + Na]
+. 
 
HRMS  (ES+) calcd for C29H44INO7SiNa [M + Na]
+ 696.1824 , found 696.1808. 
 
 
(3S,5S)- and (3S,5R)-tert-Butyl-3-(5,6-dihydroxy-1-(trimethylsilyl) hex-1-yn-3-
yloxy)-2-iodo-(4-ethyl tert-butyl carbonate) benzylmethylcarbamate (5.42) 
 
 
 
C29H46INO9Si 
Mw = 707.67 gmol
−1 
Colourless oil 
 
Following the procedure of Dupau et al.,
146 alkene (+)-5.41 (8.05 g, 12.0 mmol) was 
dissolved in t-BuOH/water (1:1, 16 mL) and treated with citric acid (2.76 g, 14.3 
mmol).  The solution was stirred for 5 min before OsO4 (2.3 mL, 2.5 wt% sol in t-
BuOH, 0.18 mmol) and NMO (1.68 g, 14.4 mmol) were added.  The reaction was 
stirred at rt for 26 h.  The reaction was quenched by the addition of sodium dithionite 
(4.0 g, 23.0 mmol) and the reaction was stirred for 20 min.  The reaction mixture was 
added to EtOAc (50 mL) and the layers were separated.  The aqueous layer was 
extracted with EtOAc (3 x 50 mL) and CH2Cl2 (6 x 50 mL).  The separate organic 
layers were washed with water (1 x 10 mL) and brine (1 x 10 mL), dried over MgSO4 
and concentrated in vacuo.  The residue was purified by column chromatography 
(eluent 15-50% EtOAc/hexane) to give the title compound as a colourless oil (5.55 g, 
7.8 mmol, 65%) and recovered alkene (+)-5.41 (989 mg, 1.4 mmol, 12%).  The (3S,5S) 
and (3S,5R) epimers were formed in a 1:1 ratio (
1H NMR).     187
 
IR  νmax (neat) 3446 (br w), 2975 (w), 2930 (w), 1742 (m), 1696 (m), 1476 
(m), 1393 (m), 1275 (m), 1251 (s), 1154 (m), 844 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3)  δ 7.06-6.67 (2H, m, 2 x CArH), 5.47 (1H, br s, 
CHOCAr), 4.59-4.36 (4H, m, CH2N & CArOCH2CH2), 4.35-4.27 (1H, m, 
OH), 4.26-4.13 (2H, m, CArOCH2), 3.81-3.68 (1H, m, CHHOH), 3.68-
3.52 (1H, m, CHHOH), 3.34 (0.5 H, d, J = 3.8 Hz, CHOH), 3.13 (0.5H, 
d, J = 3.8 Hz, CHOH), 2.95-2.70 (3H, m, NCH3), 2.43-2.05 (3H, m, 
CH2CHOCAr & OH), 1.60-1.35 (18H, m, 2 x C(O)OC(CH3)3), 0.03 (9H, 
s, Si(CH3)3).  Spectrum exhibited broadening of peaks due to restricted 
rotation. 
 
13C NMR  (75 MHz, CDCl3)  δ 155.9 (NC(O)O), 153.2 (OC(O)O), 149.4 
(CArOCH2), 146.0 (CArOCH), 133.3 (CArCH2N), 122.3 (CArH ortho to 
OCH2), 113.2 (CArH ortho to CH2N), 102.8 (SiC≡C), 93.4 (SiC≡C), 
82.9 (OC(O)C(CH3)3), 79.8 (NC(O)OC(CH3)3), 70.2 & 69.9 (CHOH), 
69.5 (CHOCAr), 68.7 (CArOCH2CH2), 66.9 & 66.5 (CH2OH), 64.8 
(CArOCH2), 57.6 (NCH2), 39.4 & 39.3 (CH2CHOCAr), 34.1 (NCH3), 
28.4 (NC(O)C(CH3)3), 27.7 (OC(O)C(CH3)3), –0.4 (Si(CH3)3).  No CArI 
peak observed. 
 
LRMS
  (ES+) m/z 730 [M + Na]
+. 
 
HRMS  (ES+) calcd for C29H46INO9SiNa [M + Na]
+ 730.1879, found 730.1885. 
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(3S,5S)-(+)-tert-Butyl-3-(5-hydroxyoct-7-en-1-yn-3-yloxy)-2-iodo-4-(ethyl  tert-butyl 
carbonate) benzylmethylcarbamate ((+)-5.44) 
 
 
 
C28H40INO8 
Mw = 645.52 gmol
−1 
Orange oil 
 
Following the procedure of Marshall et al.,
159 protected alkyne (+)-5.31 (4.11 g, 5.7 
mmol) was dissolved in THF (20 mL) and cooled to 0 ºC before TBAF (11.40 mL, 1.0 
M sol in THF, 11.4 mmol) was added dropwise turning the colourless solution a dark 
red colour.  The ice bath was removed and the solution was stirred for 30 min.  The 
reaction was re-cooled to 0 ºC and ice water (20 mL) was added.  The aqueous layer 
was extracted with Et2O (3 x 50 mL).  The combined organic layers were washed with 
water (1 x 50 mL) and brine (1 x 50 mL), dried over MgSO4 and concentrated in vacuo.  
The residue was purified by column chromatography (eluent 30% EtOAc/hexane) to 
give the title compound as an orange oil (3.34 g, 5.2 mmol, 91%). 
 
[α]D  +2.7 (c 1.00, CHCl3, 23 °C). 
 
IR  νmax (neat) 3452 (br w), 3290 (w), 2977 (w), 2930 (w), 1741 (m), 1690 
(m), 1476 (m), 1392 (m), 1274 (s), 1253 (s), 1154 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.08-6.61 (2H, m, 2 x CArH), 5.90 (1H, ddt, J = 
17.2, 10.1, 7.0 Hz, CH=CH2), 5.50 (1H, td, J = 6.9, 2.1 Hz, CHOCAr), 
5.25-4.99 (2H, m, CH=CH2), 4.63-4.31 (4H, m, CH2N & 
CArOCH2CH2), 4.22 (2H, t, J = 4.5 Hz, CArOCH2), 4.17-4.03 (1H, m, 
CHOH), 2.85 (3H, br s, NCH3), 2.68 (1H, d, J = 4.0 Hz, OH), 2.41 (1H, 
d, J = 2.1 Hz, C≡CH),  2.35 (2H, t, J = 7.0 Hz, CH2CH=CH2), 2.27-2.08 
(2H, m, CH2CHOCAr), 1.65-1.29 (18H, m, 2 x C(O)OC(CH3)3).  
Spectrum exhibited broadening of peaks due to restricted rotation.     189
13C NMR  (75 MHz, CDCl3)  δ 155.9 (NC(O)O), 153.2 (OC(O)O), 149.7 
(CArOCH2), 146.0 (CArOCH), 134.6 (CH=CH2), 133.6 (CArCH2N), 
123.0 & 122.0 (CArH ortho to OCH2), 117.7 (CH=CH2), 113.4 (CArH 
ortho  to CH2N), 82.8 (OC(O)C(CH3)3), 81.5 (C≡CH), 79.8 
(NC(O)OC(CH3)3), 76.1 (C≡CH), 70.3 (CHOH), 68.6 (CHOCAr), 66.9 
(CArOCH2CH2), 64.9 (CArOCH2), 57.6 & 56.7 (NCH2), 42.7 
(CH2CH=CH2), 42.0 (CH2CHOCAr), 34.3 (NCH3), 28.4 
(NC(O)C(CH3)3), 27.7 (OC(O)C(CH3)3).  No CArI peak observed. 
 
LRMS
  (ES+) m/z 668 [M + Na]
+. 
 
HRMS  (ES+) calcd for C28H40INO8Na [M + Na]
+ 668.1691, found 668.1686. 
 
 
(3S,5S)-(–)-tert-Butyl-3-(5-[(tert-butyldimethylsilyl)oxy]-7-en-1-yn-3-yloxy)-2-iodo-
4-(ethyl tert-butyl carbonate)benzylmethylcarbamate ((–)-5.46) 
 
 
 
C34H54INO8Si 
Mw = 759.78 gmol
−1 
Pale yellow oil 
 
Alcohol (+)-5.44 (2.33 g, 3.6 mmol) was dissolved in CH2Cl2 (10 mL), treated with 2,6-
lutidiene (0.84 mmol, 7.2 mmol) and cooled to −78 ºC.  TBSOTf (0.87 mL, 3.8 mmol) 
was added dropwise and the resulting solution was stirred at −78 ºC for 5 min before it 
was warmed to 0 ºC and stirred for 20 min.  The reaction was quenched by the addition 
of a sat aq NH4Cl (50 mL).  The reaction mixture was extracted with Et2O (3 x 50 mL).  
The combined organic layers were washed with NaHCO3 (1 x 75 mL) and brine (1 x 75 
mL), dried over MgSO4 and concentrated in vacuo.  The residue was purified by 
column chromatography (eluent 10-20% EtOAc/hexane) to give the title compound as a 
pale yellow oil (2.49 g, 3.3 mmol, 92%). 
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[α]D  –4.4 (c 0.98, CHCl3, 23 °C). 
 
IR  νmax (neat) 3290 (br w), 2929 (w), 2856 (w), 1742 (m), 1694 (m), 1474 
(m), 1391 (m), 1273 (s), 1252 (s), 1154 (s), 836 (m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 6.98-6.65 (2H, m, 2 x CArH), 5.87 (1H, ddt, J = 
17.1, 10.1, 7.1 Hz, CH=CH2), 5.25 (1H, br t, J = 6.5 Hz, CHOCAr), 5.17-
4.98 (2H, m, CH=CH2), 4.61-4.31 (4H, m, CH2N & CArOCH2CH2), 4.21 
(2H, t, J = 4.8 Hz, CArOCH2), 4.14-4.02 (1H, m, CHOTBS), 3.06-2.61 
(3H, br m, NCH3), 2.51-2.19 (4H, m, C≡CH, CH2CHOCAr  & 
CHHCH=CH2),  2.16-2.04 (1H, m, CHHCH=CH2), 1.65-1.29 (18H, m, 
2 x C(O)OC(CH3)3), 0.88 (9H, s, Si(C(CH3)3)), 0.09 (6H, s, Si(CH3)2).  
Spectrum exhibited broadening of peaks due to restricted rotation. 
13C NMR  (75 MHz, CDCl3)  δ 155.9 (NC(O)O), 153.3 (OC(O)O), 150.1 
(CArOCH2), 146.6 (CArOCH), 134.5 (CH=CH2), 133.6 (CArCH2N), 
123.0 & 122.5 (CArH ortho to OCH2), 117.4 (CH=CH2), 114.2 & 114.0 
(CArH ortho to CH2N), 82.4 (OC(O)C(CH3)3), 81.7 (C≡CH), 79.7 
(NC(O)OC(CH3)3), 75.9 (C≡CH), 70.2 (CHOTBS), 68.8 (CHOCAr), 
67.0 (CArOCH2CH2), 64.8 (CArOCH2), 57.6 & 56.8 (NCH2), 42.9 
(CH2CH=CH2), 41.9 (CH2CHOCAr), 34.3 (NCH3), 28.4 
(NC(O)C(CH3)3), 27.7 (OC(O)C(CH3)3), 25.9 (SiC(CH3)3), 18.0 
(SiC(CH3)3), –4.3 & –4.6 (2 x SiCH3).  No CArI peak observed. 
 
LRMS
  (ES+) m/z 782 [M + Na]
+. 
 
HRMS  (ES+) calcd for C34H54INO8SiNa [M + Na]
+ 782.2556, found 782.2550. 
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(1S,5S)-(–)-tert-Butyl-3-(5-[(tert-butyldimethylsilyl)oxy]-2-(2-hydroxyethyl) 
cyclohex-2-en-1-yloxy)-2-iodo-4-(ethyl tert-butyl carbonate) 
benzylmethylcarbamate ((–)-5.47) 
 
 
 
C34H56INO9Si 
Mw = 777.80 gmol
−1 
Colourless oil 
 
Diene (–)-5.32 (1.51 g, 2.0 mmol) was treated with 9-BBN (12.0 mL, 0.5 M sol in THF, 
6.0 mmol) and stirred at rt for 42 h.  2 N NaOH (10 mL) was added followed cautiously 
by H2O2 (4 mL, 30% sol in H2O) over 15 min.  Stirring continued for 5 min before the 
layers were partitioned between Et2O and H2O.  The aqueous layer was extracted with 
Et2O (2 x 50 mL).  The combined organic layers were washed with brine (1 x 75 mL), 
dried over MgSO4 and concentrated in vacuo.  The residue was purified by column 
chromatography (eluent 25% EtOAc/hexane) to give the title compound as a colourless 
oil (1.19 g, 1.5 mmol, 75%). 
 
[α]D  –9.0 (c 1.27, CHCl3, 24 °C). 
 
IR  νmax (neat) 3468 (br w), 2929 (w), 2857 (w), 1743 (m), 1686 (m), 1474 
(m), 1391 (m), 1274 (s), 1251 (s), 1153 (s), 1103 (s), 836 (s), 730 (s) 
cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 6.87 (1H, d, J = 8.4 Hz, CArH ortho to OCH2), 
6.84-6.75 (1H, m, CArH ortho to CH2N), 5.55 (1H, br d, J = 4.6 Hz, 
CHOCAr), 5.41 (1H, br m, C=CH), 4.68-4.29 (4H, m, CH2N & 
CArOCH2CH2), 4.28-4.11 (2H, m, CArOCH2), 3.99-3.62 (3H, m, 
CHOTBS & CH2OH), 2.99-2.76 (3H, br m, NCH3), 2.76-2.60 (1H, m, 
CHHCH2OH), 2.50 (1H, ddd, J = 14.0, 6.9, 6.8 Hz, CHHCH2OH), 2.37-
2.20 (1H, m, CHHCHOCAr), 2.14 (1H, br d, J = 9.7 Hz, CHHCHOCAr),     192
2.04 (1H, br t, J = 5.3 Hz, OH), 1.88 (2H, dd, J = 10.1, 8.4 Hz, 
C=CHCH2), 1.65-1.30 (18H, m, 2 x C(O)OC(CH3)3), 0.82 (9H, s, 
Si(C(CH3)3)), 0.00 (3H, s, SiCH3), –0.02 (3H, s, SiCH3).  Spectrum 
exhibited broadening of peaks due to restricted rotation. 
 
13C NMR  (75 MHz, CDCl3)  δ 155.8 (NC(O)O), 153.2 (OC(O)O), 149.5 
(CArOCH2), 145.6 (CArOCH), 136.0 (C=CH), 133.8 (CArCH2N), 123.9 
(C=CH), 122.3 & 121.7 (CArH ortho to OCH2), 113.3 (CArH ortho to 
CH2N), 82.7 (OC(O)C(CH3)3), 79.7 (NC(O)OC(CH3)3), 77.7 
(CHOTBS), 67.3 (CHOCAr), 66.8 (CArOCH2CH2), 64.9 (CArOCH2), 
61.6 (CH2OH), 57.8 & 56.9 (NCH2), 38.9 (CArOCHCH2), 36.1 
(CH2CH2OH), 35.9 (C=CHCH2), 34.1 (NCH3), 28.4 (NC(O)C(CH3)3), 
27.7 (OC(O)C(CH3)3), 25.8 (SiC(CH3)3), 18.1 (SiC(CH3)3), –4.6 
(Si(CH3)2).  No CArI peak observed. 
 
LRMS
  (ES+) m/z 800 [M + Na]
+. 
 
HRMS  (ES+) calcd for C34H56INO9SiNa [M + Na]
+ 800.2661, found 800.2647. 
 
 
(+)-tert-Butyl-N-[((1aS,9aS,11aR)-11a-[(tert-butyldimethylsilyl)oxy]-1-
(hydroxyethyl)-6-(ethyl  tert-butyl carbonate)-1,9a,10,11a-tetrahydrodibenzo 
[b,d]furan-12-yl)-3-methyl]-N-methylcarbamate ((+)-5.48) 
 
 
 
C34H55NO9Si 
Mw = 649.89 gmol
−1 
Yellow oil 
 
To a solution of iodide (–)-5.47 (1.19 g, 1.5 mmol) in toluene (45 mL) was added 
Ag2CO3 (1.27 g, 4.6 mmol), dppp (95 mg, 0.2 mmol) and Pd(OAc)2 (45 mg, 0.2 mmol).  
The reaction mixture was stirred at rt for 10 min and then heated to 90 ºC for 28 h.  The     193
solvent was removed in vacuo and the residue was purified by column chromatography 
(eluent 25-40% EtOAc/hexane) to give the title compound as a yellow oil (777 mg, 1.2 
mmol, 78%). 
 
[α]D  +7.2 (c 1.15, CHCl3, 24 °C). 
 
IR  νmax (neat) 3435 (br w), 2929 (w), 2857 (w), 1742 (m), 1681 (m), 1392 
(m), 1367 (m), 1252 (s), 1147 (s), 1092 (s), 836 (s), 730 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 6.74 (1H, d, J = 8.3 Hz, CArH ortho to OCH2), 6.56 
(1H, d, J = 8.3 Hz, CArH ortho to CH2N), 6.06 (1H, br s, CCH=CH), 
5.79 (1H, d, J = 10.1 Hz, CCH=CH), 4.84 (1H, dd, J = 11.5, 4.8 Hz, 
CHOCAr), 4.62 (1H, br s, NCHH), 4.39 (2H, t, J = 4.7 Hz, 
CArOCH2CH2), 4.35-4.27 (2H, m, NCHH & CHOTBS), 4.23 (2H, t, J = 
4.7 Hz, CArOCH2), 3.65-3.39 (2H, m, CH2OH), 2.79 (3H, br s, NCH3), 
2.37-2.17 (1H, m, CHHCHOCAr), 2.02-1.62 (4H, m, CHHCHOCAr, 
CH2CH2OH & OH), 1.61-1.29 (18H, m, 2 x C(O)OC(CH3)3), 0.86 (9H, 
s, Si(C(CH3)3)), 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3).  Spectrum 
exhibited broadening of peaks due to restricted rotation. 
 
13C NMR  (75 MHz, CDCl3)  δ 155.9 (NC(O)O), 153.3 (OC(O)O), 147.1 
(CArOCH2), 143.2 (CArOCH), 134.0 (CCH=CH), 130.4 (CArC), 128.0 
(CCH=CH), 127.1 (CArCH2N), 121.1 & 119.9 (CArH ortho to OCH2), 
114.1 (CArH ortho to CH2N), 84.8 (CHOCAr), 82.3 (OC(O)C(CH3)3), 
79.8 (NC(O)OC(CH3)3), 67.0 (CArOCH2CH2), 65.3 (CHOTBS), 65.1 
(CArOCH2), 59.4 (CH2OH), 50.3 (CCH=CH), 48.9 (NCH2), 41.8 
(CArOCHCH2), 37.0 (CH2CH2OH), 34.0 (NCH3), 28.4 
(NC(O)C(CH3)3), 27.7 (OC(O)C(CH3)3), 25.7 (SiC(CH3)3), 18.1 
(SiC(CH3)3), –4.6 (SiCH3), −4.8 (SiCH3). 
 
LRMS
  (ES+) m/z 672 [M + Na]
+. 
 
HRMS  (ES+) calcd for C34H55NO9SiNa [M + Na]
+ 672.3538, found 672.3534.     194
tert-Butyl-N-[((1aS,9aS,11aR)-11a-[(tert-butyldimethylsilyl)oxy]-1-(bromoethyl)-6-
(ethyl  tert-butyl carbonate)-1,9a,10,11a-tetrahydrodibenzo[b,d]furan-12-yl)-3-
methyl]-N-methylcarbamate (5.49) 
 
 
 
C28H40BrNO8 
Mw = 598.52 gmol
−1 
Colourless oil 
 
Following the procedure of Baughman et al.,
148 alcohol (+)-5.48 (50 mg, 0.077 mmol) 
and CBr4 (28 mg, 0.085 mmol) were dissolved in CH2Cl2 (3 mL) and cooled to 0 °C 
before PPh3 (22 mg, 0.085 mmol) was added turning the colourless solution pale 
yellow.  The solution was stirred at rt for 2 h.  The solvent was removed in vacuo and 
the residue was purified by column chromatography (eluent 20-100% EtOAc/hexane) to 
give the title compound as a colourless oil (13 mg, 0.022 mmol, 28%). 
 
IR  νmax (neat) 3435 (br w), 2955 (w), 2926 (m), 2853 (w), 1742 (m), 1695 
(m), 1275 (s), 1255 (s), 1158 (s) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 6.78 (1H, d, J = 8.4 Hz, CArH ortho to OCH2), 6.63 
(1H, d, J = 8.4 Hz, CArH ortho to CH2N), 6.00 (1H, dd, J = 9.9, 3.8 Hz, 
CCH=CH), 5.88 (1H, br s, CCH=CH), 4.78 (1H, t, J = 5.3 Hz, 
CHOCAr), 4.54 (1H, br s, NCHH), 4.46-4.33 (3H, m, CArOCH2CH2 & 
NCHH), 4.28-4.17 (3H, m, CArOCH2 & CHOH), 3.30 (1H, dt, J = 11.7, 
5.1 Hz, CHHBr), 3.11 (1H, ddd, J = 11.7, 10.2, 5.1 Hz, CHHBr),  2.81 
(3H, br s, NCH3), 2.55-2.40 (1H, m, CHHCH2Br), 2.36-2.11 (4H, m, 
CHHCH2Br, CH2CHOCAr & OH), 1.61-1.41 (18H, m, 2 x 
C(O)OC(CH3)3).  Spectrum exhibited broadening of peaks due to 
restricted rotation. 
 
LRMS
  (ES+) m/z 620 [M + Na]
+, 622 (Br isotope peak). 
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 tert-Butyl-N-[((1aS,9aS,11aR)-11a-[(tert-butyldimethylsilyl)oxy]-1-(oxoethyl)-6-
(ethyl  tert-butyl carbonate)-1,9a,10,11a-tetrahydrodibenzo[b,d]furan-12-yl)-3-
methyl]-N-methylcarbamate (5.50) 
 
 
 
C34H53NO9Si 
Mw = 647.87 gmol
−1 
Colourlass oil 
 
Alcohol (+)-5.48 (27 mg, 0.042 mmol) was dissolved in CH2Cl2 (1 mL) and was treated 
with Dess-Martin periodinane (23 mg, 0.054 mmol).  The solution was stirred at rt for 
45 min during which time it became cloudy.  The reaction mixture was concentrated in 
vacuo and the residue was purified by column chromatography (eluent 20% 
EtOAc/hexane) to give the title compound as a colourless oil (18 mg, 0.028 mmol, 
67%). 
 
IR  νmax (neat) 2956 (w), 2928 (w), 2857 (w), 1742 (m), 1730 (m), 1694 
(m), 1367 (m), 1273 (m), 1254 (s), 1146 (m), 1091 (m), 837 (m), 777 
(m) cm
−1. 
 
1H NMR  (300 MHz, CDCl3) δ 9.56 (1H, t, J = 2.3 Hz, C(O)H), 6.76 (1H, d, J = 
8.4 Hz, CArH ortho to OCH2), 6.60 (1H, d, J = 8.4 Hz, CArH ortho to 
CH2N), 6.16 (1H, br s, CCH=CH), 5.87 (1H, d, J = 10.2 Hz, CCH=CH), 
4.87 (1H, dd, J = 11.7, 4.9 Hz, CHOCAr), 4.73 (1H, br s, NCHH), 4.45-
4.38 (2H, m, CArOCH2CH2), 4.37-4.31 (1H, m, NCHH), 4.28-4.22 (2H, 
m, CArOCH2), 4.21-4.15 (1H, m, CHOTBS), 2.79 (3H, br s, NCH3), 
2.68 (2H, d, J = 2.3 Hz, CH2C(O)H), 2.36-2.18 (1H, m, CHHCHOCAr), 
1.85-1.66 (1H, m, CHHCHOCAr), 1.55-1.43 (18H, m, 2 x 
C(O)OC(CH3)3), 0.88 (9H, s, Si(C(CH3)3)), 0.09 (3H, s, SiCH3), 0.08 
(3H, s, SiCH3).  Spectrum exhibited broadening of peaks due to 
restricted rotation.     196
LRMS
  (ES+) m/z 670 [M + Na]
+. 
 
 
(+)-tert-Butyl-N-[((1aS,9aS,11aR)-11a-[(tert-butyldimethylsilyl)oxy]-1-(ethyl(4-
methyl benzenesulfonate)))-6-(ethyl tert-butyl carbonate)-1,9a,10,11a-
tetrahydrodibenzo[b,d]furan-12-yl)-3-methyl]-N-methylcarbamate ((+)-5.51) 
 
NBoc
O OTBS
O
OBoc
H
OTs
 
 
C41H61NO11SSi 
Mw = 803.37 gmol
−1 
Colourless oil 
 
To a solution of alcohol (+)-5.48 (372 mg, 0.57 mmol), TsCl (218 mg, 1.15 mmol) and 
DMAP (17 mg, 0.14 mmol) in CH2Cl2 (4 mL) was added Et3N (0.20 mL, 1.43 mmol) 
and the solution was stirred at rt for 2 h.  The reaction mixture was diluted with CH2Cl2 
(5 mL) and was washed with HCl (1 x 5 mL) and brine (1 x 5mL), dried over MgSO4 
and concentrated in vacuo.  The residue was purified by column chromatography 
(eluent 20% EtOAc/hexane) to give the title compound as a colourless oil (394 mg, 0.49 
mmol, 86%). 
 
[α]D  +23.7 (c 1.30, CHCl3, 28 °C). 
 
IR  νmax (neat) 2952 (w), 2929 (w), 2857 (w), 1741 (m), 1689 (m), 1391 
(m), 1366 (m), 1252 (s), 1174 (s), 1095 (s), 836 (s), 731 (s), 554 (s) cm
−
1. 
 
1H NMR  (300 MHz, CDCl3) δ 7.72 (2H, d, J = 8.2 Hz, CArH ortho to SO2O), 7.33 
(2H, d, J = 8.2 Hz, CArH meta to SO2O), 6.73 (1H, d, J = 8.4 Hz, CArH 
ortho to OCH2), 6.54 (1H, d, J = 8.4 Hz, CArH ortho to CH2N), 6.03 
(1H, br s, CCH=CH), 5.81 (1H, d, J = 10.2 Hz, CCH=CH), 4.71 (1H, 
dd, J = 11.7, 4.9 Hz, CHOCAr), 4.64 (1H, br s, NCHH), 4.45-4.35 (2H,     197
m, CArOCH2CH2), 4.33-4.17 (4H, m, NCHH, CHOTBS & CArOCH2), 
4.08-3.95 (1H, m,  SO2OCHH), 3.88 (1H, dt, J = 10.2, 7.1 Hz, 
SO2OCHH), 2.75 (3H, br s, NCH3), 2.44 (3H, s, CArCH3), 2.28-2.16 
(1H, m, CHHCHOCAr), 2.15-2.01 (1H, m, SO2OCH2CHH), 1.94-1.80 
(1H, m, SO2OCH2CHH), 1.77-1.61 (1H, m, CHHCHOCAr), 1.60-1.31 
(18H, m, 2 x C(O)OC(CH3)3), 0.87 (9H, s, Si(C(CH3)3)), 0.08 (3H, s, 
SiCH3), 0.07 (3H, s, SiCH3).  Spectrum exhibited broadening of peaks 
due to restricted rotation. 
 
13C NMR  (75 MHz, CDCl3)  δ 155.8 (NC(O)O), 153.3 (OC(O)O), 147.0 
(CArOCH2), 144.8 (CArCH3), 143.3 (CArOCH), 135.2 (CCH=CH), 132.9 
(CArSO2O), 130.8 (CCH=CH), 129.8 (CArH meta to SO2O), 127.8 (CArH 
ortho  to SO2O), 126.5 (CArCH2N), 121.1 & 119.7 (CArH ortho to 
OCH2), 114.4 (CArH ortho to CH2N), 84.2 (CHOCAr), 82.4 
(OC(O)C(CH3)3), 79.9 (NC(O)OC(CH3)3), 67.0 (CArOCH2CH2), 66.9 
(SO2OCH2), 65.2 (CHOTBS), 65.1 (CArOCH2), 49.7 (CCH=CH), 48.7 
(NCH2), 37.3 (SO2OCH2CH2), 36.3 (CArOCHCH2), 33.8 (NCH3), 28.4 
(NC(O)C(CH3)3), 27.7 (OC(O)C(CH3)3), 25.7 (SiC(CH3)3), 21.6 
(CH3CAr), 18.1 (SiC(CH3)3), –4.6 (SiCH3),  −4.8 (SiCH3).  One CAr 
quaternary centre was not observed. 
 
LRMS
  (ES+) m/z 826 [M + Na]
+. 
 
HRMS  (ES+) calcd for C41H61NO11SSiNa [M + Na]
+ 826.3627, found 
826.3624. 
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6.3  Radiochemistry 
Procedure for the [
18F]-fluoridolysis of the RLV constructs 
 
[
18F]-Fluoride (<400 MBq) in water (100-300 μmL) was drawn into a Wheaton vial 
followed by 1,10-diazo-4,7,13,16,21,24-hexaoxabicyclo [8.8.8] hexacosan (4 mg, 10.6 
μmol) in MeCN (200 μmL) and aq K2CO3 (50 μL, 0.1 moldm
-3, 5 μmol) which were 
added through the dip tube inlet.  The mixture was azeotropically dried with a flow of 
nitrogen and heating at 100 °C for 20 min.  The reaction vessel was cooled to rt and 
resin (30-40 mg) was added followed by MeCN (500 μmL). The stirred reaction 
mixture was heated to 100-110 °C for 15 min before being cooled and filtered through 
an acrodisc.  The Wheaton vial was rinsed with water (1.5 mL) and MeCN (500 μmL), 
which was also filtered.  The sample was analysed by reverse-phase HPLC (Luna 
C18(2) column, 150-4.6 mm, 100 μL loop size, 1 mL/min pump speed, 254 mn 
wavelength, eluent 40-95% MeCN/water).  To formulate the sample it was diluted to a 
volume of 10 ml with H2O, loaded onto a conditioned light C18 Sep-Pak cartridge and 
flushed with H2O (2 ml) and EtOH (0.5ml) into a P6 vial before phosphate buffered 
saline (4.5 ml) was added and HPLC analysis was repeated. 
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